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Abstract 
 
Lipoproteins are self-assembled nanoparticles for water-insoluble lipid transportation in 
the circulation. Lipoprotein particles form a key metabolic system in a variety of normal 
physiological processes but also play an essential role in many pathological conditions. In 
particular, certain lipoprotein abnormalities are associated with the development of 
atherosclerosis, a disease state of arteries, common in cardiovascular disease. 
 
Computational modelling is a potential but so far rarely used method to study lipoprotein 
particles. This thesis contributes to lipoprotein research by various computational 
approaches where experimentally isolated and biochemically characterised lipoprotein 
particles serve as a starting point. This thesis deals with estimating the number of lipid 
molecules within lipoprotein particles, i.e., composition information, and approximating the 
molecular structure of lipoprotein particles in each subclass. It also proceed the 
ultracentrifugal particle isolation by a kind of in silico sub-classiﬁcation resulting from 
utilisation of the self-organising map (SOM) method. This, when applied to experimental data, 
with lipoprotein lipid concentration and composition information combined, shows that there 
is variability in the compositional/metabolic relations between individuals, i.e., distinct 
lipoprotein phenotypes. Furthermore, this thesis introduces a method to estimate lipoprotein 
particle concentrations in each subclass, which also provides a reference particle library for 
NMR-based lipoprotein particle concentration estimation. 
 
Applications of the models to experimental data show that triglyceride and cholesterol ester 
molecules, which are conventionally held as core lipids, may also locate in signiﬁcant amounts 
in the surface. The lipoprotein phenotype analysis shows that per particle compositions, 
which appear as a fundamental issue in metabolic and clinical corollaries, can not be deduced 
solely from the regularly measured plasma lipid concentrations nor from the particle 
concentration estimates. 
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lipoprotein concentration 
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Lipoproteiinit ovat nanokokoisia hiukkasia, jotka kuljettavat veteen liukenemattomia 
rasvoja verenkierrossa. Lipoproteiinit ovat osa normaalia aineenvaihduntaa, mutta ne voivat 
osallistuvat myös monien tautitilojen syntyyn. Tietyt lipoproteiinipoikkeavuudet ovat 
tärkeitä sydän- ja verisuonitaudeissa yleisesti esiintyvän ateroskleroosin eli 
valtimonkovettumistaudin riskitekijöitä. 
 
Lipoproteiinien laskennallinen mallintaminen on lupaava mutta toistaiseksi vähän käytetty 
menetelmä lipoproteiinien tutkimisessa. Tässä väitöskirjassa sovelletaan 
lipoproteiinitutkimukseen useita erilaisia laskennallisia malleja käyttäen lähtökohtana 
kokeellisesti saatua tietoa. Väitöskirjan keskeisiä aiheita ovat lipoproteiinien sisältämien 
rasvamolekyylien lukumäärien arviointi yhtä lipoproteiinipartikkelia kohti sekä 
lipoproteiinien molekyylirakenteen estimointi. Väitöskirja tarjoaa myös laskennallisen tavan 
parantaa ultrasentrifugilla eristettyjen lipoproteiinipartikkeleiden erottelua. Kokeelliseen 
dataan sovellettuna tämä menetelmä osoittaa, että ihmisten välillä on eroavaisuuksia 
lipoproteiinien koostumuksissa ja aineenvaihdunnallisissa ominaisuuksissa, ts. 
lipoproteiinifenotyypeissä. Väitöskirja esittelee myös tavan arvioida 
lipoproteiinipartikkeleiden konsentraatioita verenkierrossa. Tämä mahdollistaa myös 
vertailutietokannan rakentamisen partikkelikonsentraatioiden estimoimiseksi NMR-
lähtöisellä tavalla. 
 
Väitöskirjan mallien soveltaminen kokeelliseen dataan osoittaa, että triglyseridit ja 
kolesteroliesterit, joita tavanomaisesti pidetään lipoproteiinien ytimissä sijaitsevina 
rasvamolekyyleinä, voivat sijaita huomattavina määrinä myös hiukkasten pinnan tuntumassa. 
Lipoproteiinifenotyyppien analysointi osoittaa, että lipoproteiinihiukkasten koostumusta, 
jolla näyttää olevan merkitystä ihmisen aineenvaihduntaan ja kliiniseen tilaan, ei voida 
päätellä pelkästään plasman rasvakonsentraatioista tai lipoproteiinipartikkelien 
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1. Introduction
Lipoprotein particles are lipid transporters in the circulation of all vertebrates 
and are thus key players also in human physiology. One of the physiological 
processes is transport of triglycerides for cells' energy metabolism. Lipopro-
tein particles are also important in transporting cholesterol molecules which 
are used in cellular plasma membranes and subcellular organelles as struc-
tural elements and for production of certain important molecules such as vit-
amin D,  bile  acids  and several  hormones  including  steroid  hormones. Al-
though cholesterol is an essential molecule for proper cell functioning, it is 
harmful to the cells in large amounts and thus lipoprotein particles, as the 
main cholesterol transporters, have also key roles in human pathology. In-
terest in lipoprotein particles has arisen particularly due to their association 
with cardiovascular disease, which is the major cause of death in the Western 
World1. The main cause of cardiovascular disease is atherosclerosis, which is 
a  disease  state  of  arterial  walls. The  etiology  of  atherosclerosis  is  not, 
however, yet totally explained although much has been learned over decades 
about this complex disease. Nevertheless, the role of lipoprotein particles in 
the development of atherosclerosis is currently widely acknowledged. This in-
troductory chapter reviews the common history of atherosclerosis and lipo-
protein particle research and gives the framework to the following chapters of 
lipoprotein particles.
1.1 The history of atherosclerosis and lipoprotein research 
In the 19th century, atherosclerosis was recognised as an inevitable accom-
paniment of ageing about which nothing much could be done. Nevertheless, 
the century provided grounds to the development in the following century: a 
lipid molecule, which became also called the molecule of the 20th century, was 
discovered. It was found in the early 19th century by a French chemist Michael 
E. Chevreul who was the first to isolate and purify the lipid from gallstones2. 
Chevreul also named the molecule cholesterol from Greek words chol for bile 
and stereos for solid. By the end of the 19th century, the presence of cholester-
ol in human blood was also confirmed, cholesterol was observed in athero-
1
sclerotic lesions, and, interestingly, blood lipid accumulation was suggested 
to cause atherosclerosis as reviewed elsewhere3.
First suggestions about the association between high blood 
cholesterol and the development of atherosclerosis
The current era of atherosclerosis research began in 1913 when a young ex-
perimental pathologist Nikolai Anitschkow showed that simply feeding rab-
bits purified cholesterol dissolved in sunflower oil induced vascular lesions 
while the control rabbits fed only the sunflower oil showed no lesions4, 5. In 
addition, the cholesterol-induced lesions resembled those of human athero-
sclerosis both grossly and microscopically. Over the ensuing years, Anitsch-
kow and colleagues established sharp-eyed overview of essential parts of the 
development of atherosclerosis known today6. These included infiltration of 
leukocytes into the arterial wall, their enrichment with cholesterol, develop-
ment into early and further into advanced lesions over time. They also con-
ducted that the cholesterol came from the blood, the degree and the duration 
of increased blood cholesterol effected on the extend of the lesions, and that 
the early lesions were also reversible. 
The seminal work by Anitschkow was, however, rejected or at least not fol-
lowed up and the serious role of cholesterol in human atherosclerosis did not 
really become appreciated until years later. Some laboratories actually tried 
to confirm Anitschkow's finding, but, instead of using rabbits as laboratory 
animals, most used rats and dogs with which they were more familiar with7. 
Those animals are, however, very efficient in converting cholesterol to bile 
acids and thus, even on very high cholesterol intake, the diet does not in-
crease their blood cholesterol levels appreciably to enhance the development 
of atherogenic lesions. As a result, these new cholesterol feeding studies failed 
and the investigators concluded that Anitschkow's results must reflect some 
peculiarity of the rabbit. Thus, unfortunately, the rabbit model was dismissed 
as irrelevant for human disease. In retrospect, the misfortune was not direc-
ted only on the choice of the laboratory animals, but the researchers should 
have  recognised  an  important  causal  relation  relevant  for  atherosclerosis: 
feeding of the cholesterol followed by increase in blood cholesterol levels. 
Another reason why Anitschkow's work was not taken seriously was that his 
rabbits  had extraordinary high blood cholesterol  levels  ranging from 500-
1000 mg/dl (13-26 mmol/l) or even higher. In humans, cholesterol levels that 
high are rarely measured and extrapolation was felt unwarranted. Soon after 
the first study, Anitschkow showed that more modest increases of cholesterol 
levels in rabbits were sufficient to induce lesions although it took longer7. The 
general prejudice was, however, strong among the  cholesterol disbelievers: 
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how cholesterol feeding within a few months can cause the illness which was 
generally accepted to be an inevitable accompaniment of ageing.
Interestingly,  the  rarely  occurring  individuals  with  extraordinary  high 
plasma cholesterol levels (up to 1000 mg/dl, 26 mmol/l) could have proved 
the Anitschkow's case. As early as in 1889, Lehzen and Knauss8 had reported 
case studies of children with xanthomas, large deposits of lipids just beneath 
the skin or attached to tendon sheaths on the backs of the hands or at the 
ankles. At that time, it was noted that a number of these children developed 
serious heart problems at a startlingly early age and the disease had high fa-
milial expression. These cases were, however, very rare, and xanthomas were 
much more commonly associated with liver disease or diabetes, or most com-
monly, found in healthy older human subjects. About twenty years later, and 
a few years before Anitschkow's results, Pinkus and Pick had found that the 
individuals with xanthomas have high plasma cholesterol levels and the lipids 
in xanthomas were cholesterol esters9. They also had suggested that the cho-
lesterol in the deposits originated from the blood and attached to tendons and 
vascular walls. It is impossible to say if Anitschkow was aware of these stud-
ies, and whether he had realised the value of these early studies to his results. 
Anyhow, the next interesting observations of xanthomas came from Carl 
Müller, a Norwegian professor of internal medicine, who in 1939 reviewed the 
concurrent familial expression of xanthomas, hypercholesterolemia and heart 
disease. He was also able to add observations of almost a hundred cases from 
almost 20 Norwegian families10. At the time, consanguineous marriages were 
still fairly common in some isolated communities in Norway increasing the 
prevalence of the rarely occurring individuals with high plasma cholesterol 
levels  with the  classical  xanthomas of  skin  and tendons.  Professor  Müller 
concluded in his now-classical paper10 that:
“The  reports  I  have  presented  confirm  the  previous  observations  on 
xanthomatosis as a cause of hereditary heart disease. They reveal further that the 
syndrome of cutaneous xanthomatosis, hypercholesterolemia and angina pectoris  
presents itself as a well defined clinical entity. There can be hardly any doubt but  
that xanthomatous deposits in the coronary artery and consecutive myocardial  
ischemia are the cause of the angina pectoris.”
Thus Müller stated that a familially occurring high plasma cholesterol level, 
or familial hypercholesterolemia, was the cause of heart diseases. Over the 
next twenty-five years, Müller's characterisation of familial  hypercholester-
olemia borne out a series of extensive studies which established familial hy-
percholesterolemia as a monogenic defect implying that the arterial disease 
was secondary to the elevated blood cholesterol analogous to the pathogenes-
3
is of Anitschkow's rabbits11-13. Thus the linkage of hypercholesterolemia and 
cardiovascular disease was shown in human beings.
Discovery of lipoprotein particles – a competitor to the blood 
cholesterol
During the two first decades of 20th century, a number of researchers began to 
think  that  the  considerable  amount  of  cholesterol  molecules  should  be 
present in plasma either within some sort of emulsion particles or associated 
with proteins. The first definitive studies of these lipid transporters, which 
were named lipoproteins,  were reported by Macheboeuf  and colleagues in 
192914. Over the next 10 to 20 years, they succeeded in purifying and charac-
terising  a lipoprotein  from horse serum. During  World War  II,  Cohn and 
coworkers15 and Oncley, Scatchard and Brown16 at Harvard developed large-
scale  methods  to  fractionate  human serum to  provide  materials  useful  in 
treating wounded. The method turned out to be useful also in lipoprotein re-
search since the developers noticed that human serum contained not one but 
two major lipoprotein fractions named α- and β-lipoproteins which were later 
on  called  high-density  lipoproteins  (HDL)  and  low-density  lipoproteins 
(LDL),  respectively.  At  the time, nothing was known about the origin,  the 
fate, or the biological significance of lipoprotein particles but they were soon 
associated with the development of atherosclerosis. In 1951, Russ, Eder and 
Barr17 used the methods developed in the Cohn/Oncley laboratory and found 
that women before menopause had consistently higher blood levels of the α-
lipoproteins than men. The authors speculated that the difference may ex-
plain the lower incidence rate of coronary artery disease (CAD) in pre-meno-
pausal women. In retrospect, this view is still currently supported but even 
more importantly, Russ, Eder and Barr brought new perspective on athero-
sclerosis  research  by  suggesting  that  different  lipoprotein  fractions  might 
have distinct biological functions and that there may be a linkage between 
specific lipoprotein patterns and the risk of coronary artery disease. 
The results of Russ, Eder and Barr induced questions about the total num-
ber of different lipoprotein particles and their function in human beings. The 
man who was to answer several of these questions was John W. Gofman. Gof-
man's  background was appropriate to enhance the lipoprotein and athero-
sclerosis research; he had roots both in medicine and physics, and he was 
thus able to apply methods and ideas from one field to another. Gofman was 
also  familiar  with Anitschkow's  work which he,  unlike  most  others at  the 
time, took very seriously. Anitschkow's work, together with the limited genet-
ic, biochemical and epidemiological evidence available, had convinced Gof-
man that  blood cholesterol  was centrally important in the development of 
4
atherosclerosis. 
Gofman was also familiar with a technique called analytical ultracentrifuga-
tion which was developed by Theodor H. E. Svedberg in Sweden. The method 
proved to be invaluable for characterising proteins and measuring their mo-
lecular sizes and relative concentrations in mixtures. Gofman wanted to see if 
this  methodology could be used to  separate  lipoprotein particles  and pur-
chased an ultracentrifuge, which was the second of its kind, in his laboratory 
in California. It turned out that the analytical centrifuge was indeed useful in 
characterising lipoproteins18. After a while, Gofman with his colleagues Frank 
T. Lindgren and Harold Elliot managed to devise an accurate and reprodu-
cible  way to  separate  lipoproteins in plasma into fractions and to  reliably 
measure their amounts in mass units. This was a breakthrough in lipoprotein 
research and enabled Gofman and his  colleagues to study the relationship 
between coronary artery disease and not just total  cholesterol but also the 
amounts of the lipoprotein particles that carried that cholesterol. Gofman and 
his colleagues believed that it mattered a great deal in which lipoprotein frac-
tions the blood cholesterol was carried, and in 1950 they presented prelimin-
ary data on a limited number of patients suggesting that the Sf 10-20 fraction 
was particularly pro-atherogenic19.  This  fraction corresponds closely to  the 
so-called  intermediate  density  lipoprotein  (IDL)  particles  which  are  also 
today realised to be strongly pro-atherogenic20-23. 
A few years later, Gofman and his colleagues published a formula, a  lipo-
protein index24, to weight the different lipoprotein classes according to their 
atherogenicity. Gofman and his colleagues suggested that the different classes 
of lipoproteins should be weighted differently in estimating the risk of coron-
ary  artery  disease  using  this  atherogenic  index.  However,  the  number  of 
samples on which the conclusions were based was quite small,  and thus a 
large prospective study was needed to make the case. There were, however, 
various problems on the way: large prospective studies would require hun-
dreds of blood samples and there were only two analytical ultracentrifuges in 
the  country,  ultracentrifuges  were  extraordinary  expensive  and technically 
difficult to operate and National Institutes of Health (NIH) had turned down 
Gofman's grant application. The study25 was, however, done in collaboration 
with three other laboratories supported by a large grant from NIH. Unfortu-
nately, the attempt fell into technical problems with the analytical ultracentri-
fuge; after the study had already begun, Gofman noticed a technical glitch in 
his methodology but could correct it. However, by that time, a large number 
of samples had already been used up or there was not enough left to reanalyse 
them. As a result, the final report from three of the four participating laborat-
ories had to be based on the original method only, whereas the results from 
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Donner laboratory, where Gofman was working, were corrected and reported 
in both the original and the revised, more accurate form. The final report25, 
published in 1956, contained two formal Discussion sections, one for Donner-
's laboratory and the another for the three other laboratories dividing the au-
thors into two parties.  The original  report  suggested that  the total  plasma 
cholesterol level and lipoprotein particle amounts were equally good predict-
ors of coronary artery disease risk while the researchers in Donner laboratory 
favoured the lipoprotein measures. 
The study was epochal in many ways. Before the study, the battle had been 
between researches who either believed or disbelieved that cholesterol mo-
lecules have a key role in the development of atherosclerosis. Now, the believ-
ers were also divided into two parties, the ones who had faith in plasma cho-
lesterol levels and the ones who became interested in lipoprotein particles as 
predictors of the risk of coronary artery disease. Thus among the lipoprotein 
believers, the work of Gofman and his colleagues induced a huge increase in 
research on the plasma lipoprotein particles and their relationship to athero-
sclerosis.
High blood cholesterol strengthens its role in the development of 
atherosclerosis
At the  same time as  Gofman was  working  with lipoproteins,  the National 
Heart Institute was carrying out a study in the small town of Framingham, 
Massachusetts,  and  the  study  became  known as  The  Framingham  Heart 
Study26-28,  the most impacted single epidemiological study in atherosclerosis 
research. At the time, a large majority of the 28 000 residents of Framingham 
agreed to participate in the study which was designed to gather large-scale in-
formation on most of the potentially relevant factors of coronary artery dis-
ease known at the time. In later years, additional measurements were added 
as more was learned about atherosclerosis and the study is actually continu-
ing actively to this day studying the offsprings of the original cohort29.
The first article of the Framingham project was published in 195728 after 
four years of follow-up, and papers have been published on the project after 
that almost annually. The Framingham Heart Study was the first to provide 
solid and unarguable evidence that individuals with higher blood cholesterol 
levels are more likely to experience a heart attack. However, the Framingham 
study was also the first to show that several other factors than high plasma 
cholesterol, such as high blood pressure and smoking, may increase the risk 
of atherosclerotic heart disease at least in additive manner. 
The cholesterol believers were not, however, completely pleased with the 
results. Daniel Steinberg described the feelings after the first results from the 
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Framingham project is his historical review30 as: 
“What was needed was an intervention trial, a controlled experiment that would  
show that lowering cholesterol levels as a single variable could reduce coronary 
risk. However, safe and effective drug treatment for hypercholesterolemia was  
still some way down the road, and the effectiveness of manipulating dietary fat  
was only becoming clear in the late 1950s.”
The era of large-scale clinical dietary intervention trials was beginning at the 
time encouraged by the results of the Framingham Heart Study. 
Diet-heart hypothesis and dietary studies
When coming to the 1960s, American Heart Association, whose goal is to pre-
vent and reduce the incidence of cardiovascular disease in the United States, 
was convinced about a causal relationship of increased blood cholesterol and 
atherosclerotic heart disease31. The American Heart Association also recom-
mended, based on limited, small sized dietary trials at the time, that people at 
high risk should be advised to modify their diet to avert heart attacks. Inter-
estingly, however, the modifications concerned the amount and, even more 
interestingly, the quality of fatty acids rather than the amount of cholesterol 
in diet. Some years later these recommendations were extended to include 
the general public. These recommendations became known among researches 
as a so-called  diet-heart hypothesis;  eating less saturated fats lowers serum 
cholesterol levels, and the lower serum cholesterol leads to a reduced risk of 
heart attacks. 
Some investigators took the chance to test the effect of the diet-heart hypo-
thesis. Obviously, the freshly started studies would take years before publi-
cising and thus Ancel Keys, a pioneer in nutritional research, who had been 
convinced much earlier that blood cholesterol level was determined signific-
antly by the amount and the nature of the fat in the diet32, hurried to publish 
his results first.  The study,  The Seven Countries Study33,  was published in 
1966.
In the late 1940s, Keys, with his colleagues, had decided to launch an am-
biguous  study  to  test  the  hypothesis  that  populations  with  high  fat-diets 
should  have  higher  blood cholesterol  levels  leading  to  higher heart  attack 
rates than other populations. Keys and his colleagues selected seven countries 
which spanned the full range of blood cholesterol levels. These countries in-
cluded Japan,  Yugoslavia,  Italy,  the  Netherlands,  Finland,  Greece and the 
United  States.  In  each country,  blood samples  were  drawn for  cholesterol 
measurements, the nature of diet was determined by a questionnaire and the 
coronary artery disease death rate (per 1000 men over 10-year period) was 
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then correlated with these two variables. It turned out that when coronary 
artery death rate was plotted against the blood cholesterol levels for all the 
seven  countries,  the  data  points  fell  roughly  on  the  same  straight  line, 
strongly suggesting that the population risk was roughly proportional to the 
blood cholesterol level over the range of values studied33. Similarly, the blood 
cholesterol concentrations plotted against the contribution of saturated fats 
to the daily calorie intake fell roughly along a straight line33. Thus, taken to-
gether, the data showed that the population risk of fatal  heart attacks was 
proportional to the blood cholesterol level, which was, in turn, proportional 
to the dietary intake of saturated fats.
The  relationship between saturated  fats  and blood cholesterol  level  was, 
however, only correlational, although strong, and thus it could not establish 
causality. Conceivably, genetic differences or other differences in living habits 
might be the true explanation for the correlation.  Keys and his  colleagues 
were aware of this limitation in their study design. At the same time, a group 
of researchers in Hawaii investigated Japanese immigrants in Hawaii and San 
Francisco and compared them with native Japanese living in Japan34.
Hawaii and San Francisco have a very large population of Japanese immig-
rants who have lived in their new home country only a few generations and 
thus their gene pools could not have changed significantly. The investigators 
determined the blood cholesterol levels and heart attack rates of these Japan-
ese immigrants and compared them with the same measures in native Japan-
ese in Japan. The result was striking: The Japanese who had moved to Hawaii 
had higher cholesterol levels and heart attack rates than the Japanese in Ja-
pan34. The difference was even more striking in those who had settled in San 
Francisco. Since these results could not be explained by genetic factors, the 
rise in blood cholesterol levels and the accompanying increase in heart attack 
rates following the migration must have been due to environmental factors, 
most likely changes in dietary habits34. 
The results of several dietary intervention trials, which were started after 
the first results of the Framingham Heart Study, became available a few years 
later. Three studies in particular – the Leren Oslo Study35,  the Wadsworth 
Veterans Administration Study36 and the Finnish Mental Hospital Study37, 38 – 
confirmed the results  from The  Seven Countries  Study that  saturated fats 
tend to increase the serum cholesterol levels but also showed that diets rich in 
polyunsaturated  fat  could  significantly  lower  the  serum cholesterol  levels. 
Thus it became clear that the quality of dietary fats has a marked effect on 
blood cholesterol levels.
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Associations between lipid and lipoprotein variables – lipoprotein 
phenotypes
Work  on  the  association  of  lipoproteins  with  atherosclerosis  was  also 
proceeding;  Donald S.  Fredrickson, working at  NIH, was convinced of the 
correctness  of  Gofman's  view  that  patterns  of  lipoproteins  might  contain 
valuable information beyond the measurements of the component lipids only, 
namely  plasma  or  serum  levels  of  cholesterol  and  triglyceride  molecules. 
Fredrickson  was,  however,  also  aware  that  Gofman's  method,  analytical 
ultracentrifugation, was just too complicated and expensive for clinical use. 
Fredrickson felt that it was important to bring easier methods to the clinics 
and got soon familiar  with a technique called paper electrophoresis  which 
was introduced to him by his young colleague. Fredrickson immediately saw 
the enormous clinical potential of the method; Paper electrophoresis could 
separate  the  lipoprotein  classes,  based  on their  mobility,  to  four  different 
bands39. In the following years, Fredrickson and this colleagues studied and 
classified lipoprotein patterns of hundreds of patients referred to the Clinical 
Centre at NIH and found that most of them could be classified into one of five 
or six lipoprotein types, or phenotypes40-43, as shown in Table 1.1. 
Table 1.1 Fredrickson's phenotypes
C, cholesterol; TG, triglyceride; CM, chylomicrons; LDL, low-density lipo-
proteins;  VLDL,  very low-density  lipoproteins;  IDL,  intermediate-density  
lipoproteins. 
At the time Fredrickson was formulating the lipoprotein phenotype classi-
fication with his colleagues, it was known that also triglyceride molecules, in 
addition to cholesterol molecules, are located within lipoprotein particles and 
that there are two classes of lipoproteins which are specialised in transporting 
these triglycerides, namely chylomicrons and VLDL particles. Thus, Fredrick-
son's  classification of  hyperlipidemias related both plasma cholesterol  and 
triglyceride levels to increased relative numbers of specific lipoprotein frac-
tions and could also distinguish several  new familial  syndromes with high 
plasma triglyceride levels. The phenotypes which were classified as the most 
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atherogenic were the ones containing elevated IDL or LDL particles in ac-
cordance with the results of Gofman and his coworkers some years earlier.
Fredrickson's phenotyping of lipoproteins was warmly welcomed in clinical 
practice in the United States and also abroad. In addition, World Health Or-
ganization (WHO) recommended the lipoprotein  phenotyping  system as  a 
worldwide standard in 1970. It was,  however,  obvious from the beginning 
that the phenotypes were neither homogeneous entities nor true genotypes 
but were frequently secondary to other, although unknown, conditions. The 
phenotyping system had, though, an important role in lipoprotein research 
since it introduced lipoprotein particles to physicians. The designation of in-
dividuals into the Fredrickson's phenotypes was also the first step toward bet-
ter diagnosis and management of hyperlipidemia; there were unique clinical 
features in each phenotype, different responses to both diet and drug regi-
mens as well as important differences in the complications of the hyperlip-
idemia and in familial expression.
When entering  into  1970s,  Fredrickson  and  his  colleagues  continued  to 
make the lipoprotein phenotyping system more practical.  At  the time, the 
electrophoretic measurements were performed in local or regional laborator-
ies and the diagnoses of the printouts, which were sent to the practitioners, 
were regularly poor in identifying Fredrickson phenotype III with high IDL. 
The phenotype, although rare, brought a lot of attention once recognised and 
treated since the condition was highly atherogenetic with visually observable 
xanthomatous skin deposits which melted away within a few weeks of proper 
treatment. The practitioners were becoming, however, annoyed by the situ-
ation which led Fredrickson and his colleagues to search of algorithms and 
other tools for the use of practitioners with minimum extra laboratory analys-
is. 
Friedewald's formula – a transform from lipoproteins to lipid 
variables
At the same time, various laboratories were publishing average compositions 
of VLDL particles (see, for example,44 and references therein). Using these 
compositions and observations made from hundreds of patients with high 
plasma triglyceride levels, Fredrickson and his colleagues were searching a 
way to estimate LDL particle concentrations45.  The main idea of Fredrickson 
and his colleagues was that the ratio of triglyceride to cholesterol molecules in 
VLDL particles was constant. Thus the amount of cholesterol molecules in 
VLDL particles could be estimated by their triglyceride content. Fredrickson 
and his colleagues also observed that in the absence of chylomicrons most of 
the triglycerides in plasma were in VLDL particles. Thus the amount of VLDL 
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triglycerides in plasma could be approximated by the plasma triglyceride con-
centration.
These estimations yielded the most well known formula in predicting the 
cholesterol content in LDL particles. The concentration of LDL cholesterol 
can be estimated by the difference of total cholesterol and cholesterol content 
in  other  lipoprotein  particles,  such  as  HDL  and  VLDL  particles,  namely,
c LDL−C=c totalC−cHDL−C−
cTG
2.2
, (1.1)
where  cLDL−C and  cHDL−C  are  the concentration of  cholesterol  in 
LDL and in HDL particles, respectively, and c totalC  and cTG  are the 
concentration of plasma total  cholesterol and triglycerides,  respectively,  in 
mol/l21, 46. The last term in this equation represents the concentration of cho-
lesterol in VLDL particles. The formula is called Friedewald's formula46 in the 
honour of biometrics expert, William Friedewald, who checked the validity of 
the formula for Fredrickson and his colleagues. Use of the equation was re-
stricted to individuals with less than 4.5 mmol/l of plasma triglycerides21, 46. 
This  equation became popular because it  utilises  variables which can be 
easily measured in any laboratory. The equation is also pretty good in estim-
ating ultracentrifuged LDL cholesterol although it tends to overestimate the 
LDL cholesterol in individuals with elevated IDL cholesterol levels21. Beyond 
the  success in  LDL cholesterol  estimation,  the  purpose  of  the model  was, 
however, to find a way to estimate LDL particle concentration indirectly via 
calculated LDL cholesterol concentration. The quality of this estimate, to the 
best of the author's knowledge, has not been published. The good correlation 
between calculated and experimental LDL cholesterol measures was incor-
rectly thought to prove the case. Thus, despite the work of Gofman and his 
colleagues as well as the improvements in lipoprotein research by Fredrick-
son, this estimate of particle concentrations led part of the lipoprotein believ-
ers from the lipoprotein values back to the lipid values. This time the term 
total plasma cholesterol was only replaced by the word LDL cholesterol.
Progress in atherosclerosis research 
Anitschkow's  work became slowly  acknowledged:  In  the  1930s,  lesions  in 
cholesterol-fed rabbits  and in human coronary arteries  were noticed to  be 
similar in most respects47. In the 1950s, the accumulation of cholesterol and 
other lipids in lesions was found to be one of the most striking morphologic 
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features of  both human and experimental  cholesterol  atherosclerosis48 and 
macrophages laden with lipids were observed in the vessels of cholesterol-fed 
rabbits49. In the 1960s, smooth muscle cells were detected as the predominant 
cell type in larger lesions and some of these smooth muscle cells were found 
to contain lipid droplets50. In the 1970s lesions in rabbits and in non-human 
primates were perceived to regress when hypercholesterolemic diet was dis-
continued51, 52.
In the late 1960s and early 1970s, the research of the development of ather-
osclerosis among pathologists was directed to the role of smooth muscle cells. 
Two hypotheses of the initiation and the development of atherosclerosis were 
proposed and became widely accepted. Interestingly, the hypotheses were not 
based on hypercholesterolemia although high plasma cholesterol was accep-
ted as a primary causative factor of atherosclerosis by the American Heart As-
sociation31 just a few years earlier. These two hypotheses were proposed by 
Earl Philip Benditt and John M. Benditt (group 1) and Russell Ross and John 
Glomset (group 2) working in the same department at the University of Wash-
ington, and the hypotheses were named as the monoclonal hypothesis53 and 
the response-to-injury hypothesis54, 55, respectively, both published initially in 
1973.
Benditt and Benditt proposed that the smooth muscle cell accumulation in 
any given localised atherosclerotic  lesion originated from a single cell  that 
had, for some reason, been triggered to grow rapidly to become a tumour of 
no danger to health53. In the same year, Ross and Glomset were studying cul-
tured smooth muscle cells when they suddenly found the missing piece in 
their colleagues' study: a growth factor56. Ross and Glomset found that serum 
from  blood  that  had  been  allowed  to  clot  contained  a  growth  factor  for 
smooth muscle cells that was absent in serum separated from whole blood 
not allowed to clot. Thus, the growth factor was evidently present in platelets 
and was released when the platelets aggregated. Ross and Glomset combined 
this observation with the existing evidence that mechanical injury to the en-
dothelium could lead to platelet aggregation and thickening of the inner layer 
of the vessel  walls.  Thus,  the response-to-injury hypothesis54,  55 stated that 
some still-unidentified form of insult occurs to the arterial endothelium, part 
of endothelium erodes and exposures underlying matrix to which platelets 
adhere and release growth factor(s). The growth factor(s) access the cells in 
the subendothelial space and stimulate smooth muscle cell proliferation. Re-
petition of such injuries over years, or chronic injuries, then led to complex 
lesions. The hypothesis was further developed so that the type of the injury 
was changed from mechanical to functional57, 58 after the endothelium overly-
ing the initial lesion was found unaltered49, 59-61. Later on, Ross reviewed the 
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factors which might be responsible for the  injury to endothelium and men-
tioned hypercholesterolemia in this context with the same weight as homo-
cysteinemia,  hypertension,  infection  and  some  other  potential  pro-inflam-
matory factors57. 
The mystery of familial hypercholesterolemia and an LDL-
receptor
Also the research branch of lipoprotein particles, initiated by Gofman and his 
colleagues and continued by various researches including Fredrickson, was 
proceeding further. Fredrickson's phenotyping had been strictly phenotypic 
and  little  was  known about  the  origin  and the  metabolism of  lipoprotein 
particles or their relationships to one another. The mechanisms behind Fre-
drickson's phenotypes remained unknown, and it was unclear to what extent 
the phenotypes were genetically determined. However, the situation was go-
ing to change. It was established in 1973 that the relationships of myocardial 
infarctions with elevated plasma triglyceride and/or plasma cholesterol con-
centrations were complex. In a few cases the disorders were monogenic and 
inherited in a Mendelian fashion. In many families hypercholesterolemia was 
genetically determined but involved multiple genes and, finally, there were 
multiple cases where elevated triglyceride levels appeared not to be genetic62-
64. The accordance of this new classification with Fredrickson's phenotyping 
was poor; sometimes two or more phenotype patterns appeared from a single 
genetic disorder. Over the next few years, the new classification system was 
confirmed and revised by more sophisticated studies of lipoprotein metabol-
ism and improved methods of genetic analysis. 
The time seemed right for two forthcoming Nobel Prize winners, Joseph L. 
Goldstein and Michael S. Brown, to solve the mystery of familial hypercholes-
terolemia which had been popping out once in a while in the history of ather-
osclerosis research. These two men had sought the opportunity to work to-
gether for years and their collaboration got under way at Southwestern Med-
ical School at the University of Texas Health Science Center in Dallas from 
the beginning of 1970s and the collaboration is actually still going on after al-
most forty years!
Goldstein and Brown wanted  to  investigate  metabolic  diseases and both 
were  intrigued  by  the  still-mysterious  disorder,  familial  hypercholester-
olemia. At the time Goldstein and Brown started their collaboration, it was 
known that individuals with familial hypercholesterolemia had high lipopro-
tein levels, particularly LDL particles43, 65, and had a high prevalence of ather-
osclerosis10. It was also known that the disease was caused by a single gene 
mutation10, 12, 13, 66 although the target gene was still unknown. Thus, Goldstein 
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and Brown started their search with the rate-limiting enzyme in the synthesis 
of  cholesterol,  3-hydroxy-3-methylglutaryl-Coenzyme  A  (HMG-CoA)  re-
ductase, that had recently been partially purified and characterised by Brown 
with his colleagues67. Goldstein and Brown hypothesised that the cells in indi-
viduals with familial hypercholesterolemia might be producing cholesterol at 
an abnormally high rate secondary to a genetic flaw in the reductase enzyme 
or in its regulation and planned a series of studies to confirm the hypothesis.
Goldstein and Brown decided to test their hypothesis by growing cells in 
culture.  Since  the  fundamental  role  of  the  liver  in  lipid  metabolism  was 
already known68,  the obvious choice of cells to grow would have been liver 
cells. The human liver cells were not, however, available and thus Goldstein 
and Brown chose human skin fibroblasts  which were recently  successfully 
used  to  discover  and  characterise  several  gene  abnormalities  underlying 
metabolic disorders. They planned to assay the activity of the HMG-CoA re-
ductace enzyme and take that as a measure of the rate of cholesterol synthes-
is. 
In their very first set of experiments69, Goldstein and Brown found that nor-
mal cells grown in the presence of serum synthesised low amounts of choles-
terol.  However,  when  the  serum  was  removed  and  cells  were  incubated 
overnight in a simple, protein-free medium, the rate of cholesterol synthesis 
rose sharply, as much as 10-fold. In contrast, cells from individuals with fa-
milial hypercholesterolemia always showed a high rate of cholesterol synthes-
is, even in the presence of serum. Moreover, the addition of LDL to the medi-
um, which reduced synthesis 10-fold in normal cells, had absolutely no inhib-
itory effect on cells from individuals with familial hypercholesterolemia. The 
cells from individuals with familial  hypercholesterolemia did,  however,  re-
spond similarly as normal cells if pure cholesterol dissolved in alcohol was 
added to the culture medium instead of LDL particles. 
By 1972, it was known that the rate of cholesterol synthesis is suppressed by 
cholesterol  in  diet  and  that  cholesterol  synthesis  in  cultured  cells  is  sup-
pressed by cholesterol in the incubation medium. By using this knowledge, 
Goldstein and Brown deduced that they were visualising a system for regulat-
ing the synthesis of cholesterol that was faulty in individuals with familial hy-
percholesterolemia. In more detail, the defect was caused by one of the genes 
involved in the feedback regulation. Furthermore, the defective feedback reg-
ulation should have something to do with  internalisation of LDL particles 
since cells in individuals with familial hypercholesterolemia could not take up 
cholesterol when it  was offered as a component of LDL but could respond 
normally to cholesterol once it got inside the cells. 
These observations by Goldstein and Brown70-72 led to the birth of concepts 
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of  LDL-receptor and  LDL-receptor pathway  for internalisation mechanism 
for LDL particles and the regulation of cholesterol synthesis via the LDL-re-
ceptors, respectively (see Fig. 1.1). The discovery of LDL-receptors was a ma-
jor milestone in the lipoprotein field and beyond since it was the first trans-
port receptor of many to be characterised. Eventually, the LDL-receptor path-
way was characterised in detail: The amount of LDL-receptors at the cell sur-
face is regulated by the cellular cholesterol content and thus internalisation of 
cholesterol decreases the amount of the receptors as well as cell's own choles-
terol synthesis and increases the storage of cholesterol molecules as choles-
terol esters in the cytoplasm. Defective LDL-receptors, on the contrary, do 
not internalise lipoprotein particles at the normal rate leading to an increase 
in the number of IDL and LDL particles in plasma, and secondary in the level 
of plasma cholesterol,  and cause atherosclerosis in individuals with familial 
hypercholesterolemia.
Figure 1.1 LDL particles bind to LDL-receptors (LDL-R) at the cell surface 
and  become internalised  and  hydrolysed  in  lysosomes.  The  resulting  in-
crease in cellular cholesterol content decreases the LDL-receptor and cellu-
lar cholesterol synthesis and increases the cellular stores of esterified choles-
terol as cholesterol esters via action of acyl-CoA cholesteryl acyl transferase 
(ACAT).
The discovery of Scavenger receptor A
The discovery of LDL-receptors did, however, leave an open question of how 
increased numbers of IDL and LDL particles in plasma could cause athero-
sclerosis in individuals with familial hypercholesterolemia. It was clear that 
these individuals had defective LDL-receptors which caused decreased inter-
nalisation of IDL and LDL particles by most cells, and particularly cells in the 
liver. However, evidently these individuals had cells in xanthomas and in ath-
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erosclerotic  lesions  which  were  heavily  loaded  with  cholesterol  suggesting 
that the cells might be taking up cholesterol rapidly. Yet, since the LDL-re-
ceptors  were  defective  in  these  individuals  and  since  the  accumulating 
particles must be IDL and LDL particles, Goldstein and Brown deduced that 
these particles have to be internalised by some alternative mechanism(s) into 
xanthomas and atherosclerotic lesions.
By the end of the 70s, the lipid-loaded cells within atherosclerotic lesions 
were shown to be largely derived from circulating monocytes rather than pro-
liferated smooth muscle cells as suggested few years earlier. Goldstein and 
Brown tried to generate lipid-loaded cells in vitro by incubating mouse peri-
toneal macrophages or circulating monocytes with high concentration of LDL 
particles. The uptake of LDL particles was, however, low even with very high 
LDL particle concentrations73. Since Goldstein and Brown were convinced of 
the key role of LDL particles in the development of atherosclerosis in indi-
viduals with familial hypercholesterolemia, they reasoned that the circulating 
LDL particles must undergo some modifications and that the modified LDL 
particles could enter into the macrophages. The obvious question was then 
how the LDL particles should be modified in vitro to enhance their internal-
isation into the macrophages, and would this modification appear in vivo. 
Goldstein and Brown explored a number of chemical and enzymatic modi-
fications of LDL particles and found one, acetylation,  which worked: acet-
ylated LDL bound with high affinity to macrophages and was taken up rapidly 
by a receptor-mediated pathway leading to strikingly increased content of cel-
lular cholesterol73. Acetylated LDL were not, however, generated in vivo, and 
Goldstein and Brown considered it unlikely to occur at all  in vivo. The first 
step of this two-stage process was, however, proven: modified LDL particles 
are  internalised  by  macrophages  via  receptors  which  were  later  on called 
scavenger receptors A. The second part, the mechanism which modifies LDL 
particles in vivo remained, however, unknown. 
In  1979,  Henriksen,  Evensen  and  Carlander  in  Oslo74 and  Hessler, 
Robertson and Chisolm in Cleveland75 independently made an interesting ob-
servation which ultimately led to the discovery of modified LDL present also 
in vivo. The researchers found that cells cultured in the presence of LDL and 
in the absence of serum underwent severe damage leading to cell death with-
in 24 h. The cell death was, however, avoided by adding serum or high dens-
ity  lipoprotein  (HDL)  particles  in  the  culture.  In  1981,  Henriksen  et  al.76 
found that during the incubation, the LDL particles had drastically changed 
becoming more dense, more electronegative and, interestingly, becoming lig-
ands for receptor(s) on macrophages. This so-called endothelial cell-modified 
LDL was  found  to  increase  the  cholesterol  content  in  macrophages  suffi-
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ciently to give macrophages foamy appearance, i.e., forming foam cells. A few 
years later, Hessler et al.77 showed that the changes in LDL particles induced 
by  incubation  with  endothelial  cells  were  free  radical-catalysed  oxidative 
modifications. Steinbrecher et al.78 came independently to the same conclu-
sion with regard to the mechanism by which endothelial cells converted LDL 
particles into ligands for macrophage receptor(s). These and later findings led 
to the development of  the oxidative modification hypothesis of LDL where 
native LDL particles penetrate in the the vessel wall, become oxidised, start to 
attract  circulating  monocytes and inhibit  exit  of  monocyte-derived  macro-
phages. Finally, oxidised LDL is internalised by macrophages turning them 
into foam cells. Oxidised LDL particles were also suggested to damage en-
dothelial cells thus further enhancing the penetration of LDL particles in the 
vessel wall. This hypothesis is now strongly supported by both in vitro and in 
vivo evidence, and more than 3000 articles have been published about the 
role of oxidised LDL in the development of atherosclerosis as reviewed else-
where79-83. 
National programmes to treat individuals with high blood 
cholesterol
In the 1970s,  many of the experts in atherosclerosis and preventive cardi-
ology, and the American Heart Association, were convinced about the causal-
ity of elevated blood cholesterol and coronary artery disease. However,  al-
most none of the general practitioners and very few practising internists or 
cardiologists were paying very much attention to their patients'  high blood 
cholesterol  levels.  The  National  Institutes  of  Health  was  thinking  about 
launching a national program to enhance the treatment of individuals with 
hypercholesterolemia. Steinberg described the situation in his recent historic-
al review84 as:
“The  National  Institutes  of  Health  (NIH)  realized  that  launching  a  national  
program to treat high blood cholesterol levels would be enormously complex and  
expensive. They could not justify that expense without first having iron clad proof  
that treatment would work. In any case, the medical community would have to be  
convinced before it could be expected to make serious efforts to implement any  
proposed treatment programs.”
Thus, the National Institutes of Health initiated in the 1970s a well-designed, 
large-scale,  long-term,  double-blinded study to  demonstrate  the  impact  of 
treatment on coronary artery disease. At the time of the initiation of this so-
called  Coronary  Primary  Prevention  Trial  (CPPT)85,  86,  several  studies  had 
briefly mentioned the effect of dietary cholesterol consumption on the serum 
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cholesterol  level35-37.  The  majority  of  these  studies  suggested  that  the  de-
creased cholesterol content of the diet decreases serum cholesterol levels, but 
the effect is less impressive than the effect of saturated/unsaturated fat con-
tent. In CPPT, a drug called cholestyramine, which inhibits cholesterol ab-
sorption from small intestine, was used to investigate its effect on lowering 
blood cholesterol and on the incidence rate of coronary artery disease. Thus 
CPPT was the first study to evaluate the role of absorbed cholesterol per se on 
plasma cholesterol concentrations and coronary artery disease without co-op-
erative action of all dietary fats. The study population included approximately 
3800 men with ages  between 35  and 59 and without  history  of  coronary 
artery disease or signs of current coronary artery disease. All the men had a 
high  baseline  blood  cholesterol  level,  more  or  equal  to  265  mg/dl  (6.8 
mmol/l) representing the highest 95 % of men of that age. The men received 
either cholestyramine or placebo. In addition, the amount of dietary choles-
terol was slightly reduced in both groups. After an average of 7 years of treat-
ment, the blood cholesterol level in the cholestyramine-group was decreased 
13 % and LDL cholesterol 20 %. The number of  events  (definite  coronary 
artery disease death and/or nonfatal myocardial infarction i.e., heart attack) 
was 19 % lower in the cholestyramine-group than in the placebo-group and 
the difference was, for the first time, significant (p< 0.05). The two groups 
did not, however, differ in total mortality. 
The reception by professionals and by the press was mainly positive, and 
the major medical journals around the world hailed the results of the trial as 
finally providing the rationale for treating hypercholesterolemia87-89. After the 
results were published in 1984, the National Institutes of Health held a Con-
sensus  Development  Conference  on  lowering  blood  cholesterol  to  prevent 
heart disease. Fourteen experts were invited to join a panel of the conference 
and,  after  reviewing  all  essential  parts  of  the  research  and  after  having 
presentations and general discussions, the panelists voted unanimously that 
the causal relationship between blood cholesterol and coronary artery disease 
was established and that they were convinced that reduction of blood choles-
terol level could prevent coronary artery disease. 
The panelists also gave recommendations to prevent coronary artery dis-
ease90. The recommendations included desirable upper limits for blood total 
cholesterol concentration for individuals of all ages as well as advice to exer-
cise, to reduce total calories to maintain normal body weight, to reduce total 
calories from dietary fat to 30 % (less than 10 % from saturated fats) and re-
duce dietary cholesterol intake to less than 300 mg. The panellists also ad-
vised that a national program should be established to educate both physi-
cians and the public on the importance of controlling cholesterol levels. The 
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program was officially launched in 1985 as the National Cholesterol Educa-
tion Program (NCEP). The most important contribution of NCEP, in addition 
to providing education,  was to  propose guidelines for diagnosis  and treat-
ment: at what level of LDL cholesterol would dietary intervention be indic-
ated and at what level would the use of drugs be warranted. In 1988, the first 
Adult Treatment Panel (ATP I) of NCEP published its detailed guidelines for 
detecting, evaluating, and treating high serum cholesterol levels in adults91. 
These guidelines identified LDL as the primary target for lowering cholester-
ol. The guidelines quickly became the gold standard on who to treat and how 
to treat. Many other countries followed the United States lead and convened 
expert groups to develop their own guidelines which were remarkable similar 
to those of NCEP.
Statins - the miracle medicines? 
At the time the first adult treatment panel was preparing its statements, a 
new cholesterol lowering drug was cleared for use by the Food and Drug Ad-
ministration in the United States84. The drug was called lovastatin. Interest in 
pharmacological approaches to lower plasma cholesterol levels had begun as 
early as the 1950s, years before the time plasma cholesterol level was shown 
to  impact  the  incidence  of  atherosclerosis  and  coronary  artery  disease. 
However, the race of the first commercially marketed statin started in the 
1980s, after introduction of the very first statin, mevastatin, in the late 1970s 
by a Japanese researcher Akira Endo.
The story of statins began in 1971 in the pharmaceutical company Sankyo 
Co. in Tokyo, where Akira Endo speculated that the broths in which fungi 
were being grown in hunt for new and better penicillin just might also contain 
natural inhibitors of cholesterol synthesis. Endo himself said later on that he 
hoped  that  some  micro-organisms  might  “produce  such  compounds  as  a 
weapon in the fight against other microbes that required sterols or other iso-
prenoids  for  growth”92.  These  thoughts  of  Endo  were  clearly  inspired  by 
Fleming's discovery of penicillin in 192893, 94 but were not directly supported 
by the knowledge of the time. Endo was, however, stubborn with this and 
kept testing for more than 6000 broths within two years with his colleagues. 
It was, however, worthwhile since they finally came up with a promising com-
pound!
In 1976, mevastatin was isolated, characterised and published95, 96. Interest-
ingly, shortly after the publication, Brown and Goldstein became aware of En-
do's paper and asked Endo for a sample to study regulation of cholesterol bio-
synthesis. Endo sent the samples and the three men met in Dallas in 1977. 
Endo, Goldstein and Brown found that their experiments on the compound 
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were concordant and published the results97 jointly in 1978 giving grounds to 
what we know now about statins. Endo's compound did not, however, ever 
reach the commercial market since Sankyo Co. dropped its million dollar pro-
ject without any public explanation.
Mevastatin belonged to a family of molecules called statins. Currently there 
are  several  different  statin  compounds  including  atorvastatin,  fluvastatin, 
lovastatin,  pitastatin,  pravastatin,  rosuvastatin and simvastatin.  Statins in-
hibit cholesterol synthesis in the liver and decrease plasma cholesterol levels. 
Statins are also called HMG-CoA reductase inhibitors since they inhibit the 
action of HMG-CoA reductase, a rate-limiting enzyme in cholesterol synthes-
is95-98. The inhibition results from competition of the action of HMG-CoA re-
ductase between structurally similar statin and HMG-CoA molecules which 
are precursors of cholesterol. The decreased cholesterol synthesis leads to in-
creased synthesis or recycling of LDL-receptors in the liver98-100 and increased 
uptake of LDL particles from the circulation. In addition to the quantitative 
effects of statins on LDL particles, they have also shown to affect the quality 
of LDL particles by increasing their size in individuals with preponderance of 
small LDL particles101. 
The effect of statins to lower LDL cholesterol was first studied in large scale 
in 1994102, and it turned out that statins are much more efficient than any oth-
er earlier drug or dietary manipulation. In the study, designed as the Scand-
inavian Simvastatin Survival Study (4S)102, 4444 patients with coronary artery 
disease and hypercholesterolemia were randomised to placebo or simvastatin 
(20 mg/day) and followed for five years. In the statin group, LDL cholesterol 
was  lowered  by  35  %  and  total  cholesterol  by  25  %.  Total  mortality,  the 
primary end point of 4S, was reduced by 30 % and all other coronary end 
points by 30 to 40 % relative to the placebo group. For the first time in the 
history of cholesterol lowering trials, the total mortality was significantly de-
creased due to the actions taken to decrease plasma cholesterol levels.  The 
results of the 4S study were quickly confirmed and extended by two other 
studies103, 104 showing that patients with history of coronary artery disease be-
nefit from the statin treatment. 
Individuals without history of coronary disease also seem to benefit from 
statins. In the West of Scotland Coronary Prevention Study105, 6595 men with 
hypercholesterolemia on pravastatin lowered their LDL cholesterol by 26 % 
and the primary end point, coronary death or nonfatal myocardial infarction, 
was reduced by 31 % relative to placebo group. In the Air Force/Texas Coron-
ary Atherosclerosis Prevention Study106,  6605 middle-aged individuals with 
average baseline total and LDL cholesterol (5.71 ± 0.54 mmol/l and 3.89 ± 
0.43 mmol/l, respectively) and below-average HDL cholesterol (0.94 ± 0.14 
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mmol/l for men and 1.03 ± 0.14 mmol/l for women) reduced their LDL cho-
lesterol by 25 % on lovastatin. The first acute major coronary events were re-
duced by 37 % in the lovastatin group compared to the placebo group. Thus, 
the first wave of statin trials taught us that individuals with multiple charac-
teristics will benefit from statin therapy. 
By the end of 1990s, the Cholesterol and Recurrent Events (CARE) Trial103, 
107 suggested that there might be a threshold of LDL cholesterol at about 3.2 
mmol/l below which reducing cholesterol would not reduce the risk of CAD. 
However, the Heart Protection Study108 showed that reducing LDL cholesterol 
from less than 3 mmol/l to less than 2 mmol/l reduced events as efficiently as 
earlier studies with higher LDL cholesterol levels. The results were confirmed 
by several other studies109, 110.
Recently, efficacy and safety of statins were discussed in a meta-analysis of 
14 statin trials with a total of 90 056 individuals111. It stated: 
“Statin therapy can safely reduce the 5-year incidence of major coronary events,  
coronary revascularisation, and stroke by about one fifth per mmol/L reduction 
in  LDL  cholesterol,  largely  irrespective  of  the  initial  lipid  profile  or  other  
presenting characteristics. The absolute benefit relates chiefly to an individual’s  
absolute  risk  of  such  events  and  to  the  absolute  reduction  in  LDL  cholesterol  
achieved.  These  findings  reinforce  the  need  to  consider  prolonged  statin  
treatment with substantial LDL cholesterol reductions in all patients at high risk  
of any type of major vascular event.”
In other words, LDL cholesterol lowering achieved by statins benefits all indi-
viduals in risk largely irrespective of their initial lipid profile.  This view has 
raised arguments of overusage of statins3 and even accusations of unscientific 
interpretation of cholesterol lowering trials3, 112. These accusations are mainly 
directed to the use of relativeness in reporting the incidence rates of coronary 
artery disease between the statin and placebo groups. For example, it is com-
mon to argue that statins have “reduced coronary artery disease risk by 30-
40 % in the 5 years statin studies”113. This 30-40 percent does not mean that 
30-40 percent  of  individuals  on statins  have  been saved from a  coronary 
event because of the statins. The figure means that statin trials have shown 
30-40 %  difference  in  the  incidence  of  coronary  end  points  between  the 
groups. For example, in the Anglo-Scandinavian Cardiac Outcomes Trial – 
Lipid lowering arm (ASCOT-LLA) study109 the rate of coronary events (either 
fatal CAD or non-fatal myocardial infarction) was 36 % after 3.3 years follow-
up. The rate of adverse events was 1.9 % in the group of patients taking ator-
vastatin (10 mg/day, 5168 individuals) and 3.0 % in the placebo group (5137 
individuals). The absolute risk reduction was 1.1 percentage units in the study 
and the relative risk reduction was 3.0 % minus 1.9 % over 3.0 % giving 36 %. 
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While 1.9 is 36 % less than 3.0, only 1.1 % of individuals on statin treatment 
actually did benefit from the treatment. In other words, for each 91 individual 
who took the drug, 1 did and the 90 did not benefit from statins in this study. 
Universally,  the number of individuals who would need to be treated with 
statins in order for one patient to get the expected benefit, i.e., to be saved 
from a coronary event, is 30 to above 100 after approximately five years treat-
ment112.  This  figure seems astonishing since statins  are  often presented as 
medicines which will save our lives113-115. This does not, however, necessarily 
mean that statins are inefficient. They may be to some extent misused due to 
inability to identify the individuals who would benefit most from the statins116, 
117 but maybe also due to low dosage113, old starting age113, early evaluation of 
the effects113, and multiple variables beyond LDL cholesterol influencing the 
treatment effect118. We may simply need more research on this including more 
detailed characterisation of patient's lipoprotein particles.
1.2 The state of the art in atherosclerosis and lipoprotein 
research 
Atherosclerosis is recognised as a systemic, progressive disease and its devel-
opment begins at early age119. It is also a multi-factorial disease affected by 
both genetic and lifestyle factors1. Atherosclerosis has been characterised by a 
complex interplay between cholesterol accumulation and chronic inflamma-
tion leading, via a series of biological responses, to appearance of hard depos-
its called plaques in the arterial wall1, 119, 120. These plaques increase in time due 
to  ongoing  cholesterol  accumulation,  migration  of  monocytes  and  smooth 
muscle cells into the plaques, and formation of smooth muscle cell-derived 
fibrous elements. The increasing size of the plaques narrows down the artery 
lumen and may reduce flow of oxygen-rich blood in the artery. The narrowing 
of the artery may also be compensated by aneurysms, local enlargements of 
the artery, leading to thinner arterial wall and possible arterial ruptures121, 122. 
Plaques may also rupture or erode forming blood clots before becoming large 
and occlusive leading to acute vascular events and insufficient oxygen supply 
to the tissues and organs119. Atherosclerosis is typically asymptomatic for dec-
ades119 but may eventually  cause severe diseases, including coronary artery 
disease119 and carotid artery disease123,  and may lead to subsequent clinical 
end-points, such as heart attacks1 and strokes123, respectively.
The cause of atherosclerosis has been under debate for the whole 20th cen-
tury. During the time, tens of risk factors, variables which have been associ-
ated with the incidence of atherosclerosis, have been reported1, 124-126. Some of 
these have been accepted as major risk factors yielding a combination of ge-
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netic  susceptibility,  unhealthy  environment  and  increased  lifespan1(Table 
1.2).  At the time, the key role of lipoprotein particles in the development of 
atherosclerosis is appreciated but the concerned risk factors are usually de-
noted via lipid  variables,  such as VLDL triglycerides and LDL cholesterol, 
rather than lipoprotein variables such as VLDL and LDL particle concentra-
tions, respectively. 
Some of the major risk factors co-occur in an individual surprisingly often 
and tend to together increase the risk of atherosclerosis and type II diabetes 
considerably124. The combination of these risk factors is called the metabolic 
syndrome and its components are all metabolic disturbances such as abdom-
inal body fat distribution, insulin resistance, atherogenic dyslipidemia denot-
ing abnormal lipid and lipoprotein levels regularly present in atherosclerosis, 
elevated  blood  pressure,  proinflammatory  state  and  prothrombotic  state 
meaning prevalence to form blood clots in the arteries. The atherogenic dys-
lipidemia is defined as raised plasma triglycerides, low concentration of HDL 
cholesterol, elevated apoB molecules as well as increased  number of small, 
dense LDL and small HDL particles. These components of the metabolic syn-
drome add to each other multiplicatively and likely have reciprocal associ-
ations although  their nature is not currently clear. Metabolic syndrome is, 
however, increasing strikingly worldwide with increasing age distribution and 
the global epidemic of obesity and insulin resistance127-129.
Table 1.2 Risk factors of  atherosclerosis  in alphabetical  order.  For refer-
ences, see1, 130.
°  These haemostatic factors include fibrinogen, plasminogen activator in-
hibitor type 1 and platelet reactivity. † Relationship of alcohol usage and the 
risk of atherosclerosis is a J-curve with risk highest for heavy drinkers, low-
est  for  light  drinkers  and  intermediate  for  teetotallers.  VLDL,  very  low 
density lipoprotein; IDL, intermediate-density lipoprotein; LDL, low-dens-
ity lipoprotein; HDL, high-density lipoprotein; hs-CRP, high-sensitive C-re-
active protein.
The  risk  of  atherosclerosis  is  detected,  evaluated,  and  treated  by  the 
guidelines of the third Adult Treatment Panel report (ATP III) from the Na-
tional Cholesterol Education Program (NCEP)131 or similar national program-
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s132-136.  For  detection  and  evaluation,  ATP III  recommends examination of 
various lipid measures such as total cholesterol, LDL cholesterol, HDL cho-
lesterol,  and  triglycerides,  and  recommends  evaluation  of  this  lipoprotein 
profile with other risk factors such as age, blood pressure, and smoking. For 
treatment, ATP III has the main focus in lowering LDL cholesterol similar to 
earlier reports although the optimal LDL cholesterol level for individuals at 
high risk is now lower, 100 mg/dl (2.6 mmol/l), than in earlier reports and 
more intensive pharmaceutical treatment is recommended to those individu-
als. In Finland, the optimal lipoprotein lipid levels are slightly different136, as 
shown in Table 1.3. The Finnish recommendations emphasise also other cho-
lesterol  measures,  such as the ratio  of  total  to  HDL cholesterol  (total  C / 
HDL-C) and cholesterol content in  all  lipoprotein particles excluding HDL 
particles, i.e., non-HDL-C concentration (total C – HDL-C), as risk factors.
Table 1.3 Optimal lipoprotein lipid concentrations according to ATP III and  
the Finnish 'Käypä hoito' - recommendations.
ATP III classifies individuals into three categories such as individuals with 0 
or 1 risk factors, individuals with 2 or more risk factors and individuals  
with CAD or CAD risk equivalent including type II diabetes. Since Finnish  
recommendations classify individuals only into two categories, for practical  
reasons, also individuals in ATP III recommendations are regrouped. Indi-
viduals with 0 or 1 risk factors are labelled under 'individuals at low risk'  
and those with two or more risk factors, CAD or CAD risk equivalent under 
'individuals at high risk'. Recommendation of LDL cholesterol level * for in-
dividuals with 0 or 1 risk factors,  ** for individuals with 2 or more risk  
factors  and  ***  for  individuals  with  CAD  or  CAD  risk  equivalent  are,  
however, given separately. These risk factors for classification in ATP III re-
commendations  include smoking,  hypertension (blood pressure  ≥ 140/90 
mmHg),  low HDL-C (less  than 1.0  mmol/l),  family history of  premature  
CAD and age (men ≥ 45, women ≥ 55). If the HDL-C level is more than 1.6 
mmol/l,  one risk factor can be subtracted. Division of individuals into low 
risk and high risk categories is quite similar also in the Finnish recommend-
ations.  The risk  can also  be  estimated by risk score calculators,  such  as 
SCORE133 and FINRISKI137.
The predictive role of extremely high total and LDL cholesterol concentra-
tions is established in the development of cardiovascular disease. However, 
the relationship between 'normal'  cholesterol levels and the risk of athero-
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sclerosis is complex. This has caused arguments for even lower optimal level 
of LDL cholesterol at least for high risk individuals108, 138-140. 
This discrepancy has also inspired active discussion of whether we are using 
the best measure(s) to identify the individuals at risk of atherosclerosis and 
should advanced lipoprotein testing, i.e., measures beyond triglyceride, total 
cholesterol,  LDL cholesterol  and HDL cholesterol  concentrations,  be  used. 
Currently, the best validated measure of CAD risk obtained from advanced 
lipid testing is the concentration of atherogenic particles via apolipoprotein-B 
(apoB) concentrations141-146 or LDL particles determined by NMR146-150. 
In most of these studies141-143, but not in all144, apoB was more closely associ-
ated  with  CAD  risk  than  LDL  cholesterol.  Similarly,  CAD  risk  was  more 
closely associated with NMR LDL particle concentrations than LDL cholester-
ol. However, in the Framingham Study145, apoB associated with CAD risk over 
a 15-years follow-up of 3322 individuals with a magnitude of association com-
parable  to  total/HDL cholesterol  concentration.  Similarly,  in the Women's 
Health Study146, apoB and NMR LDL particle concentrations associated with 
CAD risk over an 11-years follow-up of 27 000 women with a magnitude of as-
sociation comparable to total/HDL cholesterol or non-HDL cholesterol con-
centrations. 
The poor predictive power of LDL cholesterol for risk of CAD has also em-
phasised the potential role of particle properties such as altered LDL particle 
size20,  151. Particularly small, dense LDL particles (sdLDL) have been associ-
ated with increased risk of CAD (for references, see117).  The discussion has 
also extended to other lipoprotein particles than LDL. It has been suggested 
that the quality of HDL particles is altered to less atheroprotective or pro-ath-
erogenic  particles in individuals with atherosclerosis or the metabolic syn-
drome152,  153.  Therefore, although lipoprotein particles have been studied for 
decades, there still exist unanswered questions regarding differences in the 
quantity and the quality of lipoprotein particles between individuals and as-
sociations of these properties with the risk of cardiovascular disease. 
1.3 Aims of the study
This dissertation contributes to lipoprotein research mainly by providing new 
computational models and methods to characterise lipoprotein particles. It 
deals with the three important properties of lipoprotein particles including 
structure (chapter 3, Study I), composition/metabolism (chapter 4, Study II) 
and particle concentration (chapter 5, Study III). In more detail, this thesis 
aims to clarify whether hydrophobic lipoprotein lipids locate also in the sur-
face layer of lipoprotein particles; whether computational, i.e., in silico, clas-
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sification enhances  the  experimental  ultracentrifugation-based  isolation  of 
lipoprotein data and whether computational approaches related to lipopro-
tein lipid data are  useful  in estimating lipoprotein particle concentrations. 
Summary of these models and methods are given in chapter 6. This disserta-
tion starts, however, from the basic concepts of lipoprotein particles such as 
their isolation from blood plasma, chemical composition, size, structure and 
metabolism to give grounds to the following chapters. 
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2. Basic concepts
This chapter will review the main properties of lipoprotein particles begin-
ning with their isolation and characterisation, then continuing into their gen-
eral and molecular structure and, finally, into their complex metabolism in 
plasma. The purpose of this chapter is to give the appropriate background of 
lipoprotein particles from a biochemical point of view to be able to follow the 
subsequent chapters on computational modelling of the structure and meta-
bolism of lipoprotein particles. 
2.1 Isolation and characterisation of lipoprotein particles
Lipoproteins are  highly heterogeneous particles,  and they differ  in various 
physical properties including hydrated density, surface charge, particle size 
and chemical composition. These different properties can be used to classify 
lipoproteins into several groups of particles. However, no single method can 
classify lipoproteins based on all of their properties at once and thus there are 
several isolation and characterisation methods based on the different proper-
ties. These methods include ultracentrifugation, precipitation, electrophores-
is, chromatography, enzymatic methods yielding chemical compositions and 
nuclear magnetic resonance. 
2.1.1 Isolation by hydrated density in ultracentrifugation
The hydrated density in an ultracentrifuge is the most commonly used criter-
ia to isolate lipoprotein particles, and ultracentrifugation is the gold standard 
in lipoprotein research. Hydrated densities in ultracentrifugation have also 
defined the nomenclature of lipoprotein particles. Lipoprotein particles have 
relatively low densities and will float if they are ultracentrifuged in a solvent 
of greater density. Therefore, it is possible to isolate lipoprotein fractions with 
a density less than one value but greater than another by carrying out suc-
cessive ultracentrifugation runs where the density of the solvent is increased 
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by a known amount each time. In addition, by a specific ultracentrifugation 
method,  i.e.,  density  gradient  ultracentrifugation,  several  lipoprotein  frac-
tions can also be separated simultaneously using discontinuous density gradi-
ent of the solvent. Hydrated densities of lipoprotein particles form, however, 
a continuum, and thus the limits of  five standard lipoprotein classes have 
been  chosen  discretionarily  and  they  variate  slightly  between  research 
groups.
Frequently  used  ranges  are  <  0.94  g/ml,  0.94-1.006  g/ml,  1.006-1.019 
g/ml,  1.019-1.063 g/ml and 1.063-1.21  g/ml154-156.  The  particles  of  the first 
range are  chylomicrons which were named already in 1924157,  about thirty 
years before the first ultracentrifuge. The rest of the lipoprotein particles are 
named according to their densities to very low-density lipoproteins (VLDL, 
0.94-1.006 g/ml), intermediate-density lipoproteins (IDL, 1.006-1.019 g/ml), 
low-density lipoproteins (LDL, 1.019-1.063 g/ml) and high-density lipopro-
teins (HDL, 1.063-1.21 g/ml). Because the procedure is very flexible to isolate 
particles within any density range, these main lipoprotein fractions have been 
further partitioned into narrower density ranges to represent lipoprotein sub-
classes. Particularly HDL particles are further divided to lighter HDL2(1.063-
1.125 g/ml) and denser HDL3 (1.125-1.21 g/ml) particles158. Also HDL particles 
lighter than HDL2 (HDL1,  1.055-1.063 g/ml)159 and denser than  HDL3  (very 
high-density lipoprotein, VHDL or HDL4, 1.210-1.250 g/ml)160 have been isol-
ated by ultracentrifugation although their concentrations in plasma are small. 
Moreover,  in  a  density  range  of  1.050-1.080 g/ml156,  overlapping  with the 
LDL and HDL ranges, exists lipoprotein (a) particles, abbreviated as Lp(a). 
Lp(a) is an LDL particle enriched with a specific protein,  apolipoprotein(a)161.
2.1.2 Isolation by precipitation
Lipoprotein particles  can also be isolated  from blood plasma or serum by 
various chemical precipitation techniques. In contrast to ultracentrifugation, 
precipitation technique disposes unwanted lipoprotein particles by forming of 
a solid phase in a solution during a chemical reaction. The chemical reaction 
is achieved by introducing certain precipitation agents which selectively and 
conveniently aggregate and precipitate lipoproteins with appropriate choices 
of reagents and conditions. 
The  precipitation  procedures  can  isolate  lipoprotein  fractions  and  main 
HDL subclasses from blood plasma or serum by various chemical precipita-
tion techniques  but  are  particularly  used  to  separate  HDL particles.  HDL 
particles  can  be  separated  by  precipitation  techniques  using  polyanions, 
sometimes combined with divalent cations, as these precipitation reagents se-
lectively  aggregate  lipoprotein  particles  with  a  large,  non-exchangeable 
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apoB162,  163. The precipitated apoB-containing particles can then be removed 
leaving HDL particles in the remaining solution or supernatant. Precipitation 
methods are, however, often based upon empirical findings and the precise 
physicochemical basis is not always clear.
2.1.3 Characterisation by electrophoresis
Electrophoresis can be used to characterise lipoprotein particles according to 
their surface charge or size. These methods have also been combined sequen-
tially yielding two-dimensional separation of the particles164, 165.
2.1.3.1 Agarose gel electrophoresis
Lipoprotein particles can be characterised by their surface charge as they are 
electrically charged due to their surface constituents and thus migrate in an 
electric field. Lipoprotein particles differ in their electrical charges mostly due 
to their protein contents and conformations but also by variations in phos-
pholipid species.  Hence the lipoproteins can be classified by their  electro-
phoretic mobility on porous agarose gels into four main classes, namely, α-
lipoproteins, pre-β-lipoproteins, β-lipoproteins and chylomicrons. The names 
of the classes, except chylomicrons, originate from the fact that the mobilities 
of lipoprotein particles are comparable to mobilities of globulins, heterogen-
eous families of large and less soluble serum proteins. Thus the α-lipopro-
teins and the β-lipoproteins have the same mobilities as the fast α-globulins 
and slower the β-globulins, respectively, and the mobility of pre-β-lipopro-
teins is a little greater than that of the β-lipoproteins. When α-, pre-β- and the 
β-lipoproteins  are  compared  to  those  isolated  by  ultracentrifugation,  they 
correspond mainly to HDL, VLDL and LDL particles, respectively166, 167. Chylo-
micron particles, if present in the sample, remain in the electrophoretic origin 
because their size is larger than the pore sizes of the supporting medium166. 
2.1.3.2 Non-denaturing polyacrylamide gradient gel electrophoresis
The most common procedure to characterise lipoprotein particles by size is to 
use non-denaturing polyacrylamide gradient gel electrophoresis (GGE) which 
combines electric field with a continuous molecular sieve gradient in the sup-
porting medium. Thus, the lipoprotein particles move in electric field until 
they  cannot  migrate  through the pores of  decreasing  size.  The size  of  the 
trapped particles could then be determined by comparing them to charged 
reference molecules with known size or to their migration distance. 
Non-denaturing  polyacrylamide  gradient  gel  electrophoresis  can be  used 
either  to  ultracentrifugally  isolated  lipoprotein  fractions168 or  directly  to 
plasma or serum samples169 to characterise their subclass composition. The 
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method has found lipoprotein subclasses in each of the lipoprotein fractions 
although its use has been particularly directed to LDL and HDL particles; 
VLDL have been grouped into two subclasses with diameters larger than 35 
nm and between 30 - 33 nm, respectively, and two IDL subclasses with dia-
meters 28-30 nm and 26.8-28.4 nm in density ranges of 1.008-1.022 g/ml 
and 1.013-1.028 g/ml, respectively170.  Two subclasses of IDL particles have 
also been observed in the density range of 1.006-1.030 g/ml yielding larger 
IDL-I (mean diameter 31.7 ± 0.7 nm) and smaller IDL-II particles (25.7 ± 2.4 
nm), respectively171. Similar procedures have also identified seven LDL sub-
classes (I, 27.2-28.5 nm in diameter; IIa, 26.5-27.2 nm; IIb, 25.6-26.5 nm; 
IIIa, 24.7-25.6 nm; IIIb, 24.2-24.7 nm; IVa, 23.3-24.2 nm and IVb, 22.0-23.3 
nm)20, 172, 173 or even eight LDL subclasses (LDL-8, 17.7 ± 0.6 nm) added by an 
even smaller  LDL particle observed in individuals  with severe hypertrigly-
ceridemia169, 174. HDL particles have, however, been subdivided to even more 
particle classes, displaying fourteen particles (from 12.46 nm to less than 7.86 
in diameter)175 although only five subclasses are usually met in any given indi-
vidual. These include two HDL subclasses of HDL2 (HDL2b, ~9.7-12.9 nm in 
diameter; and  HDL2a,~8.8-9.7 nm) and three of  HDL3 particles (HDL3a, ~ 
8.2-8.8 nm; HDL3b, ~7.8-8.2 nm; HDL3c, ~7.2-7.8 nm) in apparently healthy 
individuals176, 177. 
It is also possible to use two electrophoretic procedures sequentially as two-
dimensional electrophoresis. This may be done by characterising the particles 
by surface charge in the first and by size in the second dimension178-181. The 
first dimension separates the HDL particles into pre-β-, α- and pre-α-migrat-
ing particles on basis of the mobilities that  are slower than, similar to, or 
faster than albumin, respectively. Then the agarose strip is transferred on the 
top of a non-denaturing gradient gel and electrophoresed in the second di-
mension. Two-dimensional electrophoresis has then yielded five pre-β- (two 
pre-β1  particles  around  7.10  nm  in  diameter  and  three  pre-β2  particles 
around 17 nm), four pre-α- (between 17 and 8.2 nm) and three α-migrating 
particles (α1 around 11.2 nm, α 2 at 9.51 nm, and α3 at 7.12 nm). Knowledge 
of apolipoprotein concentrations in α-, pre-β- and the β-lipoproteins has also 
been increased by crossed immunoelectrophoresis combining electrophoresis 
in the first and electroimmunodiffusion in the second dimension182, 183. Elec-
troimmunodiffusion is an immunochemical method combining electrophor-
etic characterisation with immunodiffusion by incorporating antibody against 
apolipoproteins into the support medium.
2.1.4 Isolation and characterisation by chromatography
Chromatography is a collective term for a family of laboratory techniques for 
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separation of mixtures, and the separation is based on differing mobilities of 
molecules or particles within the mixtures in a supporting medium. Chroma-
tographic techniques have become common in lipoprotein research as they 
are fast and versatile. 
2.1.4.1 Apolipoprotein content in immunoaffinity chromatography
Lipoprotein  particles  have  variable  apolipoprotein  compositions  by  which 
they  can  be  separated  into  various  classes  via  immunoaffinity  chromato-
graphy. In this procedure, antibodies, raised against individual apolipopro-
tein antigens, are immobilised covalently on agarose or a similar insoluble 
chromatography matrix and the lipoproteins including the apolipoproteins in 
interest can be entrapped and then collected while the others are discarded.
The specific antibodies for all apolipoprotein molecules are available and 
they have been used to separate lipoproteins into various classes including 
apoB-containing  particles  corresponding  to  chylomicron,  VLDL,  IDL  and 
LDL  particles  and  non-apoB-containing  particles  corresponding  to  HDL 
particles. The apoB-containing particles are further classified into a class con-
taining a truncated form of apoB, apoB-48, corresponding to chylomicrons 
and  full  length  apoB,  apoB-100,  corresponding  to  VLDL,  IDL  and  LDL 
particles. Both of these classes contain also particles with or without apoC 
and apoE in all  mixtures184.  The main interest of separation of lipoprotein 
particles by immunoaffinity chromatograph is, however, directed to the non-
apoB-containing particles. 
The  non-apoB-containing  particles  are  largely  separable  into  two  main 
classes where the other contains apoA-I without apoA-II molecules, abbrevi-
ated as LpA-I, while the other contains apoA-I with apoA-II molecules, abbre-
viated as LpA-I:A-II185, 186. Positioning of these LpA-I and LpA-I:A-II particles 
to HDL subclasses derived by other methods has proved to be difficult and 
only partly converging. It has been suggested that LpA-I particles have major 
components in the density range of large, spherical HDL2 particles187 or in 
subclasses HDL2b, HDL3a and HDL3c188 while LpA-I:A-II particles are mostly 
in  the  density  range  of  small,  spherical  HDL3 particles187 or  in  subclasses 
HDL2a,  HDL3a   and  HDL3b188. Combined use of two-dimensional non-dena-
turing  gel  electrophoresis  and  immunoaffinity  studies  have,  however, 
provided the  most  sophisticated  view of  the  positioning  of  the  LpA-I  and 
LpA-I:A-II  particles:  It  seems  that  LpA-I:A-II  particles  are  present  only 
among small, spherical HDL particles (α2 and α3) while LpA-I particles are 
present among all HDL particles or at least in all except the ones including 
LpA-I:A-II particles (pre-β, α1, pre-α)189. Thus LpA-I particles are present in 
both large, spherical as well as small, discoidal, HDL particles. In addition to 
apoA-I containing HDL particles, some HDL particles may have apoE, apoA-
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IV or even some minor apolipoprotein as their only apolipoprotein molecules 
but their concentration in plasma is low190, 191.
2.1.4.2 Size exclusion chromatography
Size exclusion chromatography is a chromatographic method in which large 
molecules or particles in solution are separated based on their size192, 193. Sep-
aration of the particles is usually achieved with a column which consists of a 
hollow tube  tightly  packed with small  beads  with pores of  different  sizes. 
Therefore,  as  the  mixture  of  particles  travels  down  the  column,  smaller 
particles enter more often into the pores and thus have longer path and elu-
tion time in the supporting medium than larger particles. As a result,  the 
filtered solutions are collected in constant volumes and subjected to further 
analysis by other techniques or are analysed on-line without actual gathering.
Size  exclusion  chromatography  is  generally  considered  a  low  resolution 
chromatography. One option to increase its resolution is to utilise a pump to 
propel the solution through the column. In this case, the column may also be 
shorter and denser than in the original size exclusion chromatography. The 
increased density arises from the decreased size of the porous beads. This 
form of column chromatography is usually called high-performance or high 
pressure liquid chromatography (HPLC). 
High-performance  liquid  chromatography  has  been  used  for  decades  to 
isolate and characterise lipoprotein particles194-196.  Recently, an on-line dual 
detection method was described for lipoprotein analysis194, 195. The method al-
lows separation of twenty lipoprotein subclasses and enzymatic determina-
tion of their cholesterol and triglyceride profiles from a single injection of 
sample. This is achieved by using two different  tandem connected  gel per-
meation columns, two different reagents and a dual detection system. This 
method is used in chapter 5 of this thesis for lipoprotein isolation and charac-
terisation.
2.1.5 Characterisation by chemical composition
Lipoprotein  particles  have  complex  chemical  compositions  which  vary 
between individuals and within an individual under different physiological 
and pathological  conditions.  They contain variable  amounts of  three main 
classes  of  lipids  including  phospholipid,  triglyceride  and  cholesterol  mo-
lecules.  Cholesterol  molecules are  further divided into  unesterified or  free 
cholesterol and cholesterol ester molecules since they behave quite differently 
in lipoprotein particles. Lipoproteins have also significant amounts of pro-
teins designated apolipoproteins but they may also contain other associated 
protein components. 
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Lipoprotein particles can be characterised by determining their lipid and 
protein concentrations.  There are  numerous methods to  measure the lipid 
and protein concentrations of which the most widely used at  the time are 
based on enzymatic, colorimetric methods. These methods are widely used to 
measure the concentrations of triglyceride, (total) cholesterol, free cholesterol 
and phospholipid molecules. The concentration of cholesterol esters is then 
calculated as the difference in total cholesterol and free cholesterol molecules. 
The concentration of total  protein is most often determined by a modified 
Lowry method197,  198, a colorimetric method based on interaction of divalent 
copper ions with peptides. There are also several immunological methods to 
measure the concentration of apolipoprotein molecules in a sample182,  183,  199, 
200. 
In clinical practise, lipoprotein particles are characterised less comprehens-
ively, usually only triglyceride, total cholesterol and HDL cholesterol concen-
trations  are  measured.  HDL cholesterol  concentration is  measured by en-
zymatic methods after removal of apoB-containing particles by precipitation 
or by so-called direct methods that do not require the physical separation of 
the different lipoprotein classes201. Similarly, LDL cholesterol concentration is 
measured either by the direct methods or calculated by using Friedewald's 
equation46 (see equation 1.1 in page  11)202. The direct methods are based on 
different epitopes, i.e., targets of immune responses, on the HDL and LDL 
particles, and in 2008 there were seven different commercial direct methods 
available for HDL and LDL cholesterol concentration determination203. 
2.1.6 Characterisation by nuclear magnetic resonance 
spectroscopy
Nuclear magnetic resonance  (NMR)  spectroscopy is  a new method among 
lipoprotein characterisation procedures while it has a long history in structur-
al studies among lipoproteins and other biological aggregates. NMR provides 
an alternative for measuring sizes of lipoprotein particles in plasma although 
the sizes are held more relative than absolute. The size estimates are based on 
the subclass-specific frequencies of spectral  signals  emitted simultaneously 
by  VLDL,  LDL  and  HDL  subclasses  of  different  sizes  and  their  particle 
weight-averaged  correspondence  with  GGE-derived  or  other  subclass  size 
measures204. Lipoprotein particles produce multiple peaks in NMR spectrum 
but the composite signal of terminal methyl groups (-CH3) is enough for lipo-
protein particle quantification. This signal forms from the aggregate number 
of terminal methyl groups on the lipids contained within the particle and is 
distinguishable from the methyl signals of other subclasses by their charac-
teristic shape and frequency. This technique has identified three VLDL sub-
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classes (> 60 nm in diameter, 35-60 nm and 27-35 nm), one IDL (23-27 nm 
in diameter), three LDL subclasses (21.1-23 nm in diameter, 19.8-21.1 and 18-
19.8) as well as three HDL subclasses (8.8-13 nm in diameter, 8.2-8.8 nm and 
7.3-8.2  nm)205,  206.  The  size  ranges  of  HDL subclasses  match  closely  those 
measured by gradient gel electrophoresis while the others remain somewhat 
smaller206. Particularly LDL particles have shown to be uniformly smaller by 
approximately 5 to 6 nm compared with those determined by GGE147, 206, 207. In 
addition to NMR's ability to characterise lipoprotein particles by size, NMR 
can be used to approximate the concentrations of lipoprotein lipids based on 
its signal amplitudes.
To summarise, lipoprotein particles are heterogeneous in terms of hydrated 
density, size, surface charge, lipid composition and apolipoprotein content. 
Lipoprotein particles may be classified into various fractions and further into 
subclasses according to their different properties. Each of the isolation meth-
ods decreases the heterogeneity of the particles by the corresponding prop-
erty.  Lipoproteins may be further characterised by their chemical composi-
tion which forms basis for understanding the structure and the metabolism of 
lipoprotein particles.
2.2 General and molecular structure of lipoprotein particles
Lipoprotein particles are micellar aggregates of lipids and specific lipid bind-
ing  proteins  called  apolipoproteins208-211.  Mature  lipoproteins  are  spherical 
particles  at  physiological  temperatures with diameters ranging from a few 
nanometers to a few micrometers212,  213. Lipoprotein particles contain trigly-
ceride, cholesterol,  cholesterol ester and phospholipid molecules as well as 
variable amounts of fraction-specific apolipoproteins. 
The general structure of lipoprotein particles is well known160, 210, 211, 214-216 (see 
Fig. 2.1). The location of a bulk of the lipids and apolipoproteins is mainly de-
termined  by  their  hydrophilic  and/or  hydrophobic  nature.  Phospholipids, 
consisting of a head group, a phosphoryl group, glycerol or sphingosine back-
bone and two fatty acids, form the basis of a one-molecule thick surface layer 
of lipoprotein particles. Hydrophilic, polar phosphoryl-linked head groups of 
phospholipids are in contact with aqueous environment while their hydro-
phobic, unpolar fatty acids form the inner part of the surface layer. Apolipo-
proteins have both hydrophilic and hydrophobic regions and reside mainly at 
the surface of the lipoprotein particles forming a mixed film with the phos-
pholipids. Free cholesterol molecules are abundant in the surface as structur-
al surface lipids but are also present in the interior parts of the particles, or in 
the core, as they are only slightly polar due to their single hydroxyl group. 
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Triglycerides and cholesterol esters are hydrophobic molecules and are, thus, 
mainly buried in the core of the lipoprotein particles. However, this conven-
tional view is quite restricted regarding metabolism of lipoprotein particles, 
and the issue of location of triglycerides and cholesterol esters is thus recon-
sidered in chapter 3 of this thesis.
2.2.1 The molecular organisation of lipids in lipoprotein particles 
The molecular structure of lipoprotein particles is less clear than the general 
structure and there exists uncertainties around the details of lipid-lipid and 
lipid-protein interactions. Plenty of information is, however, available on the 
properties of lipoprotein composing lipids derived from planar layers217, 218 as 
well as spherical lipoprotein model systems such as micelles and vesicles219-224. 
It could be excepted that the main interactions between, for example, phos-
pholipids and free cholesterol molecules in these curved surface layers are 
similar210 although vesicles have a phospholipid bilayer rather than a mono-
layer present in lipoproteins and micelles.
Figure  2.1  Structure  of  lipoprotein  particles.  Lipoprotein  particles  are  
spherical, micellar structures with a core and a surface layer surrounding  
the core. Lipoprotein particles contain lipids and proteins called apolipopro-
teins. The lipids in lipoprotein particles are generally divided to surface and  
core lipids based on their main location in lipoprotein particles. Surface lip-
ids including phospholipids,  such as  phosphatidylcholine (PC),  lyso-phos-
phatidylcholine (lyso-PC) and sphingomyelin (SM), and free cholesterol mo-
lecules, while core lipids is a common term for triglyceride (TG) and choles-
terol ester (CE) molecules. Apolipoproteins reside mostly at the surface of  
lipoprotein particles.
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It is likely that  phospholipid and free cholesterol molecules are not ran-
domly distributed at the surface of lipoprotein particles since free cholesterol 
molecules do not interact equally with all  phospholipid molecules. In fact, 
free cholesterol prefers sphingosine to glycerol backbone of phospholipids, al-
though preferences also exists between phospholipids with similar glycerol 
backbone but different head groups219, 225. It is likely that this leads to forma-
tion of two types of distinct nano-sized lipid environments, i.e., nanoenviron-
ments210,  at the surface of lipoprotein particles,  namely, one that is rich in 
both sphingomyelin (with sphingosine backbone) and free  cholesterol  mo-
lecules, and the other that is rich in phosphatidylcholine (with glycerol back-
bone) but poor in free cholesterol molecules210. 
Triglycerides and cholesterol esters seem not to have any specific order in 
the core of lipoprotein particles in physiological temperatures but occur in 
random orientations210, 226. Below the physiological temperatures, cholesterol 
esters of LDL particles are capable of undergoing phase transition from li-
quid-like state into a highly ordered smectic-like liquid crystal state with two 
radial layers of cholesterol esters227-230. The transition is reversible and occurs 
at around 30°C but may vary as much as 10°C in the peak temperature de-
pending on the core lipid composition, particularly triglyceride to cholesterol 
ratio. Whether the phase transition could occur  in vivo, and its possible ef-
fects on LDL particle metabolism, are, however, unknown.
The triglyceride to cholesterol ester ratio has also an important role in parti-
tioning of  free  cholesterol  molecules between lipoprotein core  and surface 
and thus affects surface properties of lipoprotein particles. In emulsions of 
phosphatidylcholine, free cholesterol and triglyceride molecules without cho-
lesterol  esters,  80  %  of  cholesterol  molecules  were  associated  with  phos-
phatidylcholines231.  When cholesterol  esters were added into the emulsion, 
the corresponding figure was only 50 % probably due to a favourable interac-
tion  between  cholesterol  rings  in  the  core231.  In  the  lipoprotein  particles, 
which contain both triglycerides and cholesterol esters, approximately 60-70 
% of free cholesterol molecules reside in contact with phospholipids232, 233. 
Similarly to ring-ring-interactions of cholesterol moieties, also fatty acids 
likely interact with each other. Thus it seems natural that fatty acids of trigly-
cerides and cholesterol esters would interpenetrate towards the fatty acids of 
phospholipid molecules in a radial order210 as long as they are shielded from 
water. In fact, several experimental studies have observed small amounts of 
triglycerides and cholesterol esters in the surface of large vesicles234-240 and 
emulsion particles241, 242 and recently triglycerides have also been observed in 
the surface of hen VLDL particles243. Although the triglycerides and cholester-
ol esters could have two different locations and multiple orientations to inter-
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penetrate  the  phospholipid  monolayer,  most  of  these  studies  suggest  that 
those triglycerides and cholesterol esters that locate in the lipoprotein-water 
interface have their fatty acids pointing towards the core.
Another possibility is that triglycerides and cholesterol esters interpenetrate 
from the core towards the surface. Interpenetration in this way is likely nan-
odomain-dependent since the surface nanodomains likely differ due to their 
different physio-chemical properties determined by their lipid constituents210. 
For example, free cholesterol molecules have a tendency to increase the order 
of phospholipid fatty acids and thus domains rich in sphingomyelin and free 
cholesterol molecules might be overly rigid to allow interpenetration of trigly-
cerides and cholesterol esters towards the surface. The phosphatidylcholine-
rich and cholesterol-poor regions, on the contrary, might favour penetration 
of triglycerides and cholesterol esters toward the surface210. This view is also 
partially supported by the fact  that  increasing amounts of  free  cholesterol 
molecules decrease the solubility of triglycerides and cholesterol esters into 
phospholipid  bilayers234,  235,  probably  because  they  compete  for  the  same 
space between fatty acid tails of phospholipids244.
2.2.2 Apolipoproteins determine the metabolic fates of lipoprotein 
particles
Lipoprotein  particles  contain  several  different  apolipoproteins  which  were 
originally named with a series of letters A-E as they were separated by elec-
trophoresis.  Soon it  became apparent that  most of  these lettered  proteins 
could be further divided into several individual proteins and thus the apolipo-
proteins are now usually referred as apoA-I, apoA-II, apoA-IV, apoB, apoC-I, 
apoC-II, apoC-III, apoD and apoE. 
The  primary structure  of  apolipoprotein  molecules  has  been discovered; 
apoA, apoC, and apoE molecules share similar amino acid sequence with 11 
and 22 amino acid homogenous repeats the latter consisting of two 11-mer-
s245. ApoB and apoD molecules, in contrast, bear little resemblance to the se-
quences of apoA, apoC, and apoE molecules or each other245-247. The second-
ary structures of apolipoproteins have also been defined; apoA, apoC, and 
apoE molecules are rich in α-helixes248-250, apoB has alternating α-helixes and 
β-sheets210,  248,  251,  and  apoD  is  composed  primarily  of  β-sheets252.  Tertiary 
structures are not currently that clear, particularly in the case of apoB (for 
more details see210, 211, 251, 253-256). Most if not all apolipoproteins seem, however, 
more or less to wrap around the lipoprotein particles and also form apolipo-
protein regions at the surface of lipoprotein particles. 
Apolipoprotein molecules interact with both the lipid constituents of lipo-
protein particles and the surrounding aqueous environment and thus help to 
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solubilise the hydrophobic triglyceride and cholesterol ester molecules within 
the lipoprotein particles.  Since apolipoprotein molecules more or  less sur-
round the lipoprotein particles, increasing amount of triglycerides and cho-
lesterol  esters,  and thus  increasing  size  of  the  particles,  require  flexibility 
from  the  apolipoproteins.  In  fact,  the  apolipoproteins  have  the  ability  to 
change  conformation to  adjust  to  changing  lipid  or  protein  contents,257-260 
compositions258,  259 and metabolic states174,  249,  261 of the lipoproteins although 
also the apolipoprotein content of lipoprotein particles per se may increase or 
decrease to adapt to these changes209. The change of apolipoprotein content is 
possible due to the capability of α-helical apoA, apoC and apoE molecules to 
dissociate from one particle and attach to another.
The  most  important  apolipoprotein  in  HDL particles  is  apoA-I  which  is 
present as multiple copies in each HDL particle. The amount of apoA-I mo-
lecules increases with increasing size of HDL particles, reaching the maxim-
um of 4-5 in the largest particles. In contrast, the most important apolipopro-
tein in chylomicron, VLDL, IDL and LDL particles is apoB, and each of the 
lipoprotein particles contains a single copy of the protein. The apoB occurs, 
however, in chylomicrons in a truncated form (apoB-48) with length of only 
48 % of the sequence from the N-terminus of the full length apoB (apoB-100) 
molecule262. The apoB molecules are non-exchangeable apolipoproteins and 
thus they are  bound into the same particle  until  particle  degradation.  Ex-
changeable apolipoproteins, apoC and apoE, transfer avidly between lipopro-
tein particles and participate in their metabolism209. 
Apolipoprotein  molecules  determine  the  metabolic  fate  of  lipoprotein 
particles; apolipoproteins function as activators or inhibitors of plasma en-
zymes. These effects are direct or indirect via influencing the conformation of 
the  activator  apolipoproteins.  For  example,  apoC-II  activates  lipoprotein 
lipase which hydrolyses triglycerides in lipoprotein particles. ApoC-III has, on 
the contrary, been shown to inhibit the action of lipoprotein lipase20, 209.
Apolipoproteins function also as ligands for cell surface receptors in particle 
endocytosis while certain apolipoproteins may also inhibit particle endocytos-
is. For example, LDL-receptors, which take up VLDL, IDL and LDL particles 
into the cells, recognise both apoB-100 and apoE molecules as their ligands. 
ApoC-I and apoC-III molecules, which are usually abundant in large trigly-
ceride-rich particles, have, however, the ability to inhibit particle endocytosis, 
likely by displacing or otherwise disturbing apoE, and may thus protect the 
newly synthesised particles from premature endocytosis20, 209, 263.
In addition to the well-known functions of apolipoproteins in lipid binding 
and solubilisation, modulation of enzyme activities and receptor recognition, 
also  other functions have been described for apolipoproteins. For example, 
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apoE and apoD have been suggested to play a key role in in situ nerve repair 
and regeneration264 as well as in neuronal protection during plaque formation 
in  Alzheimer's  disease265,  266 and  apoA-IV  in  signalling  satiety  in  the  fed 
state267, 268.
To summarise, lipoprotein particles are micellar, spherical particles of lip-
ids and proteins in the circulation. The structure of the particles may be di-
vided into two compartments, the core and the surface layer surrounding the 
core. The lipids and proteins are not randomly located in the compartments 
but are ordered according to their hydrophobic/hydrophilic properties as well 
as  lipid-lipid  and  lipid-protein  interactions.  In  a  recent  study243,  small 
amounts of triglycerides have also been observed at the surface of large hen 
lipoprotein particles. 
2.3 Metabolism of lipoprotein particles
Metabolism of lipoprotein particles can be viewed as lipid transportation phe-
nomena between the site of lipoprotein assembly and the tissues and organ-
elles consuming the lipoprotein lipids or lipoprotein particles. The lipid trans-
portation events are essential for proper metabolic functioning of human be-
ings and can be characterised as apolipoprotein-driven processes. These pro-
cesses are divided into four parts in this thesis and include exogenous lipid 
transportation,  endogenous lipid transportation,  forward cholesterol trans-
portation and reverse cholesterol transportation. The exogenous and endo-
genous lipid transportation processes concentrate mainly on transfer of diet-
ary and self-made triglycerides, respectively, for energy metabolism of tissues 
and organelles. The forward and reverse cholesterol transportation processes 
concentrate on transfer of cholesterol from the liver into extrahepatic tissues 
or in the reverse direction, respectively, to maintain cells' cholesterol homeo-
stasis. These transportation processes occur simultaneously in the circulation 
and interact or even overlap with each other. The interactions are also viewed 
in the end of the chapter.
2.3.1 Exogenous lipid metabolism
Exogenous lipid metabolism refers to the transfer of dietary lipids from the 
place of absorption into the tissues and organelles consuming them for en-
ergy or storing them for later use (see Fig. 2.2). Dietary lipids contain typic-
ally 90-95 % of triglycerides with smaller amounts of phospholipid and cho-
lesterol  molecules269.  Dietary  lipids  are  hydrolysed  in  the  small  intestine, 
emulsified with bile salts and absorbed across the epithelial cell membranes. 
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In the epithelial cells,  the dietary lipids are reassembled again and packed 
with newly synthesised lipids, apoB-48, apoA-I, apoA-II, and apoA-IV mo-
lecules to form chylomicron particles.
Chylomicron particles are the largest and lightest lipoproteins known. They 
can be separated from the density less than 0.94 g/ml154 of blood plasma and 
their  diameters  vary  in  the  range  of  80  -  1000  nm269.  Chylomicrons  are 
secreted  from intestinal epithelial cells into the lymphatics and then trans-
ported through thoracic duct into the  bloodstream.  The large, triglyceride-
rich chylomicron particles begin to appear in blood shortly after oral fat in-
take, and these triglyceride-rich chylomicrons make the greatest contribution 
to human energy metabolism after meals in a so-called postprandial state270. 
While the total triglyceride content of chylomicrons is very high in the post-
prandial state, their particle concentration is very low, less than 5 % of VLDL 
particles271 due to their rapid disposal. It is debatable whether small chylomic-
ron particles are also secreted in the fasted state in humans as shown in ro-
dents and rabbits272. In these animals,  chylomicrons are secreted constantly 
and their size rather than number depends on the availability of lipid sub-
strates272. 
Chylomicrons retain their initial composition while they remain in lymph 
but  face  multiple  lipid  and  protein  exchange  reactions  mainly  with  HDL 
particles when entered into the circulation; chylomicrons interchange some 
apoA for  apoC and apoE molecules273-277 as  well  as  receive  cholesterol  and 
phospholipid molecules from HDL particles. Thus, while in the bloodstream, 
chylomicrons contain approximately 98 % lipids by weight and all the major 
apolipoproteins including A, B, C and E154, 269, 278. Most of the lipids are trigly-
cerides (80-90 %), while the content of phospholipids is 10-20 % and the con-
tent of cholesterols is less than 2 %278, see Table 2.1. 
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Figure  2.2  Overview  of  metabolism  of  apoB-containing  lipoprotein 
particles. In exogenous lipid transport, chylomicrons deliver dietary trigly-
cerides from intestine into the extrahepatic tissues (followed by lipolysis of  
triglycerides to free fatty acids, FFAs). Chylomicrons become chylomicron 
remnants which are internalised mostly by the liver via LDL-receptors and  
LDL-receptor  related  proteins.  The  liver  uses  endogenously  synthesised  
triglyceride and cholesterol molecules as well as lipids derived from chylo-
micron remnants to synthesise VLDL. In this endogenous lipid transport,  
VLDL particles (and IDL; not shown) transport triglycerides into extrahep-
atic  tissues  in  a  similar  way as  chylomicron  particles.  Some of  the  IDL 
particles become LDL particles which are the main cholesterol transporters  
(forward cholesterol transport) in human circulation.  VLDL remnants as  
well as IDL and LDL particles are internalised mainly by the liver via LDL-
receptors and LDL-receptor related proteins. ApoB-containing particles ex-
change lipids,  particularly triglycerides and cholesterol esters, with HDL  
particles.  TG,  triglyceride;  Chol,  cholesterol;  SR-BI,  scavenger  receptor  
class  B type I,  LDL-R, LDL-receptor;  LRP, LDL-receptor related protein.  
Reprinted from279 with permission.
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Table 2.1 Size, density, main apolipoproteins and weight percentages of the  
main lipoprotein fractions and HDL subclasses.
Apo, apolipoprotein; W, weight percentage; TG, triglyceride; CE, cholester-
ol ester; FC, free cholesterol; PL, phospholipid; PROT, protein. For refer-
ences, see154, 168, 169, 269, 280.
In  addition to  these  exchange  reactions,  chylomicron  particles  promptly 
loose triglycerides into various tissues including skeletal muscles, myocardi-
um and adipose tissues. At the endothelial surface of the capillaries of these 
tissues,  each  triglyceride  is  first  hydrolysed  into  two  fatty  acids  and  a 
monoacylglycerol molecule, by apoC-II-activated action of an enzyme called 
lipoprotein  lipase  (LPL).  Then,  the  fatty  acids  pass  into  the  tissues,  the 
monoacylglycerol is transported in the liver and, after a while, the chylomic-
ron  particles  dissociate  from the  endothelial  surface  back  into  the  blood-
stream.
Transportation of triglycerides in chylomicron particles is a sequential pro-
cess.  These delipidation steps can be characterised by binding,  desorption 
and rebinding at other sites leading to progressive loss of approximately 50-
70 %278, 281 of triglycerides from each chylomicron particle. The loss of trigly-
cerides shrinks the cores of chylomicron particles and decreases the need of 
surface material covering the cores. This leads to massive reorganisation of 
molecules in chylomicron particles and shedding of phospholipid, free choles-
terol and apoC molecules from the surface. This excess surface material, or 
surface remnants, recycles back to HDL particles. The decreased apoC-II con-
tent of chylomicrons slows the delipidation, and decreased apoC-I and apoC-
III content changes the conformation of the remaining apolipoproteins. The 
delipidated chylomicrons, or chylomicron remnants, are then rapidly cleared 
from the blood plasma, mainly into the liver, through a receptor-mediated 
process where apoE molecules on chylomicron remnants serve as  ligands. 
The chylomicron remnants are internalised mainly by LDL-receptors282 or by 
LDL-receptor-related  proteins  (LRP)  which  show  sequence  homology  to 
LDL-receptors283, 284.
2.3.2 Endogenous lipid metabolism
Endogenous lipid metabolism refers to the delivery of self-made triglycerides 
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from the liver into various tissues.  These triglycerides originate essentially 
from three sources including incompletely delipidated remnant particles in-
ternalised into the liver, fatty acids entering in the liver from adipocytes, and 
de novo synthesis in the liver285.  The particles responsible for transporting 
these endogenous triglycerides in the circulation are VLDL and IDL particles. 
In addition to triglycerides, these particles also contain significant amounts of 
cholesterol  esters  which originate  from similar  sources as  triglycerides in-
cluding remnant particles and de novo synthesis but also from cholesterol re-
cycling285. 
VLDL particles are the precursors of VLDL-IDL-LDL delipidation cascade 
where parallel processing pathways generate heterogeneous IDL and further 
LDL particles from VLDL particles286-290 (see Fig. 2.2). The VLDL fraction con-
sists of heterogeneous particles with diameters of 30-80 nm280 and density of 
0.94-1.006 g/ml154. Half of the weight of VLDL particles are triglycerides, the 
content  of  both phospholipids  and cholesterol  is  approximately  20 % and 
thus the B-, C- and E-apolipoproteins account for the remaining 10 %280 (see 
Table 2.1). VLDL particles are smaller in size and denser than chylomicrons 
and have a full length apoB-100 in contrast to the truncated apoB molecule 
present in chylomicrons. The apoB-100 molecule is present in VLDL particles 
with some apoC and a few apoE at the time of secretion, and extra apoC and 
apoE molecules are attached to VLDL particles in the circulation291. 
VLDL particles are secreted from the liver into the bloodstream, and both 
the size of the secreted particles and the rate of particle secretion seem to be 
regulated, mainly by triglyceride availability in the liver20, 292-294. The synthes-
ised  VLDL  particles  are  structurally  and  metabolically  different  and  are, 
therefore, discretionarily divided into the subclasses VLDL1 and VLDL2170.
VLDL1 particles are large and triglyceride-rich295, 296 and influence most the 
plasma triglyceride level in fasted state294,  295.  VLDL1 particles  are secreted 
into the blood plasma mainly in fasted state  when insulin level292 and the 
amount of chylomicron-derived lipids in the blood is low. Thus the VLDL1 
particles  compensate  the  need  of  triglycerides  in  the  peripheral  tissues, 
mostly skeletal muscles. VLDL1 particle secretion is acutely suppressed by the 
presence of insulin in fed state292 but these particles may be produced if the 
liver  is  supplied with increased amounts of free fatty acids as  observed in 
obesity297, 298, with a diet high in simple carbohydrates299, 300, with high alcohol 
consumption301, in insulin resistance state295, and in type 2 diabetes295, 302. 
VLDL2 particles are smaller and have lower triglyceride content and higher 
cholesterol ester content than VLDL1 particles20,  303. VLDL2 particles are, in 
contrast, secreted when triglyceride availability in the liver is suppressed or 
when cholesterol synthesis and cholesterol ester availability in the liver are in-
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creased304. A significant portion of particles in the density range of VLDL2 
particles do, however, originate from delipidated VLDL1 particles286,  305 and 
are indistinguishable from the secreted VLDL2 particles by density. 
VLDL particles are sequentially hydrolysed by lipoprotein lipase similar to 
chylomicron particles yielding VLDL remnants and IDL particles. It is cur-
rently unknown how VLDL particles are destined for VLDL remnants or IDL 
particles. Evidence is,  however, emerging that  particularly VLDL1 particles 
would be readily converted into VLDL remnants305, 306, while VLDL2 particles 
are delipidated into IDL particles307. The VLDL remnants are cleared from the 
plasma mainly by the liver in a receptor-related manner, which is influenced 
by both their apolipoprotein and lipid content; VLDL remnants with a high 
number of apoE relative to apoC apolipoproteins are cleared to greater extent 
than  apoE-poor  particles308 as  apoE309,  310 molecules  serve  as  ligands  for 
mainly LDL-receptors311 and LDL-related receptors284. Increased cholesterol 
ester content, derived from action of other enzymes in the circulation, also 
seems to direct those VLDL remnants into the receptors209, 312. The VLDL rem-
nants not cleared from the blood plasma persist in the circulation in the dens-
ity range of VLDL and IDL particles and thus they might be incorrectly de-
noted as VLDL or IDL 20. 
IDL are heterogeneous particles of 25-35 nm in diameter280 and the density 
range  of  1.006-1.019  g/ml154 (see  Table  2.1).  IDL  particles  are  transient 
particles between VLDL and LDL and their concentration in blood plasma of 
healthy individuals is  low294. IDL particles are rich in cholesterol esters, ap-
proximately 30 % by weight, but still contain a significant portion of trigly-
cerides,  approximately  20  %,  while  free  cholesterol  constitutes  10  %  and 
phospholipids and proteins both approximately 20 %280.  IDL particles still 
contain apoB, apoC and apoE molecules similar to VLDL particles but their 
apoC content is reduced313, 314. 
IDL are heterogeneous particles similar to VLDL, and they can also be di-
vided into  two subclasses,  namely  IDL1 and IDL2170,  171.  IDL1 particles  are 
large,  triglyceride-rich and cholesterol  ester-poor  while  IDL2 particles  are 
small, triglyceride-poor and enriched in cholesterol esters20. The larger IDL1 
particles also contain twice as much apoC-II and apoC-III molecules as IDL2 
particles315.  The IDL subclasses may also differ by their origin. It has been 
suggested that IDL1 particles alone constitute the class of IDL particles which 
are  delipidated from VLDL, particularly from VLDL2, since their concentra-
tion increases  with  increasing  plasma triglycerides20,  171.  IDL2 particles,  in 
contrast, might by directly secreted by the liver when the triglyceride content 
in the liver is low20. 
A portion of IDL particles may be internalised, mainly via LDL-receptors 
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and LDL-related receptors using apoE as a ligand316 (see Fig. 2.2). The re-
maining IDL particles are further delipidated in the bloodstream as a result of 
action  of  lipoprotein  lipase  and  yet  another  enzyme  called  hepatic  lipase 
(HL). Hepatic lipase has homology to lipoprotein lipase and locates at the lu-
minal side of the liver parenchymal cells and in capillaries lining the tissues 
synthesising steroid hormones. Hepatic lipase hydrolyses triglycerides similar 
to  lipoprotein  lipase  but  has  affinity  also  for  phospholipid  molecules  and 
prefers smaller lipoprotein particles, i.e., IDL, LDL and HDL particles, than 
lipoprotein  lipase.  Thus,  the  delipidation pathway from VLDL particles  to 
LDL via IDL particles is finalised by hepatic lipase and results in the loss of a 
majority of triglycerides, some phospholipids, and virtually all exchangeable 
apolipoproteins from IDL particles.317
2.3.3 The forward cholesterol transport 
Most human cells are capable of synthesising small amounts of cholesterol. 
Cholesterol is also transported into the extrahepatic, peripheral cells from the 
liver in a so-called forward cholesterol transport process. The cholesterol in 
this pathway is transported within LDL particles. 
LDL particles are heterogeneous in size ranging from 18 to 29 nm in dia-
meter168,  169 in the density range of 1.019-1.063 g/ml154 (see Table 2.1). Each 
LDL particle has one apoB-100 molecule, alone forming 20 % of the weight of 
LDL280, and trace amounts of other apolipoproteins, mainly apoE174. In con-
trast to chylomicrons and VLDL particles, the major lipids in LDL particles 
are cholesterol esters (40 %)280. The content of triglycerides is approximately 
10 % and phospholipids 20 % by weight280.
LDL particles are delipidated from triglyceride-rich lipoproteins secreted by 
the  liver  although newly  secreted  particles  from the  liver  might  also  have 
density in the range of LDL particles when the level of plasma triglycerides is 
low307 (see  Fig.  2.2).  However,  it  remains  controversial  whether  these 
particles have the physiological function of LDL or whether they represent 
VLDL or IDL particles with extremely low triglyceride content. 
As many as eight distinct subspecies of LDL particles have been identified 
by gradient gel  electrophoresis168,  169.  These subspecies  have been grouped, 
based on density, into four major subclasses designated  LDL1, LDL2, LDL3 
and LDL4 in order of decreasing size and increasing density168,  318,  319.  LDL1 
particles comprise approximately a quarter of the LDL particles in plasma320 
and their concentration decreases with increasing insulin resistance, plasma 
triglycerides, obesity and activity of hepatic lipase294. LDL1 particles are sug-
gested to be delipidated from IDL2 particles secreted directly from the liver20, 
171. 
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LDL2 particles comprise the largest group of the LDL particles in individu-
als  with  normal  lipid  metabolism320.  LDL2 concentration,  relative  to  total 
LDL, has, however, been shown to decrease in CETP deficiency20, 321. The ab-
solute concentration of LDL2 particles has also been shown to decrease in 
men with a high level of plasma triglycerides294. LDL2 are suggested to be a 
product  of  VLDL2-IDL1  delipidation  pathway20 which,  in  addition  to  the 
IDL2-LDL1 pathway, is  also prominent in cases where the level of plasma 
triglycerides is low20, 304. Thus both LDL1 and LDL2 subclasses are large and 
rich in cholesterol esters. In contrast, the concentrations of the smallest LDL 
particles, LDL3 and LDL4, are usually high when the level of plasma trigly-
cerides is high20, 294, 322, 323 and they predominate in insulin resistance state322, 
324, 325. LDL3 and LDL4 are suggested to be delipidated from the VLDL1-VLDL 
remnant pathway20, 304.
LDL particles  are  internalised into cells  mainly via LDL-receptors69,  70,  72. 
LDL-receptors  are  expressed  by  most  cell  types  to  acquire  cholesterol  for 
their needs. The liver is, however, in whole-body terms the main site of LDL-
receptor-mediated removal of LDL particles326, 327. The internalisation of LDL 
particles is highly regulated by the amount of LDL-receptors at the cell sur-
faces. In healthy individuals, approximately 60-80 % of LDL particles are in-
ternalised via LDL-receptors328,  329 but several factors including age, gender, 
dietary alterations, hormonal disturbances, and administration of pharmaco-
logical agents affect the activity of LDL-receptors285. 
2.3.4 The reverse cholesterol transport
The reverse cholesterol transport refers to transport of cholesterol from the 
peripheral tissues into the liver. The reverse cholesterol transportation is an 
essential process in maintaining constant cholesterol content in the cells by 
balancing cholesterol influx and  de novo synthesis, which both increase the 
cholesterol content, by efflux of cholesterol from the cells. The reverse choles-
terol  transport process has also been suggested to play a major role in de-
creasing or preventing the development of atherosclerosis particularly by de-
creasing  the  cholesterol  load of  vessel  wall  macrophages330-334.  The reverse 
cholesterol transport contains two phases, cholesterol acquisition and choles-
terol delivery, and the HDL particles have a key role in both phases. 
HDL  particles  are  the  most  numerous  lipoprotein  particles  in  human 
plasma, their number is approximately 10-20 times that of other lipoprotein 
particles together269. HDL particles are also the smallest lipoproteins in the 
circulation ranging from 7 to 13 nm in diameter175,  176,  324, and represent the 
density range of 1.063-1.210 g/ml280 (see Table 2.1). The protein content of 
HDL  particles  is  approximately  half  of  their  weight  and  is  relatively  the 
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highest  of  all  lipoprotein  particles280.  The  apolipoprotein  essential  for  the 
formation of a HDL particle is apoA-I which accounts for approximately 60-
70 % of total HDL protein335, 336. ApoA-I occurs with or without other apolipo-
proteins  including  apoA-II,  apoA-IV,  apoC  and  apoE335,  336.  HDL  particles 
without apoA-I but with apoA-IV or apoE with sequence similarity to apoA-I 
have been identified in human plasma although their concentration is low190, 
191. The most typical lipid in the HDL particles is phospholipid (30 %) due to 
the small size of HDL particles; the particles contain less than 20 % of choles-
terol esters and 5 % of triglycerides280.
HDL particles are regularly divided into subclasses by their density in ultra-
centrifuge yielding HDL1 (1.055-1.063 g/ml), HDL2 (1.063-1.125 g/ml), HDL3 
(1.125-1.210 g/ml) and  HDL4 (1.210-1.250 g/ml) subclasses158-160.  HDL2 and 
HDL3 are the main subclasses present in human beings and can be further di-
vided into  HDL2b (9.8–12.9 nm)  and  HDL2a (8.8–9.8 nm)  as well  as into 
HDL3a (8.2–8.8 nm), HDL3b (7.7–8.2 nm) and HDL3c (7.2–7.7 nm) accord-
ing to their size in non-denaturing gradient gel electrophoresis176, 324. 
The concentration of HDL subclasses seems to alter in a reciprocal manner. 
Case-control and angiographic studies suggest that the risk of cardiovascular 
disease  may  increase  when  concentration  of  the  largest  HDL  particles, 
HDL2b, decreases relative to the smallest HDL particles, HDL3c and HDL3b320, 
337-339. Relative concentration of the large particles also decreases and that of 
the smallest particles increases in insulin resistance and type II diabetes324, 340, 
341. By contrast, cholesterol feeding increases the size of the HDL particles and 
the relative concentrations of HDL2b,  HDL2a and HDL3a particles342. Several 
other factors have also been associated with these larger HDL particles, i.e., 
loss of excess body weight increases HDL2b and decreases HDL3b concentra-
tions relative to the total HDL particle concentration343 and elevated levels of 
HDL2a and HDL2b concentrations have been observed in heavy alcohol user-
s344-346. It is, however, unknown what regulates the subclass distribution and 
to what extent these subclasses have different functions.
The reverse cholesterol transport is conceived as the main metabolic func-
tion of HDL particles although they may also have other roles such as antiap-
optotic, antioxidative,  antiinflammatory, and vasodilatory activities347-350.  In 
the reverse cholesterol transport process, the delivery of cholesterol to the liv-
er occurs via cell surface receptors not requiring the degradation of the parti-
cipating HDL particles, and thus the metabolism of HDL particles may be 
seen as a cycle of HDL particles between lipid-rich and lipid-poor states cat-
egorising them into various HDL particle subclasses. These lipid-rich and lip-
id-poor states of HDL particles result from a complex crosstalk of lipid-hy-
drolysing enzymes,  lipid transporters and specific lipoprotein receptors af-
47
fecting significantly the size, composition and structure of HDL particles as 
well as their properties as cholesterol transporters. Due to the complexity of 
reverse cholesterol transport process, its details are still unclear and thus this 
pathway is currently under active investigation.
The  site  of  HDL particle  synthesis  depends  on  the  definition  of  a  HDL 
particle;  These  sites  include  the  liver,  the  small  intestine  and the  circula-
tion250,  334,  335,  352 (see  Fig.  2.3).  The  main  structural  components  of  HDL 
particles, apoA-I and apoA-II molecules, are synthesised in the liver and in 
the small intestine334,  352,  353 and are transported into the circulation as lipid-
free molecules334, 335, 354, nascent HDL particles334, 335, 352 or attached into the sur-
face of triglyceride-rich particles291, 312. These apoA molecules dissociate from 
the surfaces either as lipid-free or lipid-poor apolipoproteins when entered 
into the plasma compartment. In addition to the newly secreted lipid-free and 
lipid-poor apoA compounds,  also the plasma offers  similar,  likely recycled 
lipid-free  and  lipid-poor  apolipoprotein  molecules  which  are  dissociated 
either from HDL particles during their modifications in the plasma334, 335, 355 or 
from delipidated VLDL and CM particles334,  356,  357.  Thus the maturing HDL 
particles appear at first in plasma as lipid-free or small lipid-poor apolipopro-
tein-phospholipid aggregations of which the apoA-I- phospholipid and apoA-
II- phospholipid complexes are most common although also other apolipo-
protein-phospholipid complexes exists334, 358, 359.
Figure 2.3 Metabolism of HDL particles. HDL particles transport cholester-
ol from peripheral cells to the liver. HDL precursors (pre-β HDL) are pro-
duced by the liver and intestine (apoA-I/PL/FC) or derived from surface 
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material from chylomicrons and VLDL particles facilitated by PLTP after  
lipolysis (a,b,c). Pre-β HDL, HDL3 and HDL2 can accept cholesterol for re-
verse cholesterol transport. HDL particles donate cholesterol to the liver se-
lectively, i.e., without whole-particle uptake, via scavenger receptor BI (SR-
BI). Larger HDL particles with apoE molecules (HDL2 or HDL1) can deliver 
cholesterol to the liver directly via the LDL receptor. FC, free cholesterol;  
PL,  phospholipid;  CE, cholesterol  ester;  Tg,  triglyceride,  apoA-I,  apolipo-
protein A-I; apoE, apolipoprotein E; pre-β HDL, HDL precursors; HDL-E,  
high-density lipoprotein particles with apoE; VLDL, very low-density lipo-
protein; LDL, low-density lipoprotein; LCAT, lecithin-cholesterol acyltrans-
ferase; CETP, cholesteryl ester transfer protein; PLTP, phospholipid trans-
fer protein; ABCA1, ATP-binding cassette transporter A1; ABCG1/4, ATP-
binding cassette transporter G1 and G4; SR-BI, scavenger receptor class B  
type I; LDLR, LDL receptor. Reprinted from351 with permission.
In the course of HDL particle maturation, the lipid-poor apoA-I and apoA-
II compounds acquire additional phospholipid and free cholesterol molecules 
from several resources via various processes. Firstly, the lipid-free and lipid-
poor  apolipoproteins  receive  phospholipids  from  the  large  lipoprotein 
particle  surfaces in  a process which is  facilitated by phospholipid  transfer 
protein (PLTP)355,  360. PLTP transports phospholipids down their concentra-
tion  gradients,  resulting  in  phospholipid-enriched  aggregations. Secondly, 
lipid-free apoA molecules and lipid-poor apoA-phospholipid complexes re-
ceive avidly additional lipids, particularly excess intracellular free cholesterol 
molecules and phospholipids from the peripheral cell surfaces via a specific 
membrane transporter called ATP-binding cassette transporter A1 (ABCA1) 
which changes the HDL precursors into discoidal HDL particles335,  354,  361,  362. 
The  flow of  lipids into  these discoidal  HDL precursors  is  followed by the 
break-down of phosphatidylcholines into lyso-phosphatidylcholines and es-
terification of free cholesterol molecules into cholesterol esters by the action 
of lecithin-cholesterol acyltransferase enzyme (LCAT) at the surface of apoA-
I-, apoA-IV-, apoC-, or apoE-containing HDL particles359, 363, 364. The action of 
LCAT increases the amount of cholesterol esters and decreases the amount of 
free cholesterol and phosphatidylcholine molecules in the particles and thus 
maintains  the  concentration gradient  of  free  cholesterol  and phospholipid 
molecules. Thirdly, the HDL precursors gain free cholesterol molecules and 
phospholipids via diffusion from cells and other lipoprotein particles336, 362, 365. 
The enrichment of lipids, particularly the cholesterol esters, and the attach-
ment of additional freely exchanging apoA-I molecules gradually change the 
discoidal  apoA-I  containing  HDL  precursors  into  small,  spherical  HDL3 
particles335, 366. The HDL precursors containing only apoA-II remain, however, 
discoidal since LCAT is not activated by apoA-II molecules367-369. 
Small, spherical  HDL3  particles  continue  to  receive  lipids  from  various 
routes such as phospholipid and cholesterol molecules via diffusion365, phos-
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pholipids via PLTP355, 360, cholesterol via other members of ATP-binding cas-
sette super-families such as ATP-binding cassette transporter G1 and G4 (AB-
CG1 and ABCG4)370-372, as well as via a bidirectional scavenger receptor class B 
type I (SR-BI) pathway365, 373, 374, and surface lipids and apolipoproteins from 
chylomicrons and VLDL particles during their delipidation334,  356,  357. The in-
creased free cholesterol content is again partially esterified by LCAT to cho-
lesterol esters at the surface of apoA-I-, apoA-IV-, apoE- or apoC-containing 
HDL3  particles  resulting  in  an increased size  of  the  HDL3  particles. These 
HDL3 particles require additional apoA molecules to stabilise their structures 
and the apoA molecules are received from various sources including lipid-free 
apolipoproteins354, lipid-poor apolipoproteins375, 376, discoidal HDL particles in 
a LCAT-mediated particle fusion377 or fusion of two HDL3 particles facilitated 
by PLTP355.  In the LCAT-mediated fusion, a small  HDL3  particle combines 
with either a discoidal apoA-I- or apoA-II-containing particle resulting in a 
large, spherical LpA-I or LpA-I:A-II particle. In the PLTP-mediated fusion, 
two small apoA-I- containing HDL particles (having total of 2*3 apoA-I mo-
lecules) fuse to yield either three small HDL particles (3*2 apoA-I molecules) 
or a large HDL particle and two dissociated apoA-I molecules (1*4+2 apoA-I 
molecules). As a result, the subsequent increase in the content of lipids and 
apolipoproteins increases the size of the HDL3  particles and, at some point, 
shifts them into HDL2 particle range. 
In the last step of the reverse cholesterol transport, cholesterol, mainly in 
HDL2 particles334, 351, is delivered into the liver by two receptor-mediated pro-
cesses. The cholesterol in internalised mainly through receptors internalising 
apoB-containing particles311, 328, 329 but also through SR-BI receptors378-380. 
In  the  SR-BI  mediated  process,  HDL2 binds  to  a  cell  and  cholesterol, 
primarily in the form of cholesterol esters374, 381, 382, is transferred efficiently via 
the receptor to the liver in the absence of HDL particle internalisation. The 
formed lipid-depleted  HDL particle  subsequently  dissociates  from the  cell 
and re-enters into the circulation as a small  HDL3  particle and free apoA-I 
molecules366,  383. These HDL precursors are then capable of initiating the re-
verse cholesterol transport again or are degraded as lipid-poor apolipoprotein 
molecules375, 383, 384. 
HDL  cholesterol  molecules  are  also  internalised  via  LDL-receptors  and 
LDL-receptor related proteins. Most of the cholesterol esters internalised by 
this route are first transferred by cholesteryl ester transfer protein (CETP) 
into  apoB-containing  particles385-387 although  large,  apoE-containing  HDL 
particles may also be internalised directly via these receptors351, 388-390. CETP is 
a hydrophobic glycoprotein that is secreted from the liver and circulates in 
plasma bound mainly to HDL particles391, 392. It promotes the redistribution of 
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cholesteryl esters and triglycerides between plasma lipoproteins down their 
concentration gradients. Thus CETP activity results in a net mass transfer of 
cholesterol esters from HDL to apoB-containing lipoproteins in exchange for 
triglycerides from VLDL and CM particles. In apoB-containing particles, the 
HDL-derived cholesterol esters follow the metabolic path of the apoB-con-
taining particles and are received mainly by the liver via LDL-receptors or 
LDL-receptor-related proteins284, 311, 316, 328, 329. The resulting HDL particles are 
depleted of cholesterol esters and may again receive cholesterol in the circula-
tion. 
2.3.5 Atherogenic lipoprotein phenotype
Metabolism  of  lipoprotein  particles  takes  place  as  a  complex  crosstalk 
between the four lipid transportation systems. The lipid transportation pro-
cesses are all highly connected, which is mainly caused by action of enzymes 
and lipid transporters. In the following, these associations are discussed from 
the point of view of atherogenic lipoprotein phenotype where the interactions 
are clearly seen.
Broadly, the atherogenic lipoprotein phenotype is a combination of lipid or 
lipoprotein abnormalities frequently met in individuals with atherosclerosis. 
Originally, the  atherogenic lipoprotein phenotype was characterised by the 
prevalence of small, dense LDL particles, elevated plasma triglycerides and 
reduced HDL cholesterol393. Later on, when the concentrations of VLDL, LDL, 
and HDL particles per se were recognised as important variables of lipopro-
tein metabolism, the definition of the atherogenic lipoprotein phenotype was 
expanded. Therefore, currently, the  atherogenic lipoprotein phenotype con-
stitutes  elevated  plasma  triglycerides  or  VLDL  particles;  elevated  LDL 
particles particularly in their small, dense region; and reduced HDL choles-
terol or HDL particles1, 20, 206, 394. 
Elevated plasma triglyceride level seems to be one of the most important 
determinants of the atherogenic lipoprotein phenotype and abnormal lipo-
protein metabolism322,  338,  395,  396. As plasma triglyceride level is fairly easy to 
measure, elevated levels of plasma triglycerides have been studied extensively 
and linked to  various conditions including several  lifestyle  factors such as 
obesity, overweight, physical inactivity, cigarette smoking, excess alcohol in-
take, high carbohydrate diet (> 60 % of energy intake); several diseases such 
as type II diabetes, chronic renal failure, nephrotic syndrome; certain drugs 
such as corticosteroids, estrogen, retinoids and beta-blockers as well as vari-
ous genetic dyslipidemias131. Thus, there are  multiple reasons for developing 
high levels of plasma triglycerides. 
Increase in  plasma triglyceride level  results  from accumulation of  trigly-
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ceride-rich lipoprotein particles in plasma, and the particles mainly respons-
ible for the rise are VLDL1 particles322,  397. Accumulation of VLDL1 particles 
occurs due to alternative or combined metabolic defects in their lipid trans-
portation  processes  including  increased  production  and  decreased  rate  of 
conversion or catabolism.  The reason for  the  increased amount  of  VLDL1 
particles has been investigated from various directions including insulin res-
istance292,  325,  incompetent apolipoprotein compositions263,  398-400 as well  as a 
saturable delipidation pathway of VLDL and CM particles401-403. 
Production of VLDL1 particles is highly controlled by the level of insulin292. 
Thus individuals with increased insulin resistance are less sensitive to the in-
sulin-induced inhibition of VLDL1 secretion292. The overproduction of VLDL1 
particles is also the main cause of elevated VLDL1 particles in insulin-resist-
ant individuals while their delipidation rate of VLDL1 particles may also be 
decreased325.
In  apparently  healthy,  insulin-sensitive  individuals,  the  elevated  VLDL1 
particle concentrations are mostly due to decreased delipidation rate rather 
than increased production of VLDL1 particles394.  One reason for decreased 
delipidation of VLDL1 particles may be improper apolipoprotein composition 
effecting on the activity of lipoprotein lipase. For example, lipoprotein lipase 
is activated by apoC-II molecules and inhibited by several other apolipopro-
teins including apoC-III. It has been shown that apparently healthy individu-
als with high plasma triglyceride level have increased concentration of large 
VLDL particles which are rich in apoC-III compared to individuals with nor-
mal plasma triglyceride level398-400. ApoC-III has also been shown to inhibit 
hepatic clearance of triglyceride-rich lipoproteins263, 399. 
Increase  in  concentration  of  VLDL1  particles  has  also  been  observed  in 
postprandial state. Concentration of VLDL1 particles may be increased due to 
the fact that  chylomicrons and VLDL1 share a common, saturable delipida-
tion pathway401-403 since they compete for the same, active lipoprotein lipase 
molecules limiting the delipidation process. It seems that chylomicrons be-
come delipidated faster than VLDL since chylomicrons bind more avidly to 
lipoprotein lipase than VLDL particles and since their particle concentration 
is at least 20-fold lower than that of VLDL401. In the postprandial state, the in-
crease in VLDL1 particles has been observed in both insulin-resistant and in-
sulin-sensitive individuals  although the effect  is  more pronounced in indi-
viduals with insulin resistance404.
Elevated levels of VLDL1 particles and shift of LDL particles into smaller 
particle sizes occur simultaneously surprisingly often322, 396; approximately 50 
% of the variation in LDL particle size is explained by variation in plasma 
triglyceride levels20,  294. Individuals with decreased LDL size distribution are 
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designated as having LDL subclass B (pattern B) or individuals with preval-
ence  of  small,  dense  LDL  particles  (sdLDL).  The  prevalence  of  sdLDL 
particles depends highly on age and gender and is approximately 30-35 % in 
adult men, 5-10 % in young men (less than twenty years old), 5-10 % in pre-
menopausal women393, 405 and 15-25 % of post-menopausal women406, 407. The 
prevalence of sdLDL has also been linked to several gene regions important in 
LDL particle metabolism indicating that the prevalence of sdLDL is affected 
also by genetic factors408-410. In fact, there are multiple genes which may con-
tribute and the responsible genetic mechanisms may vary among families20. 
Thus it seems that both genetic and non-genetic, environment factors are im-
portant determinants of LDL particle size distribution.
The mechanism by which LDL particles  become small  and dense in  the 
presence of elevated plasma triglyceride concentration depends on the action 
of at least two lipid hydrolysing or transporting enzymes, HL and CETP160, 411, 
as well as the level of plasma triglycerides. The process also requires time and 
thus the LDL particles should have a prolonged residence time (more than 
one extra day) in plasma394. The size reduction is similar to that seen in HDL 
particles as a part of their normal metabolic cycle although here the elevated 
plasma VLDL1 concentration has changed the weight of relative CETP-medi-
ated lipid transport process between the lipoprotein particles160, 322. In the pro-
cess,  the amount of cholesterol esters in LDL particles becomes decreased 
and triglycerides  increased due to  the  decreased  cholesterol  ester  transfer 
from HDL and increased heteroexchange of LDL cholesterol esters for VLDL 
triglycerides as compared to the normolipidemic state. If this heteroexchange 
occurs to a significant degree, the triglycerides in LDL particles become hy-
drolysed by HL decreasing further the size of the particles. Thus, the com-
bined action of  CETP and HL in  the presence of  elevated level  of  VLDL1 
particles leads to the remodelling of LDL particles into cholesterol ester-de-
pleted small, dense LDL particles.
The  concentration  of  total  LDL  particles,  not  only  the  concentration  of 
small LDL particles relative to all LDL particles, seems to increase with in-
creasing plasma triglycerides322. When plasma triglyceride concentration in a 
population rises from 0.5 to 1.5 mmol/l,  there is a steady increase in LDL 
level  although the increase is  more marked in the intermediate-sized LDL 
particles and the level of small LDL remains low. Above the plasma trigly-
cerides of 1.5 mmol/l, the total LDL concentration does not seem to increase 
but the level of intermediate-sized particles falls and level of small LDL rises 
sharply322. Increase in the total number of LDL particles is also observed to 
coincide the increased concentration of small LDL particles in many recent 
clinical outcome studies147, 412-416.
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Increased levels  of  plasma triglycerides  and VLDL1 particles  affect  HDL 
particles as well160,  395,  417. When the level of VLDL particles is normal, CETP 
modulates HDL size distribution by transferring HDL cholesterol esters pref-
erentially to LDL particles392, 418 and thus enables, for its part, the normal cyc-
lic metabolism of HDL particles385-387. However, the metabolism may become 
altered when the concentration of large, triglyceride-rich VLDL1 particles is 
increased;  CETP  transfers  HDL  cholesterol  esters  preferentially  to  VLDL1 
particles for heteroexchange of VLDL triglycerides, resulting in triglyceride-
enriched HDL particles392, 418,  419. The triglyceride-enriched HDL particles are 
then modified by lipid-hydrolysing lipases, for example HL, which decreases 
the size of the HDL particles. These remnant HDL particles have also shown 
in vitro to have enhanced holoparticle binding, internalisation and degrada-
tion in tissues involved in HDL catabolism thus decreasing the HDL particle 
concentration in plasma417, 420-422. Likewise, the decreased hydrolysis of VLDL1 
particles may also inhibit the normal metabolism of HDL particles by yielding 
decreased amounts of surface lipid and apolipoprotein molecules needed to 
increase the size of HDL particles357. The shift of HDL particles to the smaller 
sizes may also have a feedback effect on the metabolism of VLDL1 particles 
since small HDL  particles usually do not contain apolipoprotein other than 
apoA417, 423 and thus cannot donate apoC-II and apoE molecules to VLDL and 
CM particles to assist their delipidation and endocytosis. 
While the lipid transportation processes per se are complicated events, the 
interactions  between  the  processes  multiply  the  complexity  resulting  in 
highly  sophisticated  lipoprotein  particle  metabolic  networks.  Lipoprotein 
particle metabolism is also susceptible to various modifications in the func-
tion of the participating components, e.g. inefficient lipolysis of triglyceride-
rich particles,  although normal  metabolism may to  some extent  be  main-
tained via alternative routes, e.g. efflux of cholesterol via various channels in 
the  reverse  cholesterol  transport.  Due  to  the  complexity  of  lipoprotein 
particle metabolism even in normal situations, the effect of each altered lipid 
transportation process on the cause of pathological conditions, such as ather-
osclerosis and cardiovascular disease, remains unclear. 
To summarise, the lipoproteins are heterogeneous particles which vary on 
various properties including density, size, surface charge and chemical com-
position. Several methodologies have been developed to isolate lipoprotein 
particles according to their different properties into lipoprotein fractions and 
further lipoprotein subclasses. All lipoprotein particles have been shown to 
have a similar micellar structure but there still exists uncertainties about the 
molecular structure of lipoprotein particles. Lipoprotein particles face com-
plex metabolism in blood plasma and their metabolism can be viewed as lipid 
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transportation phenomena between the site of lipoprotein assembly, degrada-
tion and in some cases cellular uptake. The lipid transportation processes are 
highly  interconnected  and  regulated  by  various  genetic  and  non-genetic 
factors. Association between lipoprotein metabolism and the development of 
atherosclerosis is widely studied and has led to formulation of an atheroscler-
otic lipoprotein phenotype which includes several lipoprotein particle com-
ponents  such  as  increased  VLDL  and  LDL  particles  and  decreased  HDL 
particles as well as various lipid variables including increased VLDL trigly-
ceride and decreased HDL cholesterol concentrations. Despite intensive in-
vestigation of lipoprotein particles for decades, the detailed contribution of 
lipoprotein particles to the development of atherosclerosis remains still un-
clear and novel methodologies and technologies are needed to increase our 
knowledge of various aspects of these lipid-carrying particles. 
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3. Computational modelling of 
lipoprotein particle structures
So far, we have discussed the basics of the structure and the metabolism of 
lipoprotein particles. From now on, we will move forward to discuss compu-
tational modelling of lipoprotein particles. The next four chapters deal with 
this topic and are based on the studies I have contributed to. This chapter will 
first introduce computational modelling of lipoprotein particle structures in 
general. Then, a new structural lipoprotein particle model concerning the loc-
ation of hydrophobic lipids, i.e., triglycerides and cholesterol esters, within 
lipoproteins is presented and discussed in the light of the structure-metabolic 
relationship of the particles. The research discussed in the chapter has also 
been published in a refereed journal, see424.
3.1 Current state of computational modelling of lipoprotein 
particles
The general structure of lipoprotein particles is well known. However, there 
still  exists  uncertainties about the molecular  level  structures160,  210,  211,  215,  216. 
While the general structures have been revealed by several physicochemical 
methods, including small-angle X-ray and neutron scattering230,  425-427, NMR 
spectroscopy232,  233,  428-430, and electron microscopy212,  251,  431-434, these methods 
have not been successful in revealing the molecular structures. On the other 
hand, computational modelling is expected to be particularly useful in clarify-
ing the molecular structure of lipoprotein particles. 
Lipoprotein particles are complex systems to model. They have large mo-
lecular dimensions as even the smallest of the lipoprotein particles contain 
hundreds of lipid molecules and proteins constituents consisting of a large 
number of amino acid residues. While a few hundred molecules might not 
seem a particularly high number, it nevertheless means tens of thousands of 
atoms and even more pair-wise interactions. The composition of lipoprotein 
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particles is also heterogeneous as they contain triglyceride, cholesterol ester, 
phospholipid and free cholesterol molecules as well as various apolipopro-
teins.  This  heterogeneity  increases  the  type  of  interactions  present  within 
lipoprotein particles. The lipid constituents of lipoprotein particles have also 
complex thermodynamic properties.
This  overall  complexity  of  lipoprotein  particles  presently  hampers  their 
computational modelling by techniques capable of featuring detailed lipid in-
teractions. These include molecular and dissipative particle dynamics which 
are based on tracking individual atoms or group of atoms, respectively, via 
classical Newton's equations.  Currently,  these methods have been success-
fully used to model an isotropic system of cholesterol esters435; small, discoid-
al  HDL particles436,  roughly  spherical  HDL particles437 and spherical  HDL 
particles with a half amount apoA-I molecules with somewhat limited mo-
tions438.  While  the role  of molecular and dissipative  particle dynamics will 
likely increase in computational modelling of lipoprotein particles in the fu-
ture, simpler models requiring less computational power are at present the 
only  option  to  gather  new  information  on  the  structure  of  lipoprotein 
particles by computational means.
After  the  establishment  of  micellar  structure  of  lipoprotein  particles  in 
1968208, tens of structural, computationally less demanding lipoprotein mod-
els have been constructed174, 210,  211,  214,  215,  439-441. As far we are aware, there are 
four  models  which seek the  molecular  arrangements of  lipid  molecules  in 
lipoprotein particles by calculating the number of lipids in each lipoprotein 
particle from measured biochemical data. However, in contrast to our model 
introduced here, all of these older models essentially obey the conventional 
view that all triglyceride and cholesterol ester molecules reside in the interior 
of the lipoprotein particles whereas all phospholipids and polar parts of pro-
teins locate in the surface layer of lipoprotein particles as discussed in the fol-
lowing paragraphs. 
Shen, Scanu and Kedzy assumed that all lipoprotein particles have an equal 
molecular arrangement of lipids and proteins, and the arrangement can be 
calculated based on simple linear equations215. In the model, all free choles-
terol molecules were located in the surface layer since their partition between 
the core and the surface layer was then not known. As a consequence, the 
model revealed that triglycerides and cholesterol esters form alone a core of a 
particle having a 2.05-nm-thick surface layer.  Moreover, phospholipid and 
free cholesterol molecules were tightly packed in the core-surface layer inter-
face preventing the interpenetration of triglycerides and cholesterol esters to 
the surface. Furthermore, although free cholesterol molecules resided in the 
surface layer, they were not in direct contact with water but were located un-
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der protein molecules. 
Soulages and Brenner studied the structure of high density lipophorin (in-
sect  lipoprotein)  particles439.  Lipophorins do not contain cholesterol  esters 
but hydrocarbon and diglyceride molecules in addition of triglycerides as core 
lipids. Interestingly, while all triglycerides and hydrocarbons were placed in 
the core of the particles in this model, diglycerides were assumed to locate 
both in the core and in the surface layer. The amount of diglycerides in the 
surface layer was also assumed to be proportional to the number of phosphol-
ipid molecules in the particle. The results confirmed that there actually exists 
diglycerides in the surface layer of lipophorin particles but their amount was 
very low.
Distinct  from  the  other  models,  Schnitzer  and  Lichtenberg  published  a 
model of LDL where apoB-100 was assumed to form a single cap on the sur-
face of an LDL particle, or partly within the surface layer of an LDL particle, 
without covering the phospholipid head groups441. Instead, triglyceride, cho-
lesterol ester and free cholesterol molecules could also interpenetrate under 
the apoB-cap. When the number of triglycerides or cholesterol esters was in-
creased in the model, while keeping the number of other molecules fixed, the 
interpenetration in  the  surface  layer  underneath the  protein  increased  al-
though an increase in the radius of the core was significantly faster.
The most recent geometric model was published by Teerlink et al.440. In ad-
dition to biochemical measurements, size measurements of LDL particles by 
high-performance  gel-filtration  chromatography  were  also  performed.  The 
main result of their work, the non-spherical shape of LDL particles at 25 ˚C, 
was  based on differences in measured and calculated radii of LDL particles. 
However, data on the partitioning of lipids between the core and the surface 
layer suggested that different lipids contribute different dimensions of non-
spherical LDL particles. The larger dimensions were mostly affected by free 
cholesterol molecules locating at the surface: if the content of free cholesterol 
is low, the radius is smaller due to interaction of fatty acid chains of cholester-
ol ester and phospholipid molecules whereas high free  cholesterol content 
would prevent the interaction. In contrast, triglycerides and cholesterol esters 
contributed the most to the smaller dimensions. 
To summarise, computational modelling based on lipid and protein com-
positions has been found to be a feasible way to achieve information on the 
molecular  organisation  of  lipids  and  apolipoproteins  within  lipoprotein 
particles.  The current  knowledge  of  molecular  structure  of  lipoprotein 
particles is advanced greatly by these calculations although they are charac-
terised as more straightforward and computationally less demanding than the 
molecular dynamic simulations. 
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3.2 Materials and methods: A structural lipoprotein particle 
model 
I will introduce here a new structural lipoprotein particle model which chal-
lenges the conventional view of molecular organisation of hydrophobic lipids, 
i.e.,  triglycerides  and  cholesterol  esters,  within  lipoprotein  particles.  The 
modelling is performed separately for eleven lipoprotein subclasses, includ-
ing VLDL1, VLDL2, IDL, LDL1, LDL2, LDL3, HDL2b, HDL2a, HDL3a, HDL3b 
and  HDL3c, covering the whole range of different lipoprotein particles. The 
purpose of the modelling is to find an averaged, molecular particle structure 
for each of the lipoprotein subclasses.
3.2.1. Lipoprotein isolation and compositional analysis
Data for  the  modelling  were  obtained from 12 individuals.  Blood samples 
were drawn after an overnight fast for 12 h into EDTA-containing tubes and 
the blood plasma was separated by low-speed centrifugation. Fasting plasma 
triglyceride-rich lipoproteins were separated by density gradient ultracentri-
fugation (a Backman L8-70 ultracentrifuge, a SW40 TI swinging-bucket ro-
tor). Three fractions were isolated containing large VLDL (VLDL1, Svedberg 
flotation units Sf = 60 – 400), small VLDL (VLDL2, Sf = 20 – 60) and IDL (Sf 
= 12 – 20). VLDL1, VLDL2 and IDL were isolated from 2 ml of plasma the 
density of which was increased by adding 0.341 g dry NaCl. The plasma was 
then overlaid with a density gradient consisting of NaBr solutions of decreas-
ing densities (1 ml of d = 1.0988 g/ml, 1 ml of d = 1.0860 g/ml, 2 ml of d = 
1.0790 g/ml, 2 ml of d = 1.0722 g/ml, 2 ml of d = 1.0641 g/ml and 2 ml of d = 
1.0588 g/ml). The VLDL1 (1 ml) was harvested after ultracentrifugation for 1 
hour and 21 minutes at 39 000 rpm at 23°C. Thereafter 1 ml of d = 1.0588 g/
ml saline was added and VLDL2 (0.5 ml) was isolated after centrifugation for 
16 hours and 22 minutes at 18 000 rpm and IDL (0.5 ml) after 2 hours and 18 
minutes at 39 000 rpm at 23°C. The centrifuge was allowed to stop with the 
brake off.424, 442
LDL and HDL samples for density gradient ultracentrifugation were isol-
ated by preparative ultracentrifugation (a Beckman Optima TL centrifuge, a 
Beckman TLA 100.3 rotor). For an LDL sample, tubes containing 2.0 ml of 
plasma were overlaid with 1.0 ml of NaBr solution of density 1.0190 g/ml and 
ultra-centrifuged at 100 000 rpm for 3 h at 20 °C. After ultracentrifugation a 
thin, fairly yellowish layer containing VLDL and IDL was removed from the 
top of the tubes by aspiration. The density of the infranatant containing LDL 
particles was increased to 1.0900 g/ml by adding 1.5 ml of NaBr solution d = 
1.100 g/ml and saved for later use. To obtain a HDL sample, the apoB-con-
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taining lipoprotein particles were first removed by preparative ultracentrifu-
gation. For this, 2 ml of plasma in 0.3 ml NaBr solution d = 1.535 g/ml was 
overlayered with 0.7 ml NaBr solution d = 1.0600 g/ml and ultracentrifu-
gated at 100 000 rpm for 3 h at 15 °C. Then, the supernatant layer containing 
VLDL,  IDL and  LDL was  removed by  aspiration  and  the  infranatant  was 
saved for later use.443 
LDL and HDL subclasses were then isolated by density gradient ultracentri-
fugation (a Backman L8-70 ultracentrifuge, a  SW40 TI swinging-bucket ro-
tor). For LDL subclasses, the discontinuous NaBr solution gradient was pre-
pared by layering from bottom to top: 0.5 ml d = 1.1900 g/ml; 2.5 ml sample 
(the infranatant of a volume of 1.0 ml from VLDL + IDL separation in 1.5 ml 
NaBr d =  1.100 g/ml); 1.5 ml d = 1.060 g/ml; 1.5 ml d = 1.055 g/ml; 1.5 ml d 
= 1.045 g/ml; 2.0 ml d = 1.034 g/ml; 2.0 ml d = 1.023 g/ml; and 1.0 ml d = 
1.019 g/ml. After ultracentrifugation at 40 000 rpm for 23 h 45 min at 23°C, 
the tubes were discharged from the top using Beckman Recovery System and 
by infusing Maxidens solvent (Nyegaard & C. A/S, Oslo, Norway) to the tubes. 
The protein absorbance profiles in the tubes were monitored with an absorb-
ance meter (Pharmacia, Uppsala, Sweden). The density gradient of the tubes 
was controlled with a DMA 46 density meter (Anton-Paar GmbH, Graz, Aus-
tria) placed before the fraction collector. Three LDL subclasses, LDL1 (d = 
1.024 – 1.031 g/ml), LDL2 (d = 1.031 – 1.040 g/ml) and LDL3 (d = 1.040 – 
1.054 g/ml), were collected in a volume of 2.1 ml each.443, 444
For  HDL  subclasses,  the  density  of  the  HDL  sample  was  increased  by 
adding 1.0 g dry NaBr. A 2-ml volume of the sample was pipetted to a tube 
and the discontinuous gradient was prepared by layering NaBr solutions d = 
1.250 g/ml and d = 1.220 g/ml, 1.5 ml and 6.7 ml above the sample, respect-
ively, and 2.0 ml distilled water above the salt solutions. After ultracentrifu-
gation at 40,000 rpm for 18 h at 15 °C, five 1.3-ml fractions corresponding to 
HDL2b, HDL2a, HDL3a, HDL3b and HDL3c were collected.443, 445
The concentrations of  lipids,  including total  cholesterol,  free  cholesterol, 
triglyceride  and  phospholipid  concentrations,  were  then  determined  from 
each density range with  Specific Chemistry Analyser (Kone, Finland) using 
enzymatic colorimetric methods (kits by Boehringer Diagnostica, Mannheim 
GmbH, FRG). The concentration of cholesterol esters were calculated as the 
difference between total cholesterol and free cholesterol concentrations. The 
total protein contents were measured by the modified Lowry method197, 198. 
3.2.2 Molecular composition and volume calculations
The numbers of lipid molecules in the lipoprotein particles were calculated 
based on the experimental data. Thus, the number of triglyceride, cholesterol 
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ester, phospholipid and free cholesterol molecules were obtained by the equa-
tion
N l
i , s=
cl
i ,s
p
i , s M p
s
, (3.1)
where c l
i ,s is the concentration of the particular lipid (l) in an individual 
(i) in a lipoprotein subclass (s) in mol/l,  p
i , s  is similarly the total protein 
(p) content in the sample in g/l, and M p
s is the total molecular mass of the 
proteins in each particle. 
The amount of proteins per an average lipoprotein particle was estimated 
based on recent literature184, 323, 446 (see Tables 3.1 and 3.2) and fine-tuned to 
yield appropriate weight percentages and particle sizes. Some metabolic vari-
ations take place in the apolipoprotein contents, particularly in the amount of 
exchangeable  apolipoprotein molecules184,  447,  within lipoprotein  subclasses, 
e.g., in VLDL1323. Nevertheless, we noted that even substantial variations in 
the apolipoprotein contents within the lipoprotein subclasses did not inter-
fere with the key trends in the cholesterol ester and triglyceride distributions 
within the particles (data not shown). 
This equation derived by the author is capable of characterising lipoprotein 
particles individually and is valid for all lipoprotein subclasses. It is thus an 
extension of previous equations either using average weight composition data 
over subjects215,  439,  441 or only dealing with LDL particles174,  440. The resulting 
numbers of lipids in lipoprotein particles are shown in Table 3.3.
Table 3.1 A description of protein composition within the apoB-containing 
lipoprotein subclasses.
Lipoproteins were isolated by density gradient ultracentrifugation. VLDL1,  
large VLDL particle, Svedberg flotation units Sf = 60 – 400; VLDL2, small  
VLDL particle, Sf = 20 – 60; IDL, Sf 12 – 20; LDL-1, LDL subclass in density  
range of 1.024 – 1.031 g/ml; LDL2, d = 1.031 – 1.040 g/ml; LDL3, d = 1.040 
– 1.054 g/ml; apoA, apolipoprotein A; apoB, apolipoprotein B; apoC, apoli-
poprotein C; apoE, apolipoprotein E; Total protein / apoB, the ratio of total  
protein concentration to apoB concentration. The amounts of apoA, apoB, 
apoC and apoE molecules are expressed as percent of total protein concen-
tration.
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Table 3.2 A description of protein composition within HDL lipoprotein sub-
classes.
HDL particles  were isolated by density  gradient  ultracentrifugation into  
five fractions corresponding to  HDL2b,  HDL2a,  HDL3a,  HDL3b and HDL3c.  
ApoA-I,  apolipoprotein  A-I;  apoA-II,  apolipoprotein  A-II;  Others,  other 
apolipoproteins than apoA-I and apoA-II; Mprotein, total molecular mass  
of the proteins in Daltons. The amounts of apoA-I, apoA-II and other pro-
tein molecules are expressed as percent of total protein concentration.
The volumes of the apolipoprotein molecules were estimated based on the 
protein content in each lipoprotein subclass; the number of amino acids in 
each apolipoprotein; and the volume of an average amino acid, 0.12286 nm3 
448. The estimates of lipids and proteins were then used to calculate particle 
volumes. The total volumes of the lipoprotein particles were obtained by sum-
ming the volumes of all lipid and apolipoprotein molecules. The volumes used 
for the lipid molecules were: 1.572 nm3 for triglycerides; 1.138 nm3 for choles-
terol esters; 0.656 nm3 for free cholesterol molecules and 1.284 nm3 for phos-
pholipids449.
Table 3.3 The weight percentage composition and the numbers of lipid mo-
lecules in the lipoprotein particles isolated via ultracentrifugation.
The numbers of lipids were calculated by equation 3.1 and the weight per-
centages were calculated using the molecular masses of 859.2 for  trigly-
cerides, 647.9 for cholesterol esters, 386.7 for free cholesterol molecules and  
786.0 phospholipids. The values are mean ± S.D. from 12 individuals; W,  
weight percentages;  N, numbers of  lipid molecules;  TG, triglyceride;  CE, 
cholesterol ester; FC, free cholesterol; PL,  phospholipid; PROT, total pro-
tein. Plasma cholesterol and triglyceride concentrations (mean ± S.D.) were  
4.76 ± 1.32 mmol/l  (range 2.63 – 6.58 mmol/l)  and 1.38 ± 0.59 mmol/l  
(range 0.68 – 3.02 mmol/l), respectively.
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3.2.3 The geometric lipoprotein particle model 
In the modelling process, we assume lipoproteins as spherical particles with a 
core and an approximately 2 nm thick surface layer. The volumes of the cores 
could then be calculated from the total volumes of the particles by using these 
assumptions. We made also some assumptions about the molecular organisa-
tion of lipids based on the current knowledge of lipoprotein particle struc-
tures160,  210,  211,  214,  215,  232,  233,  242. Firstly, we assumed that all phospholipids and 
proteins locate in the surface layer. Secondly, we constrained the portion of 
free cholesterol  molecules in the surface to  be directly proportional  to the 
number of phospholipid molecules in the particles. The used molar surface 
free cholesterol to phospholipid ratios were 0.6 for VLDL242, 0.55 for IDL and 
LDL233, and 0.22 for HDL2 and 0.16 for HDL3 particles232. The rest of the free 
cholesterol molecules were assumed to be in the core. Thirdly, the rest of the 
space within the particles was reserved for the triglycerides and the cholester-
ol esters.
We can now write an equation of volumes of the cores for each of the 12 in-
dividuals and for all lipoprotein subclasses separately; one side of the equa-
tion was obtained via the total volumes of the particles and the other side de-
pended on the number of triglyceride, cholesterol ester and free cholesterol 
molecules in the core. Thus the equation for the volumes of the cores is
. (3.2)
Here the numbers of triglyceride ( N TG
i,s
), cholesterol ester ( N CE
i,s
) and free 
cholesterol  ( N FC
i,s
)  molecules,  and  volumes  of  the  cores  ( V core
i,s ),  were 
obtained  from  the  twelve  (n=12)  individuals  as  described  earlier.  vTG , 
vCE  and  vFC  are  the  average  molecular  volumes  of  triglyceride, 
cholesterol  ester  and free  cholesterol  molecules,  respectively.  The alphas  (
αTG
s
, αCE
s
 and αFC
s
) are the relative portions of triglyceride, cholesterol 
ester and free cholesterol molecules in the core from which the portions of 
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triglycerides and cholesterol esters were to be solved while the portion of free 
cholesterol molecules was fixed. The portions of triglycerides and cholesterol 
esters  in  the  core  were  also  restricted  between zero  and  one  to  ensure  a 
physically relevant solution. The portions of these lipids in the surface layer 
could then be obtained as one minus the corresponding alpha.
The  alphas  were  solved  by  optimisation since  we  had two unknowns  and 
twelve equations. The optimisation was performed by minimising an error 
function that  was built  based on the equation presented above.  The error 
function  also  included  penalty  terms  taking  care  of  the  restrictions.  The 
estimates  of  distributions  and  errors  were  obtained  by  repeating  the 
optimisation 1000 times using mainly the Monte Carlo methods450 and, then, 
calculating  the  averages.  Finally,  leave-one-out  cross  validation451 was 
performed  to  estimate  the  errors  for  αTG
s ,  αCE
s ,  i.e.,  the  alphas  were 
calculated 12 times in the case of each subclass for  n-1 individuals, leaving 
each individual  out of  the analysis  once.  The standard deviations of  these 
αTG
s  and  αCE
s  values were taken to represent their errors. This kind of 
assessment provides a simple statistical estimation of the expected variations 
in the alphas in the case of more data.
3.3 Results
The key results of the optimisation and their comparison to existing experi-
mental data are shown in  Fig. 3.1. Panel  a) shows the percentages of trigly-
cerides and cholesterol esters in the surface of lipoprotein particles. As seen 
from the figure, HDL particles and apoB-100-containing particles form two 
separate  groups:  HDL particles  have high percentages of  triglycerides and 
cholesterol esters in their surface while VLDL, IDL and LDL particles have 
low percentages.  The  values  for  the  triglyceride  and cholesterol  ester  mo-
lecules are similar within both groups. 
Panel b) of Fig. 3.1 shows the percentage of triglyceride and cholesterol es-
ter molecules of all surface lipids in lipoprotein particles. In here, within both 
groups,  some co-operative behaviour can be seen: In apoB-100-containing 
particles, the percentage of triglycerides increases and that of cholesterol es-
ters decreases as their radius increases. On the other hand, in HDL particles, 
the increase in radius coincides with a decrease in the percentage of choles-
terol esters but does not particularly affect the percentage of triglycerides. 
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In all cases, the surface percentages of triglyceride and cholesterol ester mo-
lecules can be explained by a combination of the total amount of the lipid and 
its percentage in the surface layer. For example, although the percentage of 
triglyceride in the surface layer of HDL particles is high (panel a), the per-
centage of triglycerides of all  surface lipids is low (panel b) since the total 
amount of triglycerides in HDL particles is low. Correspondingly, since the 
total amount of triglycerides in VLDL1 particles is extremely high, the per-
centage of triglycerides of all surface lipids is high (panel b) although the per-
centage of triglycerides in the surface layer is low (panel a).
Figure  3.1  Distribution  of  triglyceride  and  cholesterol  ester  molecules  in  
lipoprotein particles.  Proportion of triglycerides and cholesterol  esters in 
the surface of lipoprotein particles a) and their percentages of all surface 
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lipids b). All values are mean ± S.D. (non-visible S.D.-bars are within the  
bullets). The black triangle represents the sole experimental value for native  
VLDL particles isolated from hen243. Modified from 424.
3.4 Discussion 
I have introduced here a structural lipoprotein model which was built based 
on both experimental lipid and protein concentrations in the plasma and the 
current knowledge of lipoprotein particle structures. The structural model is 
general as it is built separately for eleven lipoproteins subclasses and provides 
largely consistent results over the subclasses. The model indicates, in contrast 
to the conventional lipoprotein model, that  particle size-dependent propor-
tion  of  hydrophobic  lipids,  namely  triglyceride  and  cholesterol  ester  mo-
lecules, may locate in the surface of lipoprotein particles. 
The idea of triglycerides and cholesterol esters  locating at the surface of 
lipoprotein particles might at first appear strange due to their hydrophobic 
nature. It  should, however, be remembered that free cholesterol molecules 
and hydrated forms of triglycerides, diglycerides, which are only slightly po-
lar, have been detected at the surface of lipoprotein particles232, 233, 452. Experi-
mental data on the location of the hydrophobic triglycerides and cholesterol 
esters  in the surface of lipoprotein-like particles  is,  however,  exceptionally 
scarce. A recent 13C NMR spectroscopy study of hen VLDL particles revealed 
that the amount of triglycerides of the surface lipids was 5.1 ± 0.6 mol%243. 
This  value,  indicated as a black triangle in Fig.  3.1 panel  b, is in excellent 
agreement with our computed values for native human lipoproteins of similar 
particle size. 
The structure of native human lipoprotein particles has also been widely 
studied by 13C NMR232, 233, 428, 429. However, since 13C NMR is incapable of oper-
ating in natural abundance of 13C, the visibility of a molecule depends on its 
13C enrichment. Therefore, in the light of the hen lipoprotein 13C NMR study 
mentioned above, it is possible that the surface triglycerides and cholesterol 
esters in human lipoprotein particles have not yet been observed due to their 
insufficient 13C enrichment under the experimental conditions used. 
There is some experimental evidence that a small portion of triglycerides 
and  cholesterol  esters  locate  in  the  surface  of  vesicles  and  emulsion 
particles234-243. The vesicle systems are not, however, ideal models for lipopro-
tein particles since they have a phospholipid bilayer, which is incapable of 
solubilising  large  amounts  of  hydrophobic  lipids,  and an  interior  aqueous 
compartment  not  present  in  lipoproteins  (see  Fig.  3.2).  Furthermore,  the 
emulsion particles  have  been large,  20-100 nm in  diameter,  and thus  re-
sembled only LDL up to VLDL particles and not HDL. The surface portions of 
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triglycerides and cholesterol esters from these model systems are, however, in 
good accordance with our optimised values. Both triglycerides and cholester-
ol esters mix in similar amounts into phospholipid bilayers with as high val-
ues as 10 mol% of all the surface lipids being measured for triglycerides236, 239. 
The percentages of triglyceride and cholesterol esters of all surface lipids in 
emulsion particles were similar as in bilayers although the results seemed to 
depend significantly on the actual lipid model system leading to over 10-fold 
differences in the observed amount of triglycerides of all surface lipids in sim-
ilarly sized emulsion particles with different types of triglyceride molecules241. 
Figure 3.2  Schematic  cross-sectional  illustration of  the  overall  structural 
characteristics of vesicles as well as emulsion and lipoprotein particles. The  
vesicles  are  biophysically  distinct  from  the  emulsion  and  lipoprotein 
particles.  While the core of  an emulsion and lipoprotein  particle is  filled 
with lipids, the lipid soluble area in a vesicle is limited to the surrounding  
bilayer. PC, phosphatidylcholine; SM, sphingomyelin; FC, free cholesterol.  
Modified from 424.
As the previous lipoprotein model systems have been unable to model HDL 
particles, we concentrated on finding studies dealing with reconstituted HDL 
particles to get some references for our model. Reconstituted HDL particles 
are frequently used to study HDL particles and they are prepared as small, 
micellar  complexes of exchangeable apolipoproteins with lipids that mimic 
HDL in shape, composition and functional properties453-456. The one import-
ant property of reconstituted HDL particles is, among many, that they can be 
prepared to contain only one or few defined lipid components. 
Rye et al. have investigated the role of different phospholipid molecules af-
fecting  the  CETP-mediated  remodelling  of  HDL  particles455.  Reconstituted 
HDL particles were prepared with one type of phosphatidylcholine, free cho-
lesterol, cholesterol ester and apoA-I molecules, and the sizes of the particles 
were measured by non-denaturing gradient gel electrophoresis. By using the 
stoichiometry and the sizes of the reconstituted, unmodified HDL particles, 
we could estimate the percentages of cholesterol esters of all surface lipids 
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directly without optimisation as there were no triglycerides involved. The per-
centages increased from 2 up to 31 % the value being systematically larger for 
smaller particles. These values and the trend are comparable to the corres-
ponding results for native HDL particles of similar size in our study (Fig. 3.1, 
panel b).
While the results of the present study on surface triglycerides and cholester-
ol esters are in line with the experimental outcomes from various lipoprotein 
model systems, the results of this study were obtained by optimisation purely 
based on geometric assumptions. The fact that lipid-lipid and lipid-protein 
interactions were not considered in the model means that the similar percent-
ages of triglycerides and cholesterol esters in panel a of Fig. 3.1, cannot be 
thought of as co-operative behaviour between these lipids but rather indicate 
the molecular dimensions and absolute numbers of triglycerides and choles-
terol esters in the lipoprotein particles. 
The portions of triglycerides and cholesterol esters in the surface of lipopro-
tein particles might have been somewhat different if the  molecular interac-
tions would have been explicitly considered in the model. At present, the de-
tailed influence of these molecular interactions on the optimised triglyceride 
and cholesterol ester distributions within the lipoprotein particles cannot be 
addressed.  However, it is anticipated that a high triglyceride content in the 
core of the particles will slightly increase the proportion of cholesterol ester 
and free cholesterol molecules in the surface. Similarly, a high cholesterol es-
ter content in the core would attract the alike, i.e., cholesterol ester and free 
cholesterol molecules, and thus slightly reduce the proportion of cholesterol 
ester  and free  cholesterol  molecules and increase the proportion of  trigly-
cerides in the lipoprotein particle surface.
Fig. 3.3 illustrates the molecular structures of VLDL2, IDL, LDL2, HDL2b, 
and  HDL3c particles drawn based on the existing knowledge of lipoprotein 
particle structures208, 210, 211, 214, 215, 232, 233, 236, 239, 241, 243, 425, 435, 439-441, 449, 452, 455, 457, 458 and 
the estimates of this study, the distribution of triglycerides and cholesterol es-
ters between the core and the surface region. As shown in Fig. 3.3, trigly-
cerides and cholesterol  esters  likely penetrate  into the particle  surface via 
loosely packed phosphatidylcholine-rich, free cholesterol-poor environments 
(a-e)210. In contrast, the nanoenvironments consisting of mainly sphingomy-
elin and free cholesterol molecules are tightly packed and impede the penet-
ration of triglycerides and cholesterol esters into the surface (f)210.
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Figure  3.3  Schematic  cross-sectional  molecular  models  of  VLDL2,  IDL,  
LDL2, HDL2b and HDL3c particles with the optimised distribution of trigly-
cerides and cholesterol esters between the core and the surface layer. The  
molecular compositions are from 12 individuals with these particles isolated 
using ultracentrifugation. The penetration of triglycerides and cholesterol  
esters  into  the  particle  surface  occurs  mainly  via  loosely  packed  phos-
phatidylcholine-rich,  free  cholesterol-poor  domains210 (a-e).  Note  also  the 
tendency  of  cholesterol  rings  to  interact  (a);  CE  penetration  (b,c,e)  and 
triglyceride penetration with fatty acids chains ahead (a-e); a kinked trigly-
ceride (d) and a kinked cholesterol ester molecule in the surface (e); the nan-
odomains  consisting  of  mainly  sphingomyelin  and  free  cholesterol  mo-
lecules are tightly packed and impede the penetration of triglycerides and  
cholesterol esters into the surface layer210 (f). Modified from 424.
The  presented distributions of  triglycerides and cholesterol  esters  in  the 
particles provide a coherent structural rationale for various molecular pro-
cesses  during  lipoprotein  metabolism.  For  example,  the  portion  of  trigly-
cerides of the surface lipids decreases from VLDL to LDL particles concur-
rently with the action of lipoprotein and hepatic lipase closely associated with 
the metabolic conversion of triglyceride-rich VLDL to LDL particles. These 
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catalytic operations occur at the particle surfaces459, 460 with no unambiguous 
evidence of enzyme intrusion into the core of lipoprotein particles461. These 
findings and the occurrence of the lipid transfer at the phospholipid-protein 
interface are also in line with findings for oxysterol binding protein-related 
proteins,  ORPs462-464 acting  as  sterol  transporters  between  the  subcellular 
membranes.
The  recent  structural  information on cholesteryl  ester  transfer  protein465 
bares also an important functional link to our current findings on the high-
cholesterol  ester  and  low-triglyceride  proportion  in  the  surface  of  HDL 
particles and an opposite situation, i.e., low-cholesterol ester and high-trigly-
ceride proportion in the surface of VLDL and IDL particles (Fig. 3.1, panel b). 
As mentioned earlier, one of the key physiological functions of CETP is the 
equimolar heteroexchange of cholesterol esters from HDL particles for trigly-
cerides from apoB-100-containing lipoprotein particles392,  465,  466.  The recent 
crystal structure of CETP indicates that the transport site for the hydrophobic 
lipids is a tunnel of a limited capacity to discriminate between different neut-
ral lipids; i.e.,  CETP has similar binding affinities for cholesterol ester and 
triglyceride molecules465. Thus, the known heteroexchange of cholesterol es-
ters and triglycerides between HDL particles and apoB-100-containing lipo-
protein particles is rational only if the acceptor and donor surfaces have dif-
ferent molar proportions of cholesterol esters and triglycerides. The presen-
ted structural model, using simultaneous volumetric optimisation of choles-
terol ester and triglyceride distributions within lipoproteins, clearly reveals 
such  a  situation  for  compositionally  characterised  human  lipoprotein 
particles.424
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4. In silico phenotyping of lipoprotein 
particles 
The previous chapter dealt with the computational modelling of lipoprotein 
particle structures and introduced a method to estimate the composition of 
various lipoprotein subclass particles individually. In this chapter, I will use 
these composition variables together with the commonly measured lipid con-
centrations  to  study the  compositional/metabolic  properties  of  lipoprotein 
particles. I will also discuss the heterogeneity of lipoprotein particles and the 
limitations in the use of lipid concentrations alone to reveal the underlying 
lipoprotein particle heterogeneity. The research discussed in this chapter has 
been published in a refereed journal, see467.
4.1 Lipoprotein profile in describing lipoprotein metabolism
Lipoprotein metabolism plays a key role both in health and disease. The state 
of lipoprotein metabolism is usually examined in clinics by determining a few 
lipid measures from plasma of over-night fasted individuals131,  134, 468, 469. This 
lipoprotein  profile,  including  the  concentration  of  plasma  triglycerides, 
plasma total cholesterol, LDL cholesterol, and HDL cholesterol, is then used 
among other non-lipid variables to describe the individual's overall metabolic 
status and potential risk for atherosclerosis and vascular disease. Lipoprotein 
metabolism appears, however, significantly more complex than indicated by 
these simple lipid measures. Evidence is accumulating that these commonly 
used measures of lipoprotein metabolism cannot, at least alone, properly ac-
count  for  the  complex  interactions  prevailing  in  lipoprotein 
(patho)physiology23, 470-473.
In clinics, the components of lipoprotein profile, particularly LDL cholester-
ol and HDL cholesterol, are measured instead of the concentration of lipopro-
tein particles, i.e., concentration of LDL and HDL particles, respectively. The 
reason is purely analytical; measuring the amounts of cholesterol or trigly-
ceride in plasma or particular classes of lipoproteins (LDL, HDL) is straight-
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forward, whereas direct assessment of lipoprotein particle number is not205, 
206. This distinction between lipoprotein lipid levels and lipoprotein particle 
numbers is potentially important clinically because the two measures are not 
equivalent due to the heterogeneity of the lipoprotein particles117,  205,  206. For 
example, since LDL cholesterol level is a sum of cholesterol molecules over all 
LDL particles in a plasma sample, the LDL cholesterol concentration may be 
the same within two randomly selected individuals although they may differ 
greatly  in  their  LDL  particle  numbers.  The  reason  for  the  discrepancy  is 
particle heterogeneity among individuals. It may arise either from a different 
size distribution of the particles affecting the total lipid content per particle 
and/or the relative cholesterol content of a particle (see Fig. 4.1). 
Figure 4.1  Schematic  representation of  the  heterogeneity  of  LDL particle 
composition. The per particle cholesterol content, among the LDL particle  
concentration,  affect  substantially  the  LDL  cholesterol  concentration  in  
plasma.
The problem of particle heterogeneity has been attempted to overcome by 
physical isolation of lipoprotein particles into more homogeneous lipoprotein 
subclasses by sequential  ultracentrifugation (UCF).  These procedures have 
proved useful  in  appreciating  various  counteracting  metabolic  phenomena 
and also in assessment of the risk for various vascular outcomes474-476. UCF-
based isolations are, however, tedious and expensive thus restricting their use 
for the analysis of lipoprotein subpopulations. Detailed attention is also rarely 
paid  on  the  molecular  composition  of  the  isolated  particles  although  the 
structural  integrity  and  pertinent  molecular  composition  of  lipoprotein 
particles are the basis for the proper functioning of lipoprotein metabolism210, 
424.
Here, we focus on an extensive set of UCF-based lipoprotein data where the 
apoB-containing particles are isolated to VLDL, IDL and LDL fractions and 
the HDL particles to HDL2 and HDL3  fractions477-479. This data set provides an 
experimental extreme available for clinically oriented lipoprotein studies and 
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can therefore be considered optimal for computational, or in silico, fractiona-
tion of lipoprotein data. The subclassification of physically isolated particles 
is performed by the use of a self-organising map (SOM) method that enables 
a holistic  combination of  various lipid and lipoprotein estimates including 
lipoprotein compositions, concentrations and metabolic interactions. In the 
analysis, we used in-house, free access software termed MeliKerion which is 
essentially an enhanced self-organising map method480, 481. 
4.2 Properties of the self-organising map method
The self-organising map method is a well known, unsupervised pattern recog-
nition technique482. It has been developed as one of the most popular neural 
network methods in various disciplines483 after the initial introduction of the 
SOM method for data clustering and visualisation in early 1980’s482. The most 
characteristic feature of the self-organising map method is the ability to map 
non-linear  relations  in  multidimensional  data  sets  into  visually  more  ap-
proachable, typically two dimensional planes of nodes.
4.2.1 Clustering
SOM method clusters data, termed as input data, based on all parameters of 
all cases according to given similarity criteria. The input data from each case 
i, i.e., plasma sample from an individual i in this particular application, con-
tain  a  number  of  parameters  used  to  form  a  vector 
d i=d1i ,d 2i , .. . ,d N−1i ,d Ni   (see  Fig.  4.2).  The  SOM algorithm482 then 
transforms  the  input  data  vectors  into  various  feature  vectors  (vector  j,k 
x j,k= x1j,k ,x2j,k , .. . ,xN−1j,k ,xNj,k  ) of the same size and sophisticated, av-
eraged parameter values. Thus each feature vector represents the original  N 
dimensional parameter space and is similar, although not necessarily exactly 
the same with a small group of original parameters. In the final state of clus-
tering, each case i is attached to a feature vector with the most similar para-
meters, and thus similar cases end up in the same or similar feature vector-
s484. 
4.2.2 Visualisation
The strength of SOM analysis compared to several other clustering methods 
lies in its visualisation capabilities480, 483-485. In visualisation, each feature vec-
tor represents a node or cell (in place j,k) in a two-dimensional map with total 
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of J rows and K columns (j goes over the rows and k over the columns). The 
end product of visualisation is a group of two-dimensional maps called com-
ponent planes representing each of the N components of the feature vectors 
and thus giving a general overview of the distribution and values of the ori-
ginal parameters. In-house developed scripts also allow visualisation of other 
variables (outputs) of the cases solely based on the organisation of the input 
variables480, 481. As the maps are formed based on the feature vectors in fixed 
places, each case i is located in the same place in each component plane en-
abling direct comparison of the planes.
Each of the component planes is coloured so that the colour of a node is re-
lated to parameter-specific median over cases giving reddish, white or bluish 
colour corresponding to high, near median or low values, respectively. The in-
house scripts also enable saturation differences between the planes. The sat-
uration of the colours is related to the significance of the clustering giving 
high saturation in case of high significance. The significance is also given by 
numeric values corresponding to the probability of the clustering to occur by 
chance.  The  use  of  colour  coding  in  the  component  planes  is  particularly 
helpful since clearly coloured areas as well as correlated changes in the col-
ours of different parameters are visually easy to detect. While it is difficult to 
exactly define clusters in the organised map, subtle changes in colours are 
also good in indicating potentially diffuse borderline areas between various 
clusters.
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4.2.3 Self-organising maps applied for lipoprotein lipid data
Lipoprotein lipid data is a manifestation of a complex metabolic situation. 
This indicates that the data likely contain multi-parametric and non-linear re-
lationships demanding advanced properties from the methodologies used for 
the analysis. The self-organising map method has been recognised as an ef-
fective and advantageous tool to handle complex data in various areas  (see, 
for example,481, 484-487) and thus the applications of SOM methodology have po-
tential to produce logical and easily interpretable results also in the context of 
lipoprotein lipid data. 
In this  particular application,  the SOM analysis  is  able  to interpret  both 
compositional characteristics within each lipoprotein particle category (e.g., 
IDL)  and  metabolic  associations  between  different  lipoprotein  categories 
(e.g., VLDL and HDL2). Interestingly, the analysis also provided a kind of in 
silico subfractionation allowing to characterise various metabolic and struc-
tural  details  within  each  of  the  experimentally  distinguished  lipoprotein 
particle categories.
The SOM algorithm thus offers the possibility to generate a form of average 
representations  of  model  individuals  and  identify  both  compositional  and 
metabolic  similarity  of  individuals  out  of  multidimensional  complexity  of 
various interrelated lipoprotein lipid parameters. Comparing the component 
planes of two or more parameters in the two-dimensional map may provide 
insights into the interdependencies between the variables and their potential 
similarities or dissimilarities for the various clusters of model individuals. 
4.3 Materials and methods: An application of SOM analysis
In our study we had at our disposal biochemical lipoprotein lipid analyses 
from 302 distinct plasma samples of 233 individuals. The lipid data consisted 
of heavy alcohol drinkers (122 samples, 40 % of the samples), hysterectom-
ised postmenopausal women on estrogen replacement therapy (117 samples, 
39 %) and apparently healthy controls (63 samples, 21 %), thereby represent-
ing a wide range of plasma lipoprotein lipid values (see Table 4.1). The num-
bers of samples from women and men were almost equal, 160 (53 %) and 142 
(47 %), respectively. Blood samples were drawn after an overnight fast of 12 h 
into EDTA-containing tubes. The blood plasma was then separated by centri-
fugation at 1200 x g – 1500 x g for 10-15 min at 4°C. VLDL (d < 1.006 g/ml), 
IDL (d =  1.019-1.063 g/ml), LDL (d =  1.063-1.125 g/ml), HDL2 (d =  1.063-
1.125 g/ml)  and  HDL3 (d =  1.125-1.210 g/ml)  fractions were isolated from 
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each  individual  using  sequential  ultracentrifugation477-479.  Lipoprotein  frac-
tions were isolated from fresh plasma samples. The concentrations of total 
cholesterol,  free  cholesterol,  triglyceride, and phospholipid molecules were 
then determined from each density range using enzymatic colorimetric meth-
ods477,  478.  Concentrations of cholesterol esters were calculated as difference 
between total cholesterol and free cholesterol concentrations. The total pro-
tein contents were measured by the modified Lowry method197,  198. The lipid 
and protein analyses commenced immediately after isolation of each fraction. 
The concentration variables were expressed as mmol/l in plasma for lipids 
and mg/dl for proteins, respectively (see Table 4.1).
Table 4.1 The average plasma lipid and protein concentrations and weight  
percentage compositions (marked as *) of the lipoprotein particles isolated 
via sequential ultracentrifugation.
Values are in mmol/l for TG, C, FC and PL concentrations and mg/dl for  
protein concentration. Values are given as mean ± SD. TG, triglyceride; C,  
total cholesterol; CE, cholesterol ester; FC, free cholesterol; PL, phosphol-
ipid; PROT, total protein.
The lipoprotein lipid concentrations and protein measures were then used 
to build a set of input variables for the SOM analysis. We ended up in using 
two kinds of lipoprotein lipid measures, termed as concentration inputs and 
composition inputs, as both concentrations of lipids and the chemical com-
position of  lipoprotein  particles  are  important determinants of  lipoprotein 
particle metabolism.  The concentration inputs correspond to the concentra-
tions of triglyceride, cholesterol ester, free cholesterol and phospholipid mo-
lecules over the particles in each physically isolated lipoprotein fraction as 
such while the composition inputs approximate the molecular composition of 
the lipoprotein particles i.e., the number of lipid molecules (~mol/g) in each 
averaged lipoprotein particle. The molecular composition is obtained by scal-
ing the concentrations of lipids by the corresponding total protein measure 
individually in each fraction (see also equation 3.1 on page 62). 
The two input variable types  were deliberately used  together  in the  SOM 
analysis to enable direct association of the lipid concentration and composi-
tion information. The composition inputs are not, however, intuitive variables 
to  interpret,  and  therefore  I  will  present  the  compositional  variability 
between individuals by mass percentages which shared the essential distribu-
tions of the composition variables. Also other output variables, such as distri-
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butions of heavy alcohol drinkers, estrogen treated women, control subjects, 
men, body mass index, age as well as total cholesterol, total protein and lipo-
protein particle sizes in each fraction are presented as component planes. The 
particle sizes were estimated as described in the previous chapter. Briefly, the 
number of lipid molecules in a particular lipoprotein particle was calculated 
on the basis of the experimental data, and the known average volumes of the 
lipid and protein molecules were then used to calculate the average particle 
size.
Before the SOM analysis, some pre-processing was performed: The input 
data were scaled between -1 and 1 by rank transformation to prevent unjusti-
fied domination of any of the variables and then normalised to smooth the 
distribution of individuals into the grid. We chose a 5 x 7 map of hexagonal 
units resulting in 8.6 samples per unit on average and a Gaussian neighbour-
hood function. We also performed several runs with different map sizes lead-
ing  to  essentially  similar  results,  as  expected,  since  SOM is  known to  be 
rather insensitive to choices of its size484. After the positions of the individuals 
were computed, the component planes were coloured according to the feature 
vectors. A few numbers were localised on selected cells to show the local pre-
valence (binary variables) or mean value (continuous variables) for that par-
ticular region, and the statistical significance of the patterns was obtained by 
overall permutation estimations for the p-values480, 481. The p-value estimates 
were interpreted for the output variables while they are omitted for the input 
variables since they are no longer valid. All the analyses were performed us-
ing the in-house scripts in the MATLAB programming environment. The Me-
liKerion480, 481, for SOM analyses in the MATLAB/Octave programming envir-
onment,  is  freely  available  via  http://www.computationalmedicine.fi/soft-
ware. After constituting the SOM, the main regions with differing metabolic 
features were chosen by visual examination for further analyses. Some indi-
viduals residing in the borderline areas were excluded to obtain clearer lipo-
protein phenotypes. All the analyses were performed on a laptop PC with an 
Intel Core2 Duo, 2.0 GHz processor which trained a typical SOM and calcu-
lated the colourings in a few minutes.
4.4 Results and discussion 
4.4.1 Distribution of individuals
The data contained lipid and protein measures from three distinct groups of 
individuals  including  heavy  alcohol  drinkers,  hysterectomised  postmeno-
pausal women on estrogen replacement therapy and apparently healthy con-
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trols. The numbers of men and women were almost equal. Fig. 4.3 represents 
the distribution of these individuals in the self-organising map constructed 
based on the combined concentration and composition of lipoprotein lipid 
variables. 
Figure 4.3 Distribution of the individuals in the SOM analysis based on the 
combined lipoprotein lipid concentration and composition variables. The %-
values shown in the component planes referring to the groups are percent-
ages of the total study population in that particular cell. In all of the com-
ponent planes,  the values are colour-coded to visualise whether they are  
above (reddish), at (white) or below (bluish) the median of the variable. The 
numbers on the selected units tell the local mean value for that particular  
region. 
As evident from Fig. 4.3,  the separate groups lie differently on the map; 
Heavy alcohol drinkers locate mostly in the western region of the map where-
as estrogen treated women occupy the south-east region. Controls are mostly 
located in the east. The locations of men and women represent gender of the 
individuals in the three groups rather than distribution of men and women in 
general; most men lie in the north, west and north-west areas of the SOM 
since most heavy alcohol drinkers and some controls were men. The most 
notable  difference  in  the  distributions  is  that  while  controls  and estrogen 
treated individuals occupy the same area, the heavy alcohol drinkers separate 
quite clearly from these two groups. Fig. 4.3 also shows distribution of body 
mass index (BMI) and age. The estrogen treated women seem to be the oldest 
and  the  heavy  alcohol  drinkers  the  youngest  group  of  individuals  in  this 
study. Individuals with the highest BMI belong mostly to either controls or 
heavy alcohol drinkers. Individuals with the lowest BMI are also heavy alco-
hol drinkers.
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4.4.2 Component planes of lipids, proteins and particle sizes
Fig. 4.4 illustrates the component planes of concentration input variables for 
triglyceride, cholesterol ester, free cholesterol and phospholipid molecules in 
VLDL, IDL, LDL,  HDL2  and  HDL3  particles. The figure contains also com-
ponent planes for various output variables such as total cholesterol and total 
protein concentrations in each of the five fractions. Fig. 4.5 shows particle 
compositions as weight per cent for triglyceride, cholesterol ester, free choles-
terol,  phospholipid  and protein  molecules  in  VLDL,  IDL,  LDL,  HDL2 and 
HDL3  particles as well as the estimated sizes of the lipoprotein particles in 
each fraction.  These two figures are discussed together in the following to 
yield an appropriate view of lipoprotein particles from both lipoprotein lipid 
concentration and composition view. The two figures can also be interpreted 
in two dimensions, horizontally yielding compositional information within a 
fraction and vertically relating to a metabolic view within a lipid in several 
fractions. For convenience, the word plasma is often used to help in separat-
ing concentration variables from composition variables in the following text. 
For  example,  plasma LDL cholesterol  refers  to  the  commonly  determined 
LDL cholesterol, i.e., the concentration of cholesterol molecules over all LDL 
particles. The concentration inputs are also referred from now on without a 
asterisk  such as  VLDL-TG (plasma concentration of  triglycerides in  VLDL 
particles) and the composition variables are referred with the asterisk such as 
VLDL-TG* (weight per cent of triglycerides in a VLDL particle). 
In Fig. 4.4, the component planes of plasma concentration variables are ho-
rizontally, or within a fraction, quite similar as judged by the similar colour-
ing of the component planes. This is particularly  seen in the case of largest 
particles but the effect decreases towards smaller particles and is less pro-
nounced for triglycerides in HDL particles. This parallel relatively high (red-
dish colour) or low (bluish colour) level of lipids within a fraction is actually 
quite surprising and may be due to several reasons. Firstly, if each lipoprotein 
particle  contains  some  triglyceride,  cholesterol  ester,  free  cholesterol  and 
phospholipid molecules, then a high number of particles results in high or el-
evated plasma concentrations of all these lipids. Secondly, if the amount of a 
lipid within a lipoprotein particle is high, the plasma concentration of the lip-
id is also high even for a normal particle concentration. In this case, the coex-
isting  high  level  of  all  lipids  may  result  from some  particle  secretion-  or 
plasma metabolism-related phenomenon. The third possibility is that both 
the number of lipids within a particle and the concentration of particles are 
high within a fraction.  Fig. 4.4 shows also concentrations of proteins within 
the fractions giving similar distributions as the plasma concentrations of lip-
ids. The concentrations of proteins are particularly interesting since they es-
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timate the concentrations of lipoprotein particles if the amount of proteins 
per particle is assumed to be conserved over individuals in each lipoprotein 
fraction.
Vertically in Fig. 4.4., component planes are, in general, less similar. For ex-
ample, individuals with the highest concentration of VLDL lipids lie in the 
north-west corner and those with high LDL lipid concentrations in the north-
east  and eastern areas of  the component planes.  Furthermore,  individuals 
with high HDL2 lipids (reddish region in the south) may have either low LDL 
lipid concentrations (bluish region in south-west) or high LDL lipid concen-
trations  (reddish  region  in  the  south-east).  These  associations  are  pro-
nounced for phospholipid, free cholesterol, cholesterol ester and total choles-
terol molecules but are somewhat different between LDL-TG and HDL2-TG. 
The reason why the component planes of each lipid through the fractions are 
not similar is that lipoprotein particles face events in plasma which are quite 
fraction-specific and affect strongly both their particle composition and con-
centration. 
This view is supported by few fractions which actually have mutual similar-
ities also in the vertical direction: The distributions of plasma concentrations 
of lipids within IDL and LDL fractions seem quite similar likely because of 
similar metabolic routes i.e., they are both delipidation products of VLDL and 
compete  for  the  same cell  surface  receptors.  Likewise,  the  distribution  of 
VLDL and HDL2 lipid concentrations associate with each other although the 
relation is negative rather than positive.  This agrees with the metabolism of 
VLDL  and  HDL  particles  since  during  the  delipidation  process  of  VLDL 
particles, extra surface material, such as cholesterol, phospholipid and pro-
tein  molecules,  is  shedding  from  their  surfaces  and  transported  to  HDL 
particles488 thereby  increasing  both  the  size  and  the  number  of  HDL2 
particles489. 
In contrast to the opposite colouring of VLDL and HDL2 lipids in general, 
individuals  with  high  VLDL triglycerides  also  have  high  HDL2 and  HDL3 
triglyceride concentrations. Since this association is apparent only for trigly-
cerides rather than all VLDL and HDL lipid concentrations, the reason for the 
relation is likely the change in particle compositions rather than in particle 
concentrations. The association between VLDL and HDL likely occurs via ac-
tion of CETP which transfers triglycerides from VLDL to HDL in exchange for 
cholesterol  esters.  This  increases  the  concentration  of  HDL  triglycerides 
which would otherwise be almost negligible.
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Figure 4.4 Component planes of lipoprotein lipid concentration measures in  
mmol/l and proteins in mg/dl in the SOM analysis of the combined lipopro-
tein lipid concentration and composition variables. The p-values below the 
plots indicate the probability of observing equivalent regional variability  
for random data. The p-values of input variables are replaced by marking 
'n/a' as they are no longer valid. Importantly, the very same SOM analysis  
is the basis for all the component planes shown (holds also for Fig. 4.5) and  
thus each of them can be directly compared, i.e., the distribution of the indi-
viduals is the same in every component plane. TG, triglyceride; PL, phos-
pholipid;  FC,  free  cholesterol;  CE,  cholesterol  ester;  C,  total  cholesterol.  
Modified from 467.
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Figure 4.5 Component planes of lipoprotein composition measures and dia-
meters in the SOM analysis of the combined lipoprotein concentration and 
composition variables. For each lipoprotein fraction, the values are repres-
ented as weight percentages (*) for lipids and protein or nm for the particle  
sizes. All other details and abbreviations are as given in the caption for Fig.  
4.4. Modified form 467.
Fig.  4.5  supports  the discussion above.  The  individuals  with high VLDL 
triglycerides (VLDL-TG in the north-west region in Fig. 4.4) have also trigly-
ceride-rich VLDL, LDL, HDL2 and HDL3 particles (-TG* in the north-west in 
Fig 4.5). These LDL, HDL2 and HDL3 particles are also cholesterol ester-poor 
in line with the action of CETP. The VLDL particles are, however, not particu-
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larly enriched in cholesterol esters. Fig. 4.5 also completes the associations of 
VLDL, LDL and HDL lipid concentrations introduced above: In the south-
east region, the high HDL2 and low VLDL lipid concentrations relate to relat-
ively high concentrations of plasma LDL lipids and large IDL, LDL, HDL2 and 
HDL3  particles  together  with  small  VLDL particles.  The  LDL,  HDL2   and 
HDL3 particles are enriched in phospholipids (-PL*) and free cholesterol mo-
lecules (-FC*) while the VLDL and IDL particles are relatively phospholipid-
poor (-PL*). In contrast, in the south-west regions of the component planes, 
the high  HDL2 and low VLDL lipid concentrations are associated with low 
concentrations of plasma lipids in LDL as well as in IDL. All these apoB-100-
particles  are  also  relatively  small.  In  general,  there  are  clear  associations 
between the lipoprotein particle sizes and the phospholipid as well as protein 
weight percentages of the particles; high amounts of phospholipids and low 
amounts of proteins indicate large lipoprotein particles. 
Fig 4.4 and 4.5 also show associations of plasma LDL cholesterol levels and 
compositional subtypes of LDL.  Quite contradictory results have been pub-
lished regarding  the  association of  plasma LDL cholesterol  concentrations 
with the  composition and characteristics  of  the LDL particles.  Individuals 
with prominence of small, dense LDL particles may have the same plasma 
LDL cholesterol concentration as individuals with large LDL particles472,  473. 
On the other hand, the individuals with large LDL particles may have higher 
LDL cholesterol concentrations than the individuals with small, dense LDL 
particles323. Furthermore, it has been shown that the LDL particle numbers 
can differ without affecting the LDL-C concentration in plasma490. Increased 
number of LDL particles may, however, result either from large or small LDL 
particles since the binding of LDL particles to LDL-receptors has been shown 
to be reduced both for small, dense and large LDL particles when compared 
to LDL particles with intermediate sizes491.
Our findings indicate that the large LDL particles associate with relatively 
high LDL-C concentrations (the south-east region of the LDL-C planes) while 
the small LDL particles are mostly related to low plasma LDL cholesterol con-
centrations (western half of the LDL-C planes). These associations are not, 
however, inclusive since there are also individuals with high concentration of 
relatively small LDL particles leading to high plasma LDL concentrations (the 
north-east region). It is also worth noticing that small LDL particles associ-
ated with a high plasma LDL cholesterol concentration (LDL-C) seem to be 
rather triglyceride-poor (LDL-TG*) whereas small  LDL particles associated 
with low LDL cholesterol concentrations (LDL-C) are triglyceride-enriched 
(LDL-TG*).  Thus the chemical composition, size and particle number affect 
plasma LDL cholesterol concentrations and the apparently contradictory res-
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ults are likely only a reflection of different characteristics in the study popula-
tions.
4.4.3 In silico lipoprotein phenotyping 
Simultaneous analysis of figures 4.4 and 4.5 actually provides detailed sub-
groupings of the lipoprotein particles within each fraction,  i.e., a detailed in 
silico lipoprotein phenotyping beyond the experimental data. The term lipo-
protein phenotype is used here to denote a collection of lipoprotein subtypes 
for VLDL, IDL, LDL, HDL2 and HDL3 which each have characteristic plasma 
lipoprotein lipid concentration profiles as well as distinct compositional and 
metabolic features. An overview of the lipoprotein phenotypes is given in Fig. 
4.6. 
Fig. 4.6 shows the distinct lipoprotein phenotypes arranged on two plat-
forms,  one  for  triglyceride-enriched  and  the  other  for  triglyceride-poor 
particles due to the significant role of triglycerides particularly in apoB-con-
taining lipoprotein metabolism. The HDL particles are also arranged accord-
ingly into the two groups with respect to their relative triglyceride contents. 
Five phenotypes were discovered and they are named by alphabets from A to 
E  corresponding  to  the  regions  in  the  south-west,  north-west,  north-east, 
south-east and in the middle, respectively.
Lipoprotein phenotype B (in the north-east region) is particularly worth no-
ticing since it resembles the lipoprotein phenotype characteristic of metabolic 
syndrome492. In lipoprotein phenotype B, all lipoprotein particles are enriched 
in triglycerides except the IDL particles which are fairly triglyceride-poor. In 
addition, the concentration of HDL2 and HDL3 cholesterol is low. The VLDL 
particles are large while the IDL and LDL particles are quite small. Interest-
ingly, while the VLDL particles are also enriched in free cholesterol and phos-
pholipid molecules, the corresponding IDL, LDL, HDL2 and  HDL3  particles 
are poor in free cholesterol molecules. The concentration of VLDL particles is 
high  but  those  of  LDL  and  HDL2 are  low  and  the  concentration  of  IDL 
particles is also somewhat elevated.
These lipoprotein characteristics in phenotype B are in line with studies of 
metabolism of apoB-100-containing lipoprotein particles. Increased plasma 
concentrations of particularly large and TG-enriched VLDL have been shown 
to result in  low concentrations of LDL493 with the preponderance of small, 
TG-enriched LDL particles322,  323,  494 and elevated particle  concentrations in 
IDL density range containing VLDL remnants persisting in the plasma293, 495. 
It is also notable that the low percentage of FC in the IDL, LDL and HDL 
particles of phenotype B may be a structural property that enhances the oxid-
ative susceptibility of these lipoproteins496.
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Fig. 4.6 illustrates also the concentration of the proteins within each frac-
tion of all these five lipoprotein phenotypes. In VLDL, IDL and LDL particles, 
the total protein concentrations were virtually identical to the concentrations 
of apoB molecules (data not shown). Thus the protein concentrations in these 
lipoprotein fractions can be considered as estimates of lipoprotein particle 
concentrations. The VLDL and IDL particle concentrations are very similar in 
phenotypes A and E but the particles have significantly different composi-
tions; the VLDL and IDL particles are triglyceride-enriched and cholesterol 
ester-poor in phenotype A, and the situation is the opposite in phenotype E. 
Similarly, concentration of LDL is average in phenotypes C and E with re-
markable variations in the composition of LDL particles and even more pro-
nounced  differences  in  composition  and  sizes  of  VLDL and  IDL  particles 
between the phenotypes.  Thus it seems that the plasma lipoprotein concen-
trations alone can give only a limited view on the overall lipoprotein metabol-
ism. This is not unexpected considering that lipoprotein metabolism involves 
a complex crosstalk of various lipoprotein particles as well as enzymes and 
lipid transfer proteins affecting the concentrations of all lipid molecules with-
in lipoprotein particles.
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Figure 4.6 A metabolic overview of the lipoprotein phenotypes arisen from 
the SOM analysis illustrated in Figs. 4.4 and 4.5. The application of the SOM  
analysis to the combination of lipoprotein lipid concentration and composi-
tion data resulted in a novel perspective and provided also a subgrouping of  
the lipoprotein particles in each fraction, i.e., an in silico lipoprotein pheno-
typing beyond the experimental data. The term lipoprotein phenotype refers  
here to a collection of lipoprotein subtypes for VLDL, IDL, LDL, HDL2 and 
HDL3 related to a particular plasma lipoprotein concentration profile and 
forming a metabolically connected entity. Five different phenotypes were 
discovered (marked as A-E and colour-coded on the SOM), all with charac-
teristic plasma concentration profiles (as indicated in the bottom) as well as  
distinct compositional features (as summarised on the top). The scales in the  
concentration profiles indicate the total protein concentrations of the lipo-
protein fractions in mg/dl. The metabolic pathways of the lipoprotein phen-
otypes are organised here in two platforms, one for triglyceride-enriched  
(on  the  left  with  an  orange  background)  and  one  for  triglyceride-poor  
particles (on the right with a bluish background) since the apoB-containing 
VLDL-IDL-LDL cascade relates primarily to the transport and hydrolysis of  
triglycerides. The HDL particles are also accordingly divided into the two  
platforms with respect to their relative triglyceride content. The solid, col-
our-coded arrows represent the metabolic pathways of the apoB-containing 
lipoprotein  particles  within  each  lipoprotein  phenotype.  The  connections 
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between apoB-containing and HDL particles are indicated by the bidirec-
tional dashed arrows. The sizes of apoB-containing particles as well as HDL  
particles are in scale although the sizes of the HDL particles are enlarged by  
a factor of 6. The relative contents of the various lipids in the lipoprotein 
particles are indicated by the up- and downward arrows. Structurally char-
acteristic lipids in each particle are bolded. The abbreviations are as given 
in the caption for Fig. 4.4. Modified from 467.
As the individuals in this study had various backgrounds, effect of the back-
ground, i.e., use of alcohol and estrogen replacement therapy, on the distribu-
tion of individuals should be considered. In general, there is a clear tendency 
of the individuals in the different groups to differ on the basis of their lipo-
protein phenotypes; e.g., there is a preponderance of heavy alcohol  drinkers 
in lipoprotein phenotypes A and B (see Fig. 4.2 and 4.6) while the estrogen 
treated hysterectomised postmenopausal women and apparently healthy con-
trols relate mostly to the phenotypes C, D, and E. The separation is, however, 
unambiguous  for  none  of  the  groups,  and,  for  example,  in  the  north-east 
corner of the SOM (phenotype D), the distribution is 20 % of heavy alcohol 
drinkers, 23 % of estrogen treated women and 56 % of apparently healthy 
controls. Thus the distribution of the individuals in the SOM genuinely re-
flects the distribution of lipoprotein lipid-related variables and less the mem-
bership in one of the three groups per se. 
To summarise, the purpose of this work was to enhance the concept of lipo-
protein profile which is regularly characterised by plasma concentration val-
ues of triglycerides as well as total, LDL and HDL cholesterol molecules. Ori-
ginally,  we had 302 plasma samples which were isolated into VLDL, IDL, 
LDL, HDL2 and HDL3 fractions by ultracentrifugation and characterised fur-
ther to yield lipid concentrations of triglyceride, cholesterol ester, free choles-
terol, phospholipid molecules as well as concentration of protein molecules. 
The samples represented a wide range of plasma lipoprotein lipid values. As 
the next step, we combined the ordinary although extensive set of biochemic-
al variables in a novel way to gain information simultaneous from the concen-
trations  of  lipoprotein  lipids  and  the  compositions  of  the  lipoprotein 
particles.  This  let  us  to  define  five  distinct  lipoprotein  phenotypes  which 
differed from each other on particle size, chemical composition, and lipopro-
tein lipid and particle concentrations. The work was performed with the help 
of a self-organising map method which clustered the samples based on their 
similarity over all used variables. Thus the results are conditional to the used 
variables ensuring that they represent entirety of the variables, i.e., the over-
all metabolism of lipoprotein particles in this case. The self-organising map 
method also visualises the distribution of the variables in two-dimensional 
component planes yielding easily interpretable and directly comparable com-
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ponent planes. This is particularly useful in case of complex, multidimension-
al data such as lipoprotein lipid data since it allows to detect individuals with 
opposing course of associations between multiple variables. 
Even though detailed data on lipoprotein particles would currently be pre-
ferred in cardiovascular research, the subpopulation analysis is usually based 
on particle size (e.g., using gradient gel electrophoresis or nuclear magnetic 
resonance  spectroscopy)  and  therefore  the  chemical  composition  of  the 
particles remains unknown117,  177. In analytical lipid biochemistry, sequential 
ultracentrifugation is the gold standard for physical lipoprotein isolation al-
lowing  for  subsequent  analyses  of  the  molecular  composition  of  the 
particles477-479.  However,  the  UCF-based lipoprotein  work is  most  often re-
stricted  regarding  the  analysed  subfractions.  This  is  because  the  finer  the 
density ranges used for the isolation the more tedious and expensive the ana-
lyses become497. Consequently, it would generally be beneficial to computa-
tionally enhance the UCF-based lipoprotein data as illustrated in this work. 
In particular, deeper insight into the compositional variations in the lipopro-
tein  particles  appears  a  fundamental  issue.  The  physiology  and  patho-
physiology of lipoproteins are about transfer and exchange of various lipid 
molecules between the lipoprotein particles and tissues. Thus, not only the 
concentration but also the quality of  lipoprotein particles and the form of 
transportation are of great importance.467
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5. Towards lipoprotein particle 
concentrations
At  this  point,  I  have  discussed  two  fundamental  aspects  of  lipoprotein 
particles, the structure and the metabolism, from the point of view of compu-
tational modelling. In this chapter, I will move forward towards the third es-
sential aspect of lipoprotein particles, the lipoprotein particle concentrations, 
and I will, after an introductory section, present a model to estimate lipopro-
tein particle concentrations on grounds of lipoprotein lipid concentrations. In 
this introductory section, I will also discuss lipoprotein particle sizes which 
are, at least at times, regarded as the most atherogenic property of lipoprotein 
particles. These size estimates have recently and convincingly been related to 
the lipoprotein particle concentrations.
5.1 Lipoprotein particle concentrations in health and disease 
Lipoprotein  particle  concentrations,  particularly  LDL  concentrations,  are 
some of the most intriguing manifestations of lipoprotein particle heterogen-
eity. It is well established that lipoprotein particle concentrations in circula-
tion vary substantially among individuals depending on age, gender, food in-
take, metabolic/hormonal state, and disease state of the individual101, 324, 414, 498-
502. 
The concept of lipoprotein particle concentration dates back to late 1940s 
when Gofman and his colleagues managed to isolate the full spectrum of lipo-
protein particles by analytical ultracentrifugation18. In 1950s, Gofman and his 
colleagues showed that differences in lipoprotein mass profiles could predict 
the coronary artery disease risk24.  The time was,  however,  full  of  conflicts 
among the scientific  community  searching  for  the cause of  atherosclerosis 
and  cardiovascular  disease,  and  Gofman,  although  having  made  a  break-
through in the field, lost interest in lipoprotein research. Also the analytical 
ultracentrifugation gave way to other, technically less difficult methods which 
could  not,  however,  measure  concentrations  of  lipoprotein  particles  even 
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roughly. The next sequence of events supporting the importance of lipopro-
tein particle concentrations was the discovery of LDL-receptor by Goldstein 
and Brown in the 1970s69,  70,  72. They showed that increased number of LDL 
and IDL particles in individuals with familial hypercholesterolemia is a suffi-
cient cause for the development of atherosclerosis and cardiovascular disease. 
By the end of the 20th century,  discussion had, however, turned into the 
quality  of  lipoprotein  particles,  and particularly their  size,  rather than the 
particle concentrations117, 339, 405, 406, 503-507. At the time, the paper and agarose gel 
electrophoresis that Fredrickson was using in the 1980s, was refined to non-
denaturing  gradient  gel  electrophoresis  that  could  characterise  lipoprotein 
particles by their size168, 169. In the following years, it was observed that indi-
viduals  with  atherosclerosis  had  smaller  LDL  particles  than  apparently 
healthy individuals and thus these small, dense LDL were suggested to be the 
most atherogenic lipoprotein particles504, 508, 509.
The relationship of LDL particle size and CAD risk has been investigated ex-
tensively in approximately thirty studies as summarised elsewhere117. Most of 
the studies found a significant relation between small, dense LDL particles 
and the risk of coronary artery disease. In a few studies, however, large LDL 
particles were associated with the risk of CAD. Indeed, both the small and the 
large  LDL particles  may have decreased binding  affinity  to  LDL-receptors 
when compared to intermediate-sized particles117. Small LDL particles enter 
the arterial wall and remain in the wall more easily than larger ones, have en-
hanced  oxidation  potential  and  participate  directly  in  the  production  of 
subendothelial macrophage foam cells117, 510. Per particle basis, the larger LDL 
particles do, however, transfer more cholesterol molecules into the wall than 
the smaller particles.
In the studies of LDL particle size and CAD risk, the sizes of LDL particles 
were measured by non-denaturing gradient gel electrophoresis which meas-
ures the relative size distribution of the particles and then the most promin-
ent size, i.e., average lipoprotein particle size, is obtained as a point estimate 
of the distribution. Since the method does not directly quantify the number of 
small and large particles, the obtained size estimate reflects changes in total 
LDL particle concentration and thus, for example, a decreased LDL particle 
size may be caused either by elevated total LDL particles with elevated num-
ber of small particles or by fewer total LDL particles with fewer large LDL 
particles511. Therefore, when studying the relation of particle size with cardi-
ovascular disease, the total particle concentrations should also be taken into 
consideration.
The association of atherogenic lipoprotein particle concentrations with the 
risk of CAD has also been investigated in clinical trials either via apoB con-
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centrations141-146 or NMR-derived LDL particle numbers146-150. In most of the 
studies  apoB141-143 and  NMR-derived  LDL particle147-150 concentrations  were 
more closely associated with CAD risk than LDL cholesterol. ApoB and NMR-
derived  LDL particle  concentrations  associated  also  with CAD risk  with  a 
magnitude of association comparable to total/HDL cholesterol ratio or non-
HDL cholesterol concentration145, 146.
While the particle concentrations were comparable but not superior to that 
of standard lipids in cardiovascular disease risk prediction, it should be re-
membered  that cholesterol  molecules  are  transported  within  lipoprotein 
particles in circulation. Thus lipoprotein particle concentrations, along with 
certain other properties of the particles, i.e., their lipid content and composi-
tion, are important for a proper understanding of  the complex interactions 
prevailing in lipoprotein physiology.
Practical difficulties are, however, present in measuring lipoprotein particle 
concentrations. At present, no method can directly count lipoprotein particle 
numbers  within  various  lipoprotein  fractions.  Therefore,  a  number  of  ap-
proaches have been used to approximate lipoprotein particle concentrations 
according to the concentration of some of their constituents. However, there 
are certain disadvantages in using these variables due to lipoprotein particle 
heterogeneity. 
5.2 Surrogate variables of lipoprotein particle numbers
There are a few variables which are often used as surrogate measures for lipo-
protein particle concentrations in plasma. These include the main lipid and 
the main apolipoprotein concentrations as well as concentrations of the total 
lipids or their NMR-derived resemblance. In general, the idea of lipoprotein 
particle estimation via these variables is quite simple. In order to estimate the 
lipoprotein particle concentration individually in a chosen fraction, for ex-
ample in LDL, two related measures are needed: one which accounts for total 
amount of a constituent over the lipoprotein particles in that fraction, e.g., 
plasma LDL cholesterol, and another which accounts for amounts of that con-
stituent within a single lipoprotein particle, e.g., number of cholesterol mo-
lecules per a lipoprotein particle. Then the numbers could just be divided to 
obtain the concentration of those lipoprotein particles. In principle, this ap-
proach is an acceptable way to estimate lipoprotein particle concentrations 
but it requires certain important characteristics from the constituents; within 
a lipoprotein fraction under question, the constituent must be present in each 
particle  in  measurable  quantities,  and  each  particle  must  have  an  equal 
amount of that constituent. Since measurement of the contents of a single 
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particle is not currently possible, this assumption of homogeneous particles 
within  a  fraction  should  hold  also  between  individuals.  Lipoproteins are, 
however, heterogeneous, and thus lipoprotein particle estimation culminates 
in finding the best possible constituent(s). 
5.2.1 Concentrations of the main lipids
In most cases, lipoprotein particle concentration is related with the concen-
tration of the main lipid within the lipoprotein fraction in interest. Thus LDL 
and HDL particle concentrations are approximated by the concentration of 
cholesterol  in LDL and HDL particles,  respectively46,  205,  206,  348. By analogy, 
VLDL particle concentrations could then be estimated by the concentration of 
triglycerides in VLDL particles but it is usually characterised by plasma trigly-
ceride  concentration46,  205,  which mostly  reflects  the triglyceride  content  in 
VLDL particles in fasted state46, 322, 397, 403, 512. The use of the main lipids is justi-
fied in  the sense that  those lipids  are  always  present  in  these lipoprotein 
particles  and their  amounts are  usually  relatively high.  The estimates are, 
however, based on the lipids that face significant changes during the metabol-
ism of the particles in the circulation. 
When main  lipid  content  is  used  as  a  surrogate  variable  of  lipoprotein 
particle concentration, it is assumed that the main lipid content per particle is 
the same, although unknown, in each individual in the particular fraction. 
However, it is clear that lipoprotein particles are heterogeneous in their main 
lipid compositions and thus the use of main lipids as lipoprotein particle es-
timates, particularly LDL cholesterol as a surrogate measure of LDL particles, 
has recently faced criticism. 
A significant portion of individuals with 'normal' cholesterol values still de-
velop atherosclerosis and cardiovascular disease. On the other hand, the 'nor-
mal' value is also quite difficult to deduce, and the desirable value has been 
lowered during decades particularly due to this discordance. The error made 
by  the  assumption of  homogeneous  particle  composition  seems,  however, 
quite large. Approximately 12% change in diameter of an LDL particle (3 nm) 
represents approximately 40 % less volume in the core and on this basis, a 
person with smaller LDL particles will require 70 % more particles to carry 
equal amount of cholesterol as the person with larger LDL particles.
Besides the problems with LDL cholesterol concentration, it has still held 
its status since it is quite easy to use and for extreme cholesterol values it is 
sufficiently  accurate.  Individuals  with  high  LDL  cholesterol  values  (>  4.1 
mmol/l) have a significant probability to develop atherosclerotic cardiovascu-
lar disease while individuals with low LDL cholesterol levels (< 2.6 mmol/l) 
rarely develop the disease131, 513, 514. In these individuals, the errors made in as-
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suming a homogeneous particle composition do not significantly affect the 
outcome: in individuals with extremely high LDL cholesterol values, also the 
LDL particle concentrations must be high, and in individuals with extreme 
low LDL cholesterol values, also the LDL particle concentration must be low. 
Most of the individuals have, however, LDL cholesterol values between these 
two extremes. In those individuals, the elevated LDL cholesterol concentra-
tion may either implicate normal or even slightly reduces number of larger 
than normal LDL particles or elevated number of smaller LDL particles, but 
the  LDL cholesterol  concentration alone cannot  distinguish between these 
possibilities.
5.2.2 Concentration of the main apolipoproteins
Concentrations of the main apolipoproteins have also been used as surrogate 
variables of concentrations of  lipoprotein particles. Particularly,  the use of 
plasma apoB is justifiable to estimate the concentration of apoB-containing 
particles, such as VLDL, IDL, and LDL particles as a whole, since the particles 
contain a constant number of apoB molecules, i.e., one molecule per particle, 
throughout their metabolism. 
It has been estimated that more than 90 % of plasma apoB is associated 
with LDL particles515,  516, and, consequently, plasma apoB concentration has 
been widely used as an estimate of LDL particle concentration. However, the 
portion of LDL apoB from total plasma apoB has been observed to vary al-
most 10 % in apparently healthy individuals and to be somewhat lower in in-
dividuals with elevated VLDL particles515. Therefore, plasma apoB concentra-
tion, in contrast to LDL apoB measure, is not a particularly good estimate of 
LDL particle concentration. 
By analogy to apoB and apoB-containing lipoprotein particles, apoA-I con-
centration could be considered as an indicator of the concentration of HDL 
particles395,  517. The limitations in the use of plasma total apoA-I concentra-
tions are, however, more pronounced than those with apoB and thus the as-
sociation between the apoA-I and HDL particle concentration is rarely expli-
citly expressed. 
There are two challenges with the use of apoA-I as a surrogate variable for 
HDL particle concentration. Firstly, apoA-I molecules are present, in addition 
to HDL particles, also in CM particles154, 269. Secondly, the number of apoA-I 
molecules can vary in HDL particles due to their exchangeable nature. This 
variability is, however, highly dependent on HDL particle size423, 518 and thus 
apoA-I concentrations measured in certain HDL subclasses can be used to es-
timate their  particle  concentrations.  Therefore,  the challenges with apoA-I 
would be solved by additional lipoprotein isolation procedures in a similar 
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manner as for apoB-containing particles. 
5.2.3 Proton (1H) nuclear magnetic resonance (NMR) spectroscopy
The latest advance in lipoprotein concentration estimation has been achieved 
by a method which differs greatly from the conventional biochemical assays, 
namely,  1H NMR spectroscopy. NMR spectroscopy is a holistic, specific and 
quantitative method mainly used in organic chemistry to identify molecules 
in liquids519,  520. NMR spectroscopy is based on nuclear magnetic resonance 
which exists in measurable quantities only on high magnetic fields in nuclei 
with non-zero total spin. Each molecule has a characteristic behaviour in the 
magnetic fields which determines its specific location in the resulting signal 
spectrum of all molecules present in the liquid. This specific location can then 
be used to identify the molecule, and its signal amplitude is directly related to 
its concentration in the liquid.
During the last decades, NMR spectroscopy has gained ground also in lipo-
protein research since it is fast and can potentially replace many of the biolo-
gical assays used in the characterisation of lipoprotein particles204, 497, 521. One 
particularly important advantage of NMR spectroscopy is that lipoproteins do 
not need to be physically isolated from the serum sample beforehand. The 
method does, however, require advanced computational methods when used 
for lipoprotein quantification. Several groups have developed computational 
approaches including a commercial deconvolution method by Otvos et al.116, 
206, 414, 511, 522-526 and regression models by Ala-Korpela et al.527.
In both models, the signals used to estimate lipoprotein-related concentra-
tions come from methyl regions, or -CH3 groups, of all lipid molecules and 
thus the resulting concentrations resemble total lipid concentrations. These 
can then be transformed into lipoprotein fraction specific triglyceride or cho-
lesterol concentrations by assuming an average lipid composition of the lipo-
protein particles206, 528, 529 or, interestingly, into lipoprotein particle concentra-
tions by approximating the lipoprotein particle diameter as well as core lipid 
volume and mass206, 522-526.  The deconvolution method for lipoprotein particle 
concentration estimates has been recently used in various clinical studies and 
its performance in predicting individuals at risk of cardiovascular disease has 
been promising101, 116, 147-149, 412, 414, 415, 498, 530, 531. 
5.3 Materials and methods: Lipoprotein particle concentrations
In the following subsections, I will introduce a method to estimate lipoprotein 
particle concentrations on the grounds of chemically measured lipoprotein 
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lipid concentrations. Since Otvos et al. have used a quite similar approach to 
generate  model  particles,  or  a  reference  particle  library,  for  lipoprotein 
particle concentration estimation via NMR spectroscopy206, 522-526, also the dif-
ferences of the methods are discussed.
5.3.1 Data collection
Data for the modelling was selected to contain a group of individuals with a 
wide range of different lipoprotein variables, i.e., lipoprotein subclass concen-
trations. The blood samples from a hundred individuals were collected after 
an overnight fast for 12 h into EDTA-containing tubes and lipoproteins were 
isolation by high-performance liquid chromatography (HPLC)194, 195. Lipopro-
tein particles were separated by their size (gel permeation columns, TSK-GEL 
LipopropakXL; Tosoh) into twenty subclasses which included two chylomic-
ron subclasses (< 90 nm and 75 nm in mean diameter), five VLDL subclasses 
(64 nm, 53.6 nm 44.5 nm, 36.8 nm and 31.3 nm), six LDL subclasses (28.6 
nm, 25.5 nm, 23.0 nm, 20.7 nm, 18.6 nm and 16.7 nm) and seven HDL sub-
classes (15.0 nm, 13.5 nm, 12.1 nm, 10.9 nm, 9.8 nm, 8.8 nm and 7.6 nm). 
The  concentrations  of  triglyceride,  free  cholesterol,  cholesterol  ester,  and 
phospholipid molecules were also measured by enzymatic methods (see Table 
5.1). Numbers of lipid molecules in the table were estimated by equation (3.1) 
in page 62 or by equation (5.2) below.
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5.3.2 Calculation of the averaged lipoprotein particle 
concentrations 
In general, the concentration of lipoprotein particles can be thought of as a 
ratio of concentration of a lipid over all particles and the amount of the lipid 
per an averaged lipoprotein particle. This can be calculated individually and 
for each lipoprotein subclass separately as
      
P i,s=
cl
i,s
N l
i,s
, (5.1)
where c l
i,s  is the concentration of a lipid (l) in an individual (i) in a lipopro-
tein subclass  (s), and  N l
i,s  is the corresponding number of the lipid mo-
lecules within an averaged lipoprotein particle. The c l
i,s  in the equation (5.1) 
is an experimental quantity and the N l
i,s  can be estimated based on experi-
mental  lipid and protein concentrations by equation (3.1)  in page  62.  The 
equation was
N l
i , s=
cl
i , s
 p
i ,s M p
s , (5.2)
where ρp
i,s  is the protein concentration and the M p
s  is the estimated mo-
lecular mass of proteins per particle. When this equation is substituted into 
the equation (5.1) we have
. (5.3)
Interestingly, in this equation, the particle concentration is directly propor-
tional  to  the  concentration  of  proteins  in  lipoprotein  subclass  s,  ρp
i,s . 
However, this time we wanted to proceed with experimental lipid rather than 
protein measures. Thus we continued by estimating the concentration of pro-
teins by using the experimental lipid concentrations and some other measure 
connecting the amounts of lipids and proteins within a particle. Since we had 
size information available from each lipoprotein subclass and since lipopro-
tein particles constitute almost exclusively from lipids and proteins, we selec-
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ted the volume of the particles as the connecting measure. The total volumes 
of the particles, V s  , can be calculated from the experimental sizes by 
, (5.4)
where  d s  is the diameter of the particle in subclass  s,  or they can be ex-
pressed as sums of volumes of lipids and proteins equal to
. (5.5)
Here  V p
s  is the volume of the proteins in each particle in subclass  s  and 
N l
i,s  is again the number of lipid molecules in individual  i in lipoprotein 
subclass s and v l  is the averaged molecular volume of lipid l. The volume of 
proteins  can  be  estimated,  for  example,  by  the  number  and  the  average 
volume of amino acids in each lipoprotein subclass s. 
If we then substitute the equation (5.2) to (5.5) and rearrange the terms we 
have 
 , (5.6)
serving as an estimate for the protein concentration for each individual  i in 
lipoprotein subclass s. When this is substituted back into equation (5.3), the 
concentration of lipoprotein particles can be estimated as 
. (5.7)
Thus, the concentration of lipoprotein particles, P i , s , in lipoprotein sub-
class s is a lipid volume weighted average of the experimental lipid concentra-
tions within a subclass s. 
The  equation (5.7)  has  an interesting  form when considering  the earlier 
particle concentration estimation methods. Firstly, if concentration of any of 
the lipids in equation (5.7) increases substantially compared to the concentra-
tions of other lipids, the particle concentration approaches the concentration 
of that particular lipid. Secondly, if the molecular volumes of lipids in equa-
tion (5.7) are substituted by an averaged lipid volume, the particle concentra-
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tion becomes directly proportional to the total  lipid concentration.  Finally, 
due to the fact that the particle concentrations and the concentrations of pro-
teins are directly proportional, also the particle concentrations calculated by 
equation  (5.7)  should  correlate  strongly  with  experimental  total  protein 
measures for each particle fraction.
5.4 Results and discussion 
Lipoprotein particle concentrations calculated by equation (5.7) are shown in 
Fig. 5.1. In subfigures a)-c) the particle concentrations are in absolute scale 
(µmol/l) while subfigures d)-f) show the relative subclass particle concentra-
tions within each corresponding lipoprotein subclass. In the following, these 
absolute and relative particle concentrations as well as their correlations with 
other particle estimates are discussed.
The absolute particle concentrations differ significantly between lipoprotein 
fractions;  HDL particles  are  the  most  numerous  lipoprotein  particles  and 
LDL particles are more common than VLDL and chylomicron particles. The 
concentrations of chylomicrons are very low as usual in fasted state. The ab-
solute particle concentration values calculated in this study are in line with 
the  current  literature.  VLDL  subclass  particles  have  been  shown  to  vary 
around 10 nmol/l323, LDL subclasses in the range of 100-1000 nmol/l174 when 
estimated based on VLDL and LDL apoB concentrations. HDL particles have 
been shown to vary around 1 µmol/l when their concentrations are estimated 
based on the concentrations of apoA-I molecules in HDL density ranges and 
their amount per particle423, 532. The relative concentrations of the particle sub-
classes are also consistent with the current literature. The relative concentra-
tion of chylomicrons and large VLDL particles of all TG-rich particles is low 
while  small  VLDL  particles  are  the  most  common  TG-rich  lipoprotein 
particles. This also fits with the metabolism of the particles, i.e., conversion of 
large TG-rich particles to smaller TG-depleted ones upon lipid hydrolysis. It 
has also been shown that the most prominent LDL subclass (LDL2b; 26 ± 6 
%320) is near 26 nm in diameter20, 169, 174 while subclasses with slightly larger or 
smaller size are a little less common (around 20 %)320. The relative concentra-
tions of the smallest LDL particles have been shown to be minor (less than 10 
%)  in  apparently  healthy  individuals  as  well  as  in  subjects  with  elevated 
plasma triglyceride concentrations188,  320. All these trends can be seen in Fig. 
5.1. 
The concentration of very large HDL particles relative to intermediate and 
small HDL particles is also in accordance with the literature. The very large 
HDL particles usually require apoE rather than apoA-I as their main apolipo-
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protein and are thus rare. In addition, the inter-individual variation in HDL 
particle concentrations is high as suggested by literature188,  320,  533.  Interest-
ingly, however, the small and intermediate-size HDL particles seem to have 
quite  similar  concentrations while  individuals  in  the current literature are 
classified  into  groups  with  high  amount  of  either  small  or  large  HDL 
particles160, 178, 362, 395, 517, 533, 534. While this data set is limited in size concerning 
further analysis of this finding, the result seems not to be only due to the fact 
that  individuals in this data set were not divided into groups according to 
their plasma triglyceride level. 
The other matter worth noticing is the association of the particle concentra-
tions with the other particle concentration estimates. Fig. 5.2 shows a collec-
tion of these associations at the lipoprotein subclass level and Fig. 5.3 at the 
fraction level, i.e., summed up over several subclass level particle concentra-
tion estimates. Thus the panels in Fig. 5.3 can be held as estimates of total 
VLDL, LDL and HDL particle concentrations. The quality of the association 
in each subfigure is best graded by visual examination by comparing the loca-
tion of dots on the line drawn based on least squares fitting. Each subfigure 
also profiles square of correlation coefficient (r2) and the points' averaged de-
viation from the regression line (↕).
Figure 5.1 Absolute lipoprotein particle concentrations (a,b,c) and relative  
particle concentrations within the corresponding lipoprotein fraction (d,e,f).  
Samples were obtained  from 100 individuals  after an overnight fast.  CM 
and VLDL particles were combined in the same subfigure.  CM, chylomic-
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ron;  VLDL,  very  low-density  lipoprotein;  LDL,  low-density  lipoprotein;  
HDL, high-density lipoprotein.
The panels  a)-e)  in  Fig.  5.2  show correlations  of  particle  concentrations 
with the corresponding main lipid concentrations in some of the lipoprotein 
subclasses. Between panels a) and b), as well as panels d) and e), there is a 
large difference in the strength of the correlation. It seems that particularly 
the subclasses with the smallest particles give the worst correlations. This is 
in line with the fact that as the size of the particle decreases, the concentra-
tion of the main lipid decreases in amount and, even more importantly, also 
relative to the concentrations of other lipids. This change in relative particle 
composition occurs due to differences in lipoprotein metabolism of each indi-
vidual leading to significant inter-individual variations. This phenomenon is 
also visible in the LDL subclasses (not shown) but interestingly, it is, at least 
in this data set, more pronounced in VLDL and HDL subclasses. In Fig. 5.3, 
the amount of particles in each subclass and their subclass level association 
with the other particle concentration estimates affect the overall strength of 
the fraction level associations. Therefore, in panels a)-c), the square of the 
correlation coefficients is high in VLDL and LDL particles where the most 
abundant subclasses correlate well with the plasma triglyceride and LDL cho-
lesterol concentrations, respectively, while in HDL particles, the smallest and 
the least well associated particles with HDL cholesterol are also present in 
high numbers giving smaller coefficients.
Panels f)-i) in Fig. 5.2 show correlations of total lipids with the particle con-
centrations. When comparing these figures to panels a)-e), it is obvious that 
when  all  lipid  molecules  are  taken  into  account,  the  associations  become 
stronger at the subclass level. For example, in VLDL5 subclass, the deviation 
from the regression line decreased from 12 nmol/l to less than 1 nmol/l, and 
in HDL7 subclass,  the square of the correlation coefficient increased from 
0.34 to 0.99. The increased strength of the associations with total lipid estim-
ates stems from the fact that the total  lipid measures can overcome major 
part of the inter-individual variation in the particle compositions. This is be-
cause the inter-individual variation at the subclass level results mainly from 
exchange of lipids, particularly cholesterol ester - triglyceride exchange medi-
ated by CETP, which does not affect the total  amount of lipids within the 
particles. On the other hand, if the total lipid measure changes, also the size 
of the particle changes accordingly, causing a shift to another lipoprotein sub-
class. The resulting subclass level correlations are all  very strong and lead 
also to high fraction level correlations in panels d)-f) in Fig. 5.3. Therefore, 
based on Fig. 5.2 and 5.3, it is obvious that although the squares of correla-
tion coefficients are high with both the main lipid and the total lipid estim-
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ates, the total lipid measures are superior to main lipid estimates. 
Figure 5.2 Correlation of particle concentrations of certain VLDL, LDL and 
HDL subclasses with their  main lipid and total  lipid concentrations.  The 
subclasses were selected to show the best  of  and the worst of  the associ-
ations (VLDL, HDL subclasses) or to show one subclass in the middle of the  
size range if significant variation was not present (LDL subclasses). Also  
some of  the  associations  between these  particle  concentrations  and their  
total lipid concentrations are shown to illustrate the strengthening of the as-
sociations. VLDL, very low-density lipoprotein; LDL, low-density lipopro-
tein; HDL, high-density lipoprotein; TG, triglyceride; C, total cholesterol.
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Figure 5.3 Comparison of lipoprotein particle concentrations with main and 
total lipid measures in VLDL, LDL and HDL fractions. The figure is con-
structed  by  summing  the  corresponding,  estimated  lipoprotein  subclass  
particle concentrations and their lipid measures, respectively. VLDL, very 
low-density lipoprotein;  LDL, low-density lipoprotein; HDL, high-density  
lipoprotein; TG, triglyceride; C, total cholesterol.
Due to the good performance of total lipids in particle concentration estim-
ation,  it  is  worth  directing  further  interest  into  them.  Fig.  5.4  shows  the 
particle concentration estimates calculated by the equation (5.7) (black bars) 
as well as lipoprotein particle estimates built based on the total lipid concen-
trations (red bars). In order to compare these two estimates, we needed con-
version coefficients for the total lipid concentrations. Probably the easiest way 
to obtain these coefficients is to use least square fitting as shown in Fig. 5.2 
for some subclasses. As seen in Fig. 5.4, the differences between the methods 
are small  for all  lipoprotein particles, less than or equal to two percent in 
HDL, LDL, and small VLDL particles, and increase up to five percent in the 
largest VLDL particles. The conversion factors for total lipid concentrations 
can also be analytically calculated from equations (6.7)  by using the same 
constant for all molecular volumes of lipids. For example, the use of a simple 
averaged lipid volume over the molecular volumes of the four lipids induced 
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two to three percent differences in HDL and LDL particles while the differ-
ence increased up to twenty percent in the largest triglyceride-rich particles. 
This  larger difference is  due to  the fact  that  the use of the averaged lipid 
volume underestimates most the volume of triglyceride molecules as a trigly-
ceride  molecule  has  the  largest  volume  of  the  four  lipids. The  difference 
between the particle concentration and the total  lipid concentration could, 
however, be approximately halved by using a larger constant for the molecu-
lar lipid volumes than the average volume but then the differences in HDL 
and LDL particles tend to increase.
Figure 5.4 Comparison of the particle concentration estimates calculated by 
the equation (6.7) (black bars) with the estimates calculated based on the  
total lipid concentrations (red bars) in HDL, LDL, VLDL and CM subclasses.  
The total lipid concentrations were first converted to levels comparable with  
the particle concentrations by using the coefficients obtained from the least  
square fitting. The relative difference of the estimates in each subclass is in-
dicated as percentage units above the bars. CM, chylomicrons; VLDL, very  
low-density lipoprotein; LDL, low-density lipoprotein;  HDL, high-density 
lipoprotein.
The reference particle library which Otvos et al.  are using in their NMR 
studies206,  522-526 has been generated by a method quite similar as that intro-
duced here. However, the methods differ in the way the per particle composi-
tions are estimated and thus likely have differences particularly in the conver-
sion factors. Unfortunately, the conversion factors of Otvos et al., or the refer-
ence data behind the factors, have never been published, and thus direct com-
parison of the factors is at the moment impossible. 
Nevertheless,  Otvos et  al.  do give  a biophysical  description for  their  per 
particle  composition estimation procedures  performed separately  for  each 
lipoprotein  subclass522;  It  seems  that  Otvos  et  al.  estimate  the  amount  of 
triglyceride and cholesterol ester molecules per particle by restricting their 
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relative amount per particle and by using their averaged molecular volumes 
and the core volume calculated from the size estimates assuming spherical 
particle shape and fixed thickness of the surface layer. In other words, they 
assume that triglyceride and cholesterol ester molecules form the cores. 
The assumption Otvos et al. made on lipoprotein particle structure is rather 
restrictive and thus their method may suffer from certain drawbacks. Firstly, 
it is possible that not all triglyceride and cholesterol ester molecules reside in 
the cores as stated in chapter 3 in this thesis and, secondly, triglycerides and 
cholesterol esters are not the only molecules in the cores which contain also 
small amounts of free cholesterol molecules. The overall effect of these prob-
lems in the model of Otvos et al. is, however, difficult to assess since they bias 
the results in different directions. The first flaw tends to underestimate the 
total amount of triglyceride and cholesterol ester molecules per particle lead-
ing to overestimation of particle concentrations. The other flaw would, in-
stead, tend to decrease the particle concentrations since when the free choles-
terol molecules are ignored, the per particle triglyceride and cholesterol ester 
contents in the core increase. When the effects of these two opposite actions 
on the particle structures are studied by the model introduced in the chapter 
3, the effect of the first drawback seems stronger leading to overestimates of 
particle concentrations.
Otvos et al. have made considerable attempts to verify their method. This 
was done either by comparing so-called NMR-derived lipid levels with chem-
ically measured lipid levels or by comparing apolipoprotein levels to particle 
concentrations. These NMR-derived lipid levels are estimates of lipids from 
the methyl peak of NMR spectrum. Extraction of these features is, however, 
difficult since the signal cannot be split invariantly into the concentrations of 
various lipid molecules separately. Thus the concentrations of these lipids are 
estimated based on the particle concentration measures, and the conversion 
factors, which, at this time, transform the particle concentrations back to lip-
id concentrations, are again obtained from the reference particle library.
The correlations of plasma triglyceride, HDL cholesterol and LDL cholester-
ol concentrations with corresponding NMR-derived lipid levels drawn by Ot-
vos et al.206,  522 are shown in Fig. 5.5. The triglyceride and HDL cholesterol 
pairs have strong correlations with correlation coefficients r=0.98 (r2=0.96) 
and  r=0.96  (r2=0.92),  respectively,  from  253  individuals.  The  association 
between NMR-derived and chemically measured LDL cholesterol values cor-
related less strongly with the correlation coefficient r=0.85 (r2=0.72). These 
correlation coefficients are quite impressive and seem, at first, to provide con-
siderable  reliability  to  the model  of  Otvos  et  al.  Closer  examination does, 
however, show that the NMR-derived lipid values are not suited for judging 
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the fitness of the particle concentration estimation method. 
Figure 5.5  Comparison of  NMR-derived and chemically measured trigly-
ceride (A), HDL cholesterol (B), LDL cholesterol (C), and LDL apoB concen-
trations (D). In panels A and B, the line drawn is the identity (n=253). The  
regression lines and correlation coefficients are y=0.94x+2.7 and r=0.978 
for triglycerides and y=1.16x-9.3 and r=0.959 for HDL cholesterol. The LDL  
cholesterol  and  apoB  concentrations  are  obtained  by  first  removing  the 
VLDL fraction (density < 1.006 g/l) through ultracentrifugation and then 
either  calculated  as  the  difference  between  total  plasma  cholesterol  and 
HDL cholesterol values in the bottom fraction or subjected to nephelometric  
apoB immunoassay giving correlation coefficients of r=0.928 and r=0.846, 
respectively (n=29). LDL-P, concentration of LDL particles. Panels A, B and 
D are reprinted from 206, Copyright (2010), with permission from Elsevier.  
Panel C is reprinted from 522 with permission.
The procedure from the total lipid concentration to the NMR-derived lipid 
concentration  via  particle  concentration  estimate  utilises  two  conversion 
factors per lipoprotein subclass which are both obtained from the reference 
particle library.  The first  factor transforms the total  lipid concentration to 
particle concentrations and is inversely proportional to the per particle lipid 
composition. The second factor, on the other hand, transforms the particle 
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concentration to the selected lipid concentration and is directly proportional 
to the per particle lipid composition. Therefore, when multiplying the factors 
together, the per particle lipid composition parameters will disappear. Thus 
the NMR-derived lipid concentrations do not include information of the es-
timated per particle composition which is the cornerstone of particle concen-
trations estimation and, therefore,  cannot be used to validate  the method. 
The NMR-derived lipid concentrations per se are, however, free of the errors 
made in per particle lipid composition estimation. They do, however, suffer 
from errors caused by small differences in the relative content of lipids within 
a subclass between an individual and the corresponding averaged reference 
particle library values. 
Another approach that Otvos et al. have used to validate their method is to 
associate their estimated LDL particle concentration with chemically meas-
ured LDL apoB concentration. Since each LDL particle contains exactly one 
apoB molecule, this LDL apoB measure can be treated as experimental LDL 
particle concentration. The association of the experimental and the computa-
tional LDL particle concentration, shown in Fig. 5.5 D, is strong with a correl-
ation coefficient r=0.93 (r2=0.86), and thus the model of Otvos et al. seems 
valid  for  LDL.  Also  the  biophysical  consideration  supports  this  view.  As 
shown in Figure 3.1 in chapter 3, the conventional view of core lipids concern-
ing triglycerides and cholesterol esters is the most valid for LDL particles as 
the estimated amounts of triglycerides and cholesterol esters in the surface of 
LDL particles were around 5 % and 10 %, respectively, and when all free cho-
lesterol molecules are placed in the surface layer, these figures decrease to be 
less than a percent (data not shown). 
However, as already mentioned above, the situation is different for VLDL 
and particularly for HDL particles. In VLDL, approximately 10 % of either 
triglycerides or cholesterol esters may still reside in the surface after adjust-
ment of the effect of free cholesterol molecules. In HDL particles, the corres-
ponding figure is approximately 20-30 %, leading to considerable errors in 
particle concentration estimation.
In conclusion, it has been shown within last decades that LDL cholesterol 
concentration is not the best lipoprotein-related measure to predict the cardi-
ovascular disease risk of an individual23,  470-473.  These observations have in-
creased  the  interest  in  other  lipoprotein  measures,  such  as  lipoprotein 
particle  concentrations,  in  risk  assessment.  An  NMR-based  method,  de-
veloped in the early 1990s by Otvos et al.206, 522-526, has achieved wide attention 
in lipoprotein particle concentration estimation due to its success, particu-
larly in the case of LDL, in several recent clinical trials101, 116, 147-149, 412, 414, 415, 498, 530, 
531. However, the method is based on rather restrictive assumptions of lipo-
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protein particle structures and may thus cause errors in the other lipoprotein 
particle  concentration estimates.  Thus  there  is  a  clear  need for  a  method 
which takes into account the lipoprotein particle structures more properly. 
We aimed to fulfill this need and constructed such a model. The model per se 
requires information on the average particle size and full set of lipid concen-
trations in each lipoprotein subclass to estimate the particle concentrations. 
The method is also easily simplified to the use of  total lipid concentrations 
leading only to small differences in VLDL, LDL and HDL particle concentra-
tions as compared to the estimates obtained using the full set of lipid concen-
trations. The method may also be employed to generate a reference particle 
library for NMR-based lipoprotein particle estimation. The development of 
such an NMR-based method and demonstration of its features in clinical tri-
als are currently under way.
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6. Summary of the results
This thesis deals with various computational models and methods for lipo-
protein research. The main contribution of this thesis is related to three im-
portant concepts concerning lipoprotein particles. These include structural, 
composition/metabolic  and  particle  concentration  issues.  Experimentally 
isolated  and  biochemically  characterised  lipoprotein  particles  served  as  a 
starting point in all studies of this thesis. 
The first study modelled the molecular structure, i.e., the location of trigly-
ceride and cholesterol ester molecules, of the lipoprotein particles at subclass 
level. This modelling required also methods to estimate the number of lipids 
within a particle, i.e., composition information, as well as particle size estim-
ates.  The  model  was  applied  separately  for  11  lipoprotein  subclasses,  i.e., 
VLDL1, VLDL2, IDL, LDL1, LDL2, LDL3, HDL2b, HDL2a, HDL3a, HDL3b and 
HDL3c (very low-, intermediate-, low- and high-density lipoproteins, respect-
ively), isolated by density gradient ultracentrifugation from 12 individuals. 
While triglycerides and cholesterol esters are widely considered as core lipids 
residing in the interior regions of lipoprotein particles, in this study, a signi-
ficant portion of triglycerides was estimated to locate in the surface layer of 
large VLDL and, particularly, cholesterol esters in the surface layer of HDL 
particles. The results of the modelling gave intuitive and coherent structural 
rationale for the molecular interactions between the hydrophobic lipoprotein 
lipids and water-soluble lipolytic enzymes and lipid transporters. 
The second study found several lipoprotein phenotypes with distinct, com-
bined compositional and metabolic relationships. Data for this study included 
302 blood samples representing a wide range of lipoprotein lipid values, and 
lipoprotein  particles  were  isolated  by  ultracentrifugation  into  VLDL,  IDL, 
LDL, HDL2 and HDL3  fractions. In the study, the self-organising map meth-
od was used for classification and visualisation of structural and metabolic re-
lationships of lipoprotein particles, and both the plasma lipid concentrations, 
i.e., concentration variables, and the per particle compositions, i.e., composi-
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tion variables, were used as the classification criteria. The composition vari-
ables, and also particle size estimates, were calculated according to the meth-
od introduced in the first study. When the self-organising map method was 
applied  to  the  data,  visible  variation  in  the  structural/metabolic  relations 
between individuals was revealed. Accordingly, the individuals were classified 
into five distinct  groups, i.e., lipoprotein phenotypes, with some individuals 
locating between the groups, thus supporting the validity of the in silico clas-
sification. By comparing the phenotypes, it became clear that the traditional 
lipid measures are not capable of distinguishing different lipoprotein pheno-
types since the traditional lipid measures may be similar in many lipoprotein 
phenotypes although their particle compositions differ greatly. Similarly, the 
lipoprotein particle concentrations alone could not classify individuals prop-
erly.
The third study modelled lipoprotein particle concentrations in twenty lipo-
protein subclasses. Data for the modelling included 100 blood samples from 
subjects selected to contain a wide range of different lipoprotein profiles, i.e., 
lipoprotein subclass concentrations. Lipoprotein particles were separated by 
high-performance liquid chromatography into two chylomicron subclasses, 
five VLDL subclasses, six LDL subclasses and seven HDL subclasses accord-
ing to their size. For each lipoprotein subclass, lipoprotein particle concentra-
tion was estimated as  the ratio  of  a  lipid concentration in plasma and its 
amount in an average lipoprotein particle. The composition of averaged lipo-
protein particles was again calculated accordingly to the method introduced 
in the first study. Contrary to the previously published model for lipoprotein 
particle estimates, which assumes that all triglyceride and cholesterol ester 
molecules reside in the core of lipoprotein particles, our model is structurally 
less restricted. For example, since our model is based on four (not two) exper-
imentally measured lipoprotein lipid concentrations, our model does not re-
quire any assumption of location of the lipids within the particles. The third 
study provided also a reference particle library for NMR-based lipoprotein 
particle concentration estimation.
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